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α-Synuclein aggregation is the key pathogenic event in several important 
neurological disorders including Parkinson’s Disease, dementia with Lewy bodies 
and multiple system atrophy, giving rise to a distinct group of neurodegenerative 
diseases known as synucleinopathies. Although the molecular basis of α-syn 
toxicity has not been precisely elucidated, recent studies indicate that α-syn 
toxicity is mediated by a nucleation-dependent aggregation process. To elucidate 
the structural basis of α-synuclein mediated toxicity, we developed various 
methods to prepare different α-synuclein species of a defined size and 
morphology distribution, and we investigated their toxicity in different human 
dopaminergic cell lines. We observed that crude α-synuclein oligomers 
preparations, containing both monomeric and heterogeneous mixtures of α-
synuclein oligomers, were the most toxic species. The toxicity of α-synuclein 
aggregates was directly linked to the presence of the monomeric α-synuclein, and 
strongly dependent on its ability in seeded nucleation-dependent aggregation 
converting into amyloid fibrils. Therefore any effort to identify compounds that 
could inhibit or even reverse the aggregation process should assess the effect of 
the potential inhibitors on the seeded aggregation of α-synuclein, among others. 
We screened thirty Chinese herbal medicinal compounds for their effect on α-
synuclein aggregation, seeded polymerization and toxicity by employing 
biophysical, biochemical and cell-culture-based techniques. Among the screened 
compounds, only ginsenoside Rb1, salvianolic acid B, dihydromyricetin and gallic 
acid were shown to be strong inhibitors of α-syn fibrillation, seeded aggregation 
and toxicity. Our results showed that gallic acid, ginsenoside Rb1 and salvianolic 
acid B inhibit α-synuclein fibrillation by binding and stabilizing the structure of 
vii 
 
the soluble, non-toxic oligomers, which are devoid of β-sheet content. In contrast, 
dihydromyricetin was found to be able to bind to both oligomeric and monomeric 
species of α-synuclein. In the case of gallic acid, the inhibition of α-synuclein 
fibrillation is related to the compound’s hydroxyl moieties whose number and 
position on the phenyl ring were proven to be significant for the process of 
inhibition, as indicated by the structure activity relationship data obtained from 
fourteen structurally similar benzoic acid derivatives. Overall, the compounds 
identified herein may represent the starting point for designing new molecules that 
could be utilized as drugs for the treatment of Parkinson’s Disease and related 
disorders. 
Keywords: α-Synuclein, Parkinson’s Disease, aggregation, seeded-nucleation 




Title and Abstract (in Arabic) 
ألفا سنيوكلين والسمية المرتبطة تشخيص مركبات فريدة قادرة على منع تراكم بروتين 
 بهذا التراكم كعالج محتمل لمرض باركنسون.
يعتبر تراكم البروتين ألفا سنيوكلين عامال أساسيا في إمراضية عدد من األمراض العصبية و 
على رأسها مرض باركنسون. بالرغم من أن دور هذا البروتين ال يزال قيد البحث، إال أن 
الدراسات الحديثة تشير إلى أن سميته تبدأ  بتشكيل نواة هي الركيزة لعملية تجمع و تراكم 
. لفهم اآللية الجزيئية المرتبطة بسمية ألفا سنيوكلين، طورنا تقنيات لتحضير أشكال البروتين
مختلفة من البرويتن ذات أبعاد و تشكالت محددة، ثم قمنا بدراسة سميتها على الخاليا 
العصبية المنتجة للدوبامين ا)لدوبامنيرجية(. لقد الحظنا أن " أوليغمرات" البرويتن، الحاوية 
ير متجانس من " المونمرات" و " أألوليغمرات" المتفاوتة األبعاد، هي األكثر على خليط غ
سمية. كما ارتبطت  سمية البروتين ألفا سنيوكلين بشكل مباشر بوجود " مونمرات" البروتين 
و اعتمدت بشكل أساسي على قدرة هذه "المونمرات" على تشكيل النواة الركيزة لعملية تجمع 
ؤدي بالمحصلة لتشكيل ألياف األميلويد. بناء على ما سبق، فإن الجهود و تراكم البروتين لت
 العلمية يجب أن تركز على تطوير مركبات قادرة على تثبيط تشكل هذه النواة. 
تضمن البحث ثالثين مركبا مستخلصا من أعشاب طبية صينية، حيث تم توظيف تقنيات 
لدراسة قدرة  بحثيا العصبية كوسيط الاعتمدت على الخال و أخرى بيوكيميائية وبيوفيزيائية
 و تثبيط سميته. ألفا سنيوكلينهذه المركبات على منع تجمع أو تراكم البروتين 
ثبتت فعاليتها في تثبيط ومنع أربعة مركبات فقط أمن مجموعة المركبات التي تم دراستها, 
قد تستخدم كبداية  تراكم هذا البروتين والسمية الناتجة عن ذلك. هذه المركبات المكتشفة,
 لتصنيع عقاقير قادرة على عالج مرض باركنسون.
بروتين ألفا سنيوكلين, مرض باركنسون, تراكم البروتين, تراكم البروتين  الكلمات الدالة:
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1 Chapter 1: Introduction 
1.1  Parkinson’s Disease  
Parkinson’s disease (PD) is a neurodegenerative disorder caused by the 
gradual loss of dopaminergic neurons (Obeso et al., 2008). PD affects about 1-2% 
of the current population over the age of 65, with an average duration of 8 years. 
Although the peak age of onset for PD is between 55 to 65 years, the age of onset 
for the disease ranges from 20 to 80 years, the incidence of which rises sharply 
after the fifth decade of life, affecting 1.4% and 3.4% of the population at 55 and 
75 years of age, respectively (N. Wood, 1997). Cases of PD with an age of onset 
between 21 and 40 years have been called “young-onset Parkinson’s Disease”  
and when it starts before the age of 21 it is called juvenile parkinsonism  (Quinn, 
Critchley, & Marsden, 1987). 
PD affects a region of the brain known as the substantia nigra, resulting in a 
dramatic loss of dopaminergic neurons and a concomitant plummeting in 
dopamine levels in the striatum. As a consequence, PD is manifested by a plethora 
of clinical symptoms, with the most prominent being impaired motor activity, 
muscle rigidity and a resting tremor. Neuropathologically, PD is characterized by 
the presence of intracellular inclusions known as Lewy bodies (LBs) and Lewy 
neuritis (LNs), the main constituent of which are α-synuclein (α-syn) fibrils (El-
Agnaf et al., 1998; El-Agnaf, Jakes, Curran, & Wallace, 1998; Jakes, Spillantini, 
& Goedert, 1994; Spillantini et al., 1997). Most cases of PD are idiopathic (85%), 
which are characterized by late-onset, non-inheritable movement disorder with 




2008). Dopamine replacement by L-3-4-dihydroxyphenylalanine (L-DOPA) has 
helped to increase dopamine in the neurotransmitter-depleted striatum. Although 
this is effective treatment in the early stages of PD, it will lose its therapeutic 
qualities with time. To date there is no treatment that can arrest or reverse the loss 
of dopaminergic neurons. The etiology of PD is poorly understood, but 
convergent pathological, biochemical, animal models and genetic evidence 
suggests that the formation of α-syn protein deposits is an important and, 
probably, seminal step in the development of PD and related disorders. 
Although α-syn belongs to the family of natively unfolded proteins, which 
demonstrate little or no ordered structure, the protein has the intrinsic propensity 
to fibrillate, giving rise to insoluble fibrils similar to the ones detected in LBs 
(Conway, Harper, & Lansbury, 2000b; El-Agnaf, Jakes, Curran, Middleton, et al., 
1998; Giasson, Uryu, Trojanowski, & Lee, 1999b; Hashimoto et al., 1998b). 
Additionally, five missense mutations in the α-syn gene (SNCA), namely A53T 
(M. H. Polymeropoulos et al., 1997), A30P (Krüger et al., 1998), E46K (Zarranz 
et al., 2004), H50Q (Appel-Cresswell et al., 2013) and G51D (Kiely et al., 2013), 
have been linked to inherited forms of PD, while duplications and triplications of 
SNCA lead to autosomal dominant PD in a gene dosage-dependent fashion 
(Ibáñez et al., 2004; Singleton et al., 2003b). Moreover, transgenic animal and 
drosophila models expressing either wild-type or mutant human α-syn also 
develop fibrillar inclusions and a Parkinsonian phenotype (Cannon et al., 2013; 
Feany & Bender, 2000; Imai, Venderova, Park, Cai, & Schmidt, 2011; Kahle et 
al., 2001; Masliah et al., 2000). It is noteworthy that the fibrillation of α-syn is 
implicated in the development of a series of neurodegenerative diseases, including 




are collectively referred to as alpha-synucleinopathies (Spillantini & Goedert, 
2000; Trojanowski & Lee, 2003). Taken together, these findings indicate a central 
role for α-syn aggregation in PD pathogenesis α-syn aggregation proceeds through 
several key intermediate stages, with monomeric α-syn first assembling into 
oligomeric forms that gradually generate insoluble amyloid fibrils. Because α-syn 
aggregation plays a crucial role in PD pathogenesis and related alpha-
synucleinopathies, intensive effort has been put into identifying compounds that 
could block or even reverse the aggregation process. Over the years, polyphenols, 
a set of more than 8000 compounds that contain one or more phenolic rings, have 
emerged as potent amyloid inhibitors, interfering with the in vitro fibril assembly 
of many amyloidogenic proteins including α-syn, β-amyloid (Aβ), tau-protein and 
prions (reviewed by (Porat, Abramowitz, & Gazit, 2006). 
1.2 Synuclein family 
Synucleins are small, soluble proteins highly expressed by neuronal cells 
(Jakes, et al., 1994) . The synuclein family has three distinct members α-, - and 
-syn (reviewed by (Amer, Irvine, & El-Agnaf, 2006). Structurally, synucleins are 
characterized by the repetitive presence of the amino acid motif KTKEGV 
throughout the first 87 residues, while their C-terminal region is rich in acidic 
amino acids. Moreover synucleins are natively unfolded proteins meaning that 
they have no structure under physiological conditions and their structure is 
composed of random coils. Also, synucleins have high net charge and low 
hydropathy (reviewed by (Amer, et al., 2006). The synuclein family genes are 




However, the synuclein family is not so expressed in other tissues such as the 
heart, lung, skeletal muscle, ovaries, testes, colon and spleen. 
1.2.1 α-Synuclein 
α-Syn is a soluble protein with a sequence of 140 amino acid residues 
(Jakes, et al., 1994; Uéda et al., 1993). SNCA is the gene that α-syn is encoded by 
and it is located on the long arm of chromosome 4 (4q21-q23) (X. Chen et al., 
1995; Xia et al., 2001). Some homologous protein for α-syn  have been identified 
in electric ray (Maroteaux, Campanelli, & Scheller, 1988), rat (i.e. synuclein-1) 
(Maroteaux & Scheller, 1991), zebra finch (i.e. synelfin) (J. M. George, Jin, 
Woods, & Clayton, 1995) and other species. α-Syn was first discovered in the 
neuromuscular junction of the electric ray. Antibodies against α-syn labelled both 
synapses and nuclei lead to the name synuclein (Maroteaux, et al., 1988). Three 
isoforms of α-syn protein have been identified, 140 amino acids at full-length 
form while the other two are truncated at 3’ end resulting in 126 and 112 amino 
acids proteins (Beyer et al., 2008; Campion et al., 1995). α-Syn can form 
amphipathic helices when it interacts with phospholipid layers (J. L. George et al., 
2009), and the α-helical structure will intensify according to the binding to small 
synthetic, acidic, unimolecular vesicles (W. Sean Davidson, Ana Jonas, David F. 
Clayton, & Julia M. George, 1998). It was suggested that α-syn could be part of 
the fatty acid-binding protein family due to its biochemical properties and 
structural motif, hence α-syn could transport fatty acids between the aqueous and 
membrane phospholipid compartments of neuronal cytoplasm (Sharon et al., 
2001). The abundance of α-syn in presynaptic terminal and early stages of 




synaptic vesicle pools and maintenance of presynaptic function (Cabin et al., 
2002).  
El-Agnaf and co-workers have demonstrated that α-syn can self-aggregate 
and form amyloid-like filaments similar to those that have been isolated from 
LBs, and that the mutants α-syn proteins associated with familial form of PD 
aggregate faster than the wild-type protein (El-Agnaf, Bodles, Guthrie, Harriott, & 
Irvine, 1998).  
Animal models, genetics and biochemical studies support the hypothesis 
that accumulation of α-syn in the brain has a significant role in the pathogenesis 
of a number of neurodegenerative diseases like PD. α-Syn has little or no ordered 
structure under physiological conditions, and its secondary structure is a random 
coil (Weinreb, Zhen, Poon, Conway, & Lansbury, 1996), however, recent studies 
have indicated that α-syn occurs as a helically folded tetramer (Bartels, Choi, & 
Selkoe, 2011). The region covered by the first 100 amino acid residues of α-syn 
adopts an α-helical structure upon binding to phospholipid membranes (Chandra, 
Chen, Rizo, Jahn, & Südhof, 2003), lipid vesicles (Bussell & Eliezer, 2003b; W. 
S. Davidson, A. Jonas, D. F. Clayton, & J. M. George, 1998; Perrin, Woods, 
Clayton, & George, 2000) and detergent micelles (Bussell & Eliezer, 2003b). The 
consensus sequence KTKEGV is considered to play a key role in the α-helical 
structure assumed by α-syn (W. S. Davidson, et al., 1998; Weinreb, et al., 1996). 
The NAC region of α-syn is exceptionally hydrophobic and amyloidogenic, thus 
promoting the conformational change from random coil to -structure (El-Agnaf 
& Irvine, 2000; Uéda, et al., 1993). In contrast, the acidic C-terminal region 
remains unfolded and associates with vesicles or micelles (Eliezer, Kutluay, 




transient long-range interactions with the N-terminus and the NAC region, thus 
conferring stability to the α-syn molecule (Sung & Eliezer, 2007; K. P. Wu, Kim, 
Fela, & Baum, 2008). As far as the physiological function of α-syn is concerned, 
it remains unclear. However, research indicates that α-syn may play a role in 
neural plasticity (J. M. George, et al., 1995) and in normal SNARE protein 
assembly, which is critical for neurotransmitter release and vesicle recycling 
(Burré et al., 2010). 
1.2.2 β-Synuclein 
The -synuclein gene (SNCB) is located on chromosome 5q35 and codes for 
134 amino acid protein named -synuclein (-syn). α- and -Syn share 78% 
homology and, -syn has a conserved C-terminal domain containing three 
identically placed tyrosine residues. Both α- and -syn have similar subcellular 
localization and expression patterns in the brain. However, -syn lacks 11 
hydrophobic amino acid residues that correspond to the 72-84 residues of α-syn 
(Fig. 1.1). In a recent study, -syn was shown to have a neuroprotective role by 
inhibiting α-syn aggregation. Cells over expressing -syn are more resistant to α-
syn accumulation (Hashimoto et al., 1998a). Moreover, cells that overexpress -
syn activate the serine threonine kinase AKT (also known as protein kinase B) 
signalling pathway and are more resistant to α-syn neurotoxicity (Hashimoto et 
al., 2004). In transgenic mice, -syn reduces α-syn accumulation in the brain and 
improves survival rates, as well as motor dysfunction (Ahmad, Attoub, Singh, 












Figure 1.1: Sequence homology of synuclein family. 
 
SNCB showed a reduced accumulation of α-syn in the brain (Hashimoto, et 
al., 2004). Additionally, it has been reported that β-syn exhibits a chaperone 
activity more efficiently than α-syn (D. Lee, Paik, & Choi, 2004). However, 
unlike α-syn, β-syn has much less a tendency to aggregate and form amyloid 
fibrils. 
 
1.2.3  γ-Synuclein 
The third member of the synuclein family, the γ-syn gene (SNCG) is located 
on chromosome 10q23 and encodes a 127 amino acid protein (reviewed by 
(Ahmad, et al., 2007). The γ-syn gene was first referred to as BCSG1 (breast 
cancer-specific gene 1), the levels of which increase dramatically in breast 
carcinoma (Ji et al., 1997).  However, the name was later changed to SNCG due to 
its high homology to synuclein proteins (Lavedan et al., 1998), despite the fact 
that γ-syn is overexpressed in breast cancer tumours (Ninkina et al., 2003).  
Similar to α- and β-syn, the N-terminus of γ-syn is conserved but its C-terminus 
shows reduced homology to other members of the family. γ-Syn colocalizes with 
neurofilaments in the axons (Ninkina, et al., 2003), and alters neurofilament 




proteases (Buchman et al., 1998). Furthermore, -syn is expressed in the early 
stages of axonal outgrowth and maintained throughout its life, thus indicating that 
-syn has a role in the formation of the nervous system (Buchman, et al., 1998). 
Unlike α-syn, -syn has a weak tendency to form amyloid fibrils (Giasson, 
Murray, Trojanowski, & Lee, 2001). 
1.3 Genes associated with PD  
Genetic studies have linked several genes to PD. These genes can be 
categorized based on their mode of inheritance: autosomal dominant like α-syn 
(SNCA) and Leucine-rich repeats kinases 2 (LRRK2) or autosomal recessive like 
Parkin and  
PINK1. However, this classification can be challenging due to the reduced 
penetration in the dominant form and the putative role of single heterozygous 
mutations in the recessive form (see Table. 1.1). 
The study of PD genetics can be a complex task given the interaction of 
several genes that are encoded by nuclear or mitochondrial DNA both, or 
epigenetic (reversible, heritable change in gene expression without a change in the 
DNA sequence), not to mention the influence of environmental factors that alter 












Table 1.1. Loci and genes associated with PD adapted from Eschbach and Danzer,2013. 
 
 
1.3.1 α-Synuclein gene (SNCA) 
 To date PARK1 has been shown to play a significant role in PD as 
demonstrated in the genetic analysis of a large Italian family (Golbe, 1990). The 
clinical symptoms are similar to sporadic PD but have an early age of onset (mean 
Designation Gene Locus Protein function Inheritance LBs 
PARK 1 SNCA point 
mutation 
4q21 among others: synaptic vesicle 




PARK 2  Parkin 6q25–q27 ubiquitin ligase autosomal 
recessive (AR) 
–/(+) 
PARK 3   unknown 2p13 unknown AD + 




4q21 see above AD + 
PARK 5  UCH-L1 4p14 – 15 ubiquitin-hydrolase/ligase AD unknown 
PARK 6  PINK-1 1q35 – 36 mitochondrial protein kinase AR + 
PARK 7  DJ-1 1p36 oxidative stress response AR Unknown 
PARK 8  LRRK2 12p11.2–q13.1 protein kinase AD + 
PARK 9  ATP13A2 1p36 lysosomal type 5 P-ATPase AR unknown 
PARK 10  unknown 1p32 unknown not clear unknown 
PARK 11  GIGYF2 2q36–q37 unknown AD unknown 
PARK 12  unknown Xq21–q25 unknown X linked unknown 
PARK 13   HTRA2/Omi 2p12 HtrA2/Omi stress-regulated 
serine endoprotease 
AD + 
PARK 14  PLA2G6 22q13.1  AR unknown 
PARK 15  FBXO7 22q11.2-qter  AR unknown 








1q32 (magnesium transporter) 
RAB7L1 (small GTP-binding 
protein playing an important 
role 
in regulating exo- and 
endocytotic pathways) 
NUCKS1 (nuclear protein 
containing several consensus 
phosphor - 
ylation sites for casein kinase II 
and cyclin-dependent kinases) 
 
not clear unknown 
PARK 17 
 
GAK/DGKQ chomosome 4p GAK (cyclin G-associated 
kinase, a cell cycle regulator) 
DGKQ (diacylglycerol kinase, 




not clear unknown 
PARK 18  HLA DRA 6p21.3 class II HLA-DR antigens that 








age 45.6 years), and slightly more rapid course towards death (9.2 years). The 
missense mutation G to A transition at position 209 in exon 4 of SNCA was 
identified as the disease locus resulted in replacement of alanine with threonine at 
position 53 (A53T) (Mihael H. Polymeropoulos et al., 1997). Kruger and co-
workers have sequenced SNCA gene in a German family with familial PD, and 
they found a strong link between G for C substitution at nucleotide 88 in exon 3 of 
the SNCA gene. This substitute replaces alanine for proline at amino acid 30 
(A30P) (Kruger et al., 1998). Patients with A30P mutation will have an onset of 
PD in their 50s, slightly later than the mean age in the A53T patients. In 2004, a 
third missense mutation in SNCA responsible for autosomal dominant PD and 
dementia was found in a Spanish family. A single base pair change at position 188 
from G to A resulting in the replacement of acidic polar glutamate residue with 
the basic polar lysine residue at position 46 (E46K) (Zarranz, et al., 2004). 
Moreover, H50Q (Appel-Cresswell, et al., 2013) and G51D (Kiely, et al., 2013) 
mutations have been reported recently. Duplications (Chartier-Harlin et al., 2004) 
and triplication of SNCA (triplication involving the 1.5 Mb region) (Singleton et 
al., 2003a) have also been reported, and it is believed that the severity of PD 
depends on the dosage of SNCA.  
1.4 Aggregation of α-Synuclein 
The fact that aggregated α-syn is the major component of inclusions in α-
synucleinopathy brains suggests that α-syn aggregation may be relevant to the 
pathogenesis of neurodegenerative disorders such as PD, DLB and MSA. The 
morphology of wild type (wt) or mutant α-syn fibrils generated in vitro is similar 
to that detected in LBs (Conway, Harper, & Lansbury, 1998; El-Agnaf, Jakes, 




Hashimoto, et al., 1998b; Serpell, Berriman, Jakes, Goedert, & Crowther, 2000), 
also implying a key role of α-syn aggregation in LB pathology.  
The fibrillation of α-syn is a nucleation-dependent polymerization process 
(S. J. Wood et al., 1999), with an initial lag phase, an exponential phase and an 
equilibrium phase (Fig. 1.2) 
Figure 1.2: Nucleation-dependent polymerization model of amyloid aggregation 
(Adapted from (Kumar & Walter, 2011). 
 
During the lag phase, the formation of nuclei takes place, followed by the 
exponential growth of the fibrils, which eventually reach a dynamic equilibrium 
state with protein in solution (Kaylor et al., 2005b; Serpell, et al., 2000; Uversky, 
M  Cooper, Bower, Li, & Fink, 2002). α-Syn fibrillation proceeds through 
oligomerisation i.e. the formation of multiple non-fibrillar oligomer intermediates 
termed protofibrils, which subsequently convert into mature amyloid fibrils 
(Conway, Harper, et al., 2000b; Kaylor, et al., 2005b). The secondary structure 




(El-Agnaf, Bodles, et al., 1998; Nath, Meuvis, Hendrix, Carl, & Engelborghs, 
2010). It was shown that spheroidal oligomers assume both an α-helical and to a 
lesser degree, a β-sheet conformation, the extent of which decreases and 
increases, respectively, as aggregation proceeds (Apetri, Maiti, Zagorski, Carey, 
& Anderson, 2006).  
It was suggested that fibrils develop from oligomers by further 
aggregation. The aggregation of monomeric α-syn into fibrils runs through 
different stages, where different intermediated forms protofibrils and insoluble 
fibrils, or remains as oligomers (Caughey & Lansbury, 2003; Hoyer et al., 2002; 
Munishkina, Phelan, Uversky, & Fink, 2003).  
Various forms of protofibrils have been observed including spherical 
(Conway et al., 2000a; Ding, Lee, Rochet, & Lansbury, 2002; D. P. Hong, Han, 
Fink, & Uversky, 2011) and spheroidal (Apetri, et al., 2006), short chain-like 
(Conway, Lee, et al., 2000a), circular such as ring-like, annular (doughnut-like) 
and pore-like (Conway, et al., 1998; Ding, et al., 2002; Lashuel et al., 2002; 
Lowe, Pountney, Jensen, Gai, & Voelcker, 2004), tubular (Lashuel, et al., 2002), 
granular (Bhak, Lee, Hahn, & Paik, 2009) and globular (Apetri, et al., 2006). As 
far as the structure of α-syn fibrils is concerned, it is characterised by the presence 
of a central core composed of cross -sheet structure, in which -strands extend 
perpendicularly to the fibril axis (M. Chen, Margittai, Chen, & Langen, 2007; 
Der-Sarkissian, Jao, Chen, & Langen, 2003; Heise et al., 2005). Each -strand 
comprises approximatelly the amino acid residues 31-110 of α-syn monomer (Del 
Mar, Greenbaum, Mayne, Englander, & Woods, 2005; Der-Sarkissian, et al., 




The fibrillation of α-syn can be affected by various factors in vitro. The 
factors modulating fibrillation in vivo may differ from those operating in vitro; yet 
dissecting the in vitro aggregation of α-syn can lead to the identification of 
aggregation inhibitors and a better understanding of the underlying mechanisms.  
 
1.5 Implications of α-syn oligomers and fibrils: 
Even the LBs contain mature fibrils of α-syn, there is evidence suggesting 
that oligomeric and protofibrilar forms of α-syn are the pathogenic species in PD 
(El-Agnaf, Walsh, & Allsop, 2003; Winner et al., 2011). A number of 
mechanisms have been suggested as a potential consequences of α-syn aggregates 
or oligomers as endoplasmic reticulum stress (Smith et al., 2005), oxidative stress 
(Esteves, Arduíno, Swerdlow, Oliveira, & Cardoso, 2009), modified chaperon 
activity (Chandra, Gallardo, Fernández-Chacón, Schlüter, & Südhof, 2005), 
dysfunction of the ubiquitin proteasome system (Stefanis, Larsen, Rideout, Sulzer, 
& Greene, 2001; Y. Tanaka et al., 2001), defects in the mitochondria and Golgi 
apparatus (Gosavi, Lee, Lee, Patel, & Lee, 2002; Hsu et al., 2000; Song, Shults, 
Sisk, Rockenstein, & Masliah, 2004), defective axonal transport (A. A. Cooper et 
al., 2006; Dalfó, Barrachina, Rosa, Ambrosio, & Ferrer, 2004; Outeiro & 
Lindquist, 2003), vesicle permeabilisation (Volles & Lansbury, 2002; Volles et 
al., 2001) and lysosomal defects (Cuervo, Stefanis, Fredenburg, Lansbury, & 
Sulzer, 2004; Stefanis, et al., 2001). It has been suggested that α-syn pathology 
spread gradually throughout the neuraxis as PD progress (Braak et al., 2003). As 
the underlying mechanism of disease progression in PD is still unknown, some 




pathology as the host neurons in PD brains (Kordower, Chu, Hauser, Olanow, & 
Freeman, 2008; J. Y. Li et al., 2008) which raises the possibility that α-syn is 
released from neurons to the extracellular space and is taken up by other cells. 
This is consistant with the fact that α-syn can be detected in cerebrospinal fluid 
and plasma in measurable quantities (El-Agnaf et al., 2006; Mollenhauer et al., 
2008). Also in vitro experiments have shown that fibrillar and oligomeric forms of 
α-syn can be taken up from extracellular space by neurons via the endocytic 
process (H. J. Lee et al., 2008). Other studies showed that recombinant α-syn 
oligomers are also taken up by cultured neurons and initiate cell death (Danzer et 
al., 2007; Danzer, Krebs, Wolff, Birk, & Hengerer, 2009). The prion-like 
mechanism, could represent a possible mechanism responsible for the host-to-
graft transfer of PD pathology as suggested by Desplats and colleagues (Desplats 
et al., 2009) when they demonstrated that α-syn can be directly transmitted from 
neuronal cells overexpressing α-syn to transplanted embryonic stem cells, in 
tissue culture and transgenic animals. The increasing amount of data makes the 
possibility that a specific conformation of α-syn is transmitted from host cells that 
promote the aggregation of α-syn and trigger toxicity in adjacent neurons. The 
impact of seeding on amyloid aggregation has also been established by a number 
of studies indicating that α-syn aggregation can be induced and accelerated by the 
addition of exogenous oligomers and fibrils in cultured cells (Danzer, et al., 2007, 
Volpicelli-Daley, et al., 2011, Nonaka, et al., 2010) and in mouse brains (Luk, et 
al., 2012, Masuda-Suzukake, et al., 2013), supporting the hypothesis that the 
aggregation of the native protein is directly seeded by exogenous aggregates. 
Overall, these studies support the notion that amyloid toxicity is mediated by a 




1.6 Mutations and truncations 
1.6.1 Mutations 
Five missense mutations in the α-syn gene (SNCA), namely A53T (Mihael 
H. Polymeropoulos, et al., 1997), A30P (Krüger, et al., 1998), E46K (Zarranz, et 
al., 2004), H50Q (Appel-Cresswell, et al., 2013) and G51D (Kiely, et al., 2013), 
have been linked to severe inherited forms of PD, while duplications and 
triplications of SNCA lead to autosomal dominant PD in a gene dosage-dependent 
fashion (Ibáñez, et al., 2004; Singleton, et al., 2003b). α-Syn mutations, A30P, 
A53T E46K and H50Q , have been reported to promote the aggregation of the 
protein (Chi, Armstrong, Jones, Eisenmesser, & Liu, 2014; Conway, Harper, et 
al., 2000b; El-Agnaf, Jakes, Curran, & Wallace, 1998; Giasson, et al., 1999a; 
Greenbaum et al., 2005; Khalaf et al., 2014; J. Li, Uversky, & Fink, 2001; Narhi 
et al., 1999). Whereas A30P mutation acts by stabilizing α-syn into oligomers 
(Conway, Harper, & Lansbury, 2000a), A53T and E46K increase the propensity 
of the protein to fibrillate (Conway, et al., 1998; Conway, Harper, et al., 2000b; 
Greenbaum, et al., 2005). It was recently reported that while E46K accelerates the 
oligomerization of α-syn it can seed fibril formation more efficiently compared to 
wt and A30P oligomers (Ono, Ikeda, Takasaki, & Yamada, 2011). Recently G51D 
mutation was found to significantly attenuate α-syn aggregation in vitro and to 
decrease the ability of α-syn to bind to lipid vesicles C-terminal to the site of 
mutation (Fares et al., 2014). 
1.6.2 C-terminal truncations 
Partially truncated α-syn has been detected in LBs from DLB brains 




MSA (Gai, Power, Blumbergs, Culvenor, & Jensen, 1999) and abnormal neurites 
of Alzheimer’s Disease without LBs (Lewis et al., 2010), suggesting that C-
terminal truncations may play a role in the aggregation of α-syn. A number of in 
vitro studies showed that C-terminally truncated human α-syn, such as 1-87, 1-
102, 1-110, 1-119 and 1-120 assembles at much faster rates compared to full 
length and mutant protein (Crowther, Jakes, Spillantini, & Goedert, 1998; Lewis, 
et al., 2010; C. W. Liu et al., 2005; Murray et al., 2003; Serpell, et al., 2000), and 
certain truncated fragments can also seed the aggregation of full length α-syn by 
nucleating full-length α-syn and then forming hybrid protofibrils, which develop 
into fibrils (J. Kim, Harada, Kobayashi, Kobayashi, & Sode, 2010; C. W. Liu, et 
al., 2005; Murray, et al., 2003). An in vivo study showed that the expression of 
truncated human α-syn (1–120) on synuclein null background mouse, lead to the 
formation of pathological inclusions in the substantia nigra and olfactory bulb and 
to a reduction in striatal dopamine levels (Tofaris et al., 2006).  
Although the pathological input of C-terminally truncated α-syn is still 
unclear, it is has been suggested that the negative charges of the C-terminal 
domain of α-syn exert counteracting influences on α-syn fibrillation at the initial 
steps of polymerization and seeding (Levitan et al., 2011; McLean & Hyman, 
2002; Murray, et al., 2003).  
1.7 Post-translational modifications 
Several post-translational modifications have been described for α-syn (Fig. 
1.3), including serine and tyrosine phosphorylation, ubiquitination, oxidation and 












Figure 1.3: α-syn post-translational modifications reported on the basis of 
their identification in LB. 
1.7.1 Phosphorylation 
α-Syn accumulate in the LBs of DLB, PD, MSA and LB variant of 
Alzheimer’s Disease has been shown to be phosphorylated at S129 (p-S129 α-
syn). Furthermore, α-syn phosphorylated at S87 (p-S87 α-syn) has been detected 
in the LBs of DLB, while the levels of p-S87 α-syn were shown to be increased in 
the brains of AD, DLB and MSA patients, as well as the brains of 
synucleinopathic mice (Paleologou et al., 2010). Taken together these findings 
advocate a pathological role for phosphorylated α-syn, and much effort has been 
put into elucidating the kinases that regulate α-syn phosphorylation and the effect 
of phosphorylation on α-syn aggregation and toxicity.  
Although, several kinases have been shown to phosphorylate α-syn in vitro, 
little is known about the kinases that phosphorylate α-syn in the brain. α-Syn can 
be constitutively phosphorylated in vitro and in cultured cells at S87 by casein 
kinase (CK) 1 (Okochi et al., 2000) and the dual specificity tyrosine-regulated 
kinase 1A (Dyrk1A) (E. J. Kim et al., 2006). Also, p-S87 α-syn colocalizes with 




phosphorylation is concerned, several enzymes have been demonstrated to 
phosphorylate α-syn at this position: (a) CK1 and CK2 phosphorylate α-syn at 
S129 both in vitro and in cells (G. Lee et al., 2004; Okochi, et al., 2000; Zabrocki 
et al., 2008). P-S129 α-syn colocalizes with CK2 in the brain of PD transgenic 
mice (Wakamatsu et al., 2007), while CK2 was the major kinase isolated from rat 
brain homogenates that phosphorylated human α-syn at S129 (Ishii et al., 2007). 
Also, up regulation of CK2 by Fe(II) was shown to enhance p-S129 α-syn levels 
in cells (M. Takahashi et al., 2007), whereas inhibition of CK2 in SH-SY5Y cells 
only resulted in 30% reduction of p-S129 α-syn, suggesting that CK2 is not the 
only enzyme that phosphorylates α-syn, at least in cells (Chau, Ching, Schapira, & 
Cooper, 2009).  (b) G protein-coupled receptor kinases (GRKs), such as GRK1, 
GRK2, GRK5 and GRK6 phosphorylate α-syn in vitro and in cells (Arawaka et 
al., 2006; Pronin, Morris, Surguchov, & Benovic, 2000). (c) Polo-like kinases 
(PLK 1-3) have also been reported to specifically phosphorylate α-syn at S129 in 
vitro and in cells (Inglis et al., 2009; Mbefo et al., 2010; Waxman & Giasson, 
2011), and PLK2 was shown to increase in AD and DLB brains (Mbefo, et al., 
2010). Furthermore, α-syn can also be phosphorylated at Y125 (L. Chen et al., 
2009; Ellis, Schwartzberg, Grider, Fink, & Nussbaum, 2001; Nakamura, 
Yamashita, Takahashi, & Nakamura, 2001; Negro, Brunati, Donella-Deana, 
Massimino, & Pinna, 2002; T. Takahashi et al., 2003) in vitro and in cultured cells 
by c-Src, Fyn and Syk kinases (Ellis, et al., 2001; Nakamura, et al., 2001), at 
Y133 and Y136 (Ellis, et al., 2001; Negro, et al., 2002). Y125 phosphorylation of 
α-syn was detected in a PD Drosophila model (L. Chen, et al., 2009). 
Given the lack of knowledge of the kinases that phosphorylate α-syn in the 




studies have employed phosphorylated mutant α-syn that either mimics 
phosphorylation by introducing a negative charge, i.e. replacement of serine in 
question by aspartic or glutamic acid, S→D or E, or renders phosphorylation 
impossible by introducing an amino acid that cannot be phosphorylated, i.e. 
alanine, S→A.  
Comparison of the aggregation propensity of wt, S129A and S129D α-syn 
indicated that phosphorylation at S129 has no effect on the fibrillation of α-syn as 
all proteins produced fibrils with the same morphology and abundance (L. Chen 
& Feany, 2005), while another study comparing wt, S129A and S129E α-syn 
showed that it was the mutant that mimics the lack of phosphorylation S129A that 
promotes fibrillation, rather than the S129E mutant, which had a fibrillation 
propensity similar to wt (Paleologou, et al., 2010). An in vitro phosphorylation of 
phosphomutant α-syn S87A and S87/S129A by CK1 or CK2 showed that 
phosphorylation at S129 inhibits fibrillation of α-syn (Paleologou, et al., 2010; 
Waxman & Giasson, 2008) in a dose dependent manner (Paleologou et al., 2008). 
However, in vitro phosphorylation of wt α-syn by CK2 promoted the fibrillation 
of α-syn (Fujiwara et al., 2002). S87 phosphorylation, in vitro aggregation studies 
demonstrated an inhibitory effect on fibrillation of α-syn (Paleologou, et al., 2010; 
Waxman & Giasson, 2008). 
Expression of S129D α-syn in SH-SY5Y cells induced higher levels of cell 
death than wt and S129A α-syn (Chau, et al., 2009), expression of which has been 
associated with decreased toxicity in SH-SY5Y cells (Sugeno et al., 2008). In a 
drosophila model, S129A was shown to have a higher aggregation propensity, but 
to be less toxic, while the phosphomimic S129D or GRK2-phosphorylated α-syn 




In transgenic mice, however, S129D was associated with increased α-syn 
deposition but decreased toxicity, unlike S129A α-syn, which promoted 
dopaminergic cell loss (Gorbatyuk et al., 2008). Studies on a rat model showed 
that S129A α-syn enhances α-syn toxicity and promotes the formation, proteinase 
K-resistant and β-sheet-rich aggregates (Azeredo da Silveira et al., 2009), whereas 
S129D α-syn is not toxic but leads to the formation of fewer, larger aggregates 
(Azeredo da Silveira, et al., 2009).  Subsequent studies on a transgenic rat model 
revealed that wt, S129A and S129D α-syn resulted in comparable degrees of 
toxicity and inclusion formation, and it was proposed that the differences seen in 
the results with rodents may be due to differences in the experimental design, such 
as an incubation or dose of the α-syn delivering virus (McFarland et al., 2009). 
Variations in the results may also lie in the fact that S129D/E α-syn do not 
reproduce all structural and fibrillation aspects of native phosphorylation; 
phosphorylated α-syn has an extended conformation and does not fibrillate, while 
S129D/E mutations have a localized effect and they possess a fibrillation property 
similar to wt α-syn (Paleologou, et al., 2008).  
Interestingly, Y125 phosphorylation was shown to reduce the soluble 
oligomeric forms of α-syn induced by expression of S129D or the GRK2-
phosphorylated α-syn in Drosophila (L. Chen, et al., 2009). 
There are also certain findings suggesting that α-syn aggregation is an event 
occurs prior to phosphorylation. Indeed, fibrillar α-syn has been shown to be a 
good substrate for CK1, CK2 and PLKs in vitro (Mbefo, et al., 2010; Paleologou, 
et al., 2010; Waxman & Giasson, 2008), while in transgenic Drosophila, the 
appearance of p-S129 α-syn followed the deposition of un phosphorylated α-syn 




the phosphorylation of soluble α-syn, but it did not promote its aggregation 
(Waxman & Giasson, 2011). 
Finally, given that phosphorylation is an important post-translational 
modification that regulates protein function and subcellular localization, as well as 
a wide range of cellular functions, it can not be excluded that α-syn 
phosphorylation may have a non-pathogenic function. A proteomics-based study 
identified phosphorylation-dependent α-syn interactions (McFarland, et al., 2009), 
while there is increasing evidence that phosphorylated α-syn has a nuclear 
localization (Mbefo, et al., 2010; Wakamatsu, et al., 2007). 
1.7.2  Oxidation and tyrosine crosslinking 
Oxidation is another post translational modification that has been shown to 
affect α-syn aggregation. Although all amino acids can be potentially oxidized, 
methionine is the most readily oxidized amino acid (reviewed by (Vogt, 1995). α-
Syn contains 4 Met residues (at positions 1, 5, 116 and 127), and it was recently 
reported that Met5 is more prone to oxidation compared to the others (W. Zhou et 
al., 2010). An in vitro oxidation of which (induced by hydrogen peroxide) has 
been shown to inhibit the aggregation of the protein at normal pH (Uversky et al., 
2002), and promotes the formation of stable, non-toxic oligomers (W. Zhou, et al., 
2010). The degree of inhibition of fibrillation of oxidized α-syn was shown to be 
proportional to the number of oxidized Met that the protein contains, i.e. the more 
oxidized Met the slower the fibril formation, suggesting that the oxidation of 
individual Met has a cumulative effect on α-syn fibrillation (Hokenson et al., 
2004). Interestingly, Met-oxidized α-syn could also inhibit the fibrillation of non-
oxidized α-syn in a concentration dependent fashion (Uversky, Yamin, et al., 




Furthermore, direct oxidation of α-syn by hydrogen peroxide in the presence 
of cytochrome c or hemin was shown to induce aggregation of the protein 
possibly due to Tyr cross-linking (Hashimoto, Takeda, Hsu, Takenouchi, & 
Masliah, 1999; Olteanu & Pielak, 2004; Souza, Giasson, Chen, Lee, & 
Ischiropoulos, 2000). When exposed to hydrogen peroxide, cytochrome c forms 
tyrosyl radicals, which in turn can be transferred to Tyr residues on other proteins 
(Deterding, Barr, Mason, & Tomer, 1998), such as α-syn, which contains Tyr 
residues at positions 39, 125, 132 and 135.  
1.7.3  Nitration 
Nitrated α-syn has been detected in brain tissues of patients with PD and 
other α-synucleinopathies (Dalfó, Martinez, Muntané, & Ferrer, 2006; Giasson et 
al., 2000). α-Syn can be nitrated at Tyr residues through the action of oxygen and 
nitric oxide, as well as their products, such as peroxynitrite. Whereas it was 
initially believed that the exposure of α-syn to nitrating agents, such as 
peroxynitrite, induces aggregation of the protein (Paxinou et al., 2001; Souza, et 
al., 2000), it was later shown that in vitro Tyr nitration of α-syn inhibits the 
fibrillogenesis of protein (Norris, Giasson, Ischiropoulos, & Lee, 2003; Yamin, 
Uversky, & Fink, 2003), and it has been suggested that it is the formation of 
covalent dityrosine crosslinks rather than nitration per se that promotes the 
fibrillogenesis of the protein under oxidative conditions (Norris, et al., 2003; 
Yamin, et al., 2003). 
1.7.4  Ubiquitination 
Ubiquitin (Ub) is a small protein, the role of which is closely related to the 




conjugated to the protein to be degraded by the proteasome via a three step 
process, which requires the action of certain enzymes, that are collectively known 
as E1, E2 and E3 ligases. α-Syn can be ubiquitinated, and so far three proteins, 
namely parkin, Siah-1 (seven in absentia homologue-1) and Siah-2, have been 
identified to play the role of E3 enzymes. Siah-2 ubiquitinates the unmodified 
form of α-syn (Liani et al., 2004), while Siah-1 ubiquitinates both the glycosylated 
(Franck et al., 2006) and the unmodified α-syn (J. T. Lee, Wheeler, Li, & Chin, 
2008). Whereas the lysines at positions 21, 23, 32 and 34 are liable for in vitro 
ubiquitination, only lysines 6, 10 and 12 are used for in vivo ubiquitination, which 
resembles the ubiquitination of filaments (Nonaka, Iwatsubo, & Hasegawa, 2005). 
In LBs, α-syn has been show to be mono-, bi- and tri-ubiquitinated (Tofaris, 
Razzaq, Ghetti, Lilley, & Spillantini, 2003), while in cells, UCHL1 ubiquitinates 
α-syn at Lys-63 (Y. Liu, Fallon, Lashuel, Liu, & Lansbury, 2002), linked 
ubiquitination of which is usually not associated with proteosomal degradation, 
but promotes LB formation (Lim et al., 2005; Lim, Dawson, & Dawson, 2006). 
Similarly, the Siah-1 mono- and di-ubiquitination of α-syn does not target the 
protein for degradation in HeLa cells, but instead it promotes α-syn insolubility 
and apoptotic cell death in HeLa and PC12 cells (J. T. Lee, et al., 2008). 
Interestingly, the Siah-1 mediated ubiquitination of α-syn was shown to be 
abolished by the A30P, but not the A53T mutation, possibly due to the inhibition 
of the ubiquitination of the lysines near alanine 30 (i.e.  K21, K23, K32 and K34) 





1.7.5  Glycosylation and glycation (non-enzymatic glycosylation) 
Glycosylation is a post-translational modification during which glycans, i.e. 
oligosaccharides or polysaccharides are enzymatically attached to proteins or 
other macromolecules. Glycosylation is a site-specific modification and the major 
sites of glycosylation in proteins are the Asn and Arg (N-glycosylation), and Ser, 
Tyr and Thr (O-glycosylation). Although O-glycosylated α-syn, αSp22, has been 
identified in normal human brain (Shimura et al., 2001), it is still unknown 
whether glycosylation affects the aggregation of the protein. Nevertheless, in LBs 
from PD patients, α-syn co-localises with Advanced Glycation Endproducts 
(AGEs), a heterogeneous group of molecules formed through glycation (also 
known as non-enzymatic glycosylation, which as the name implies is, unlike 
glycosylation, non enzymatic and occurs randomly) of proteins via the Maillard 
reaction (i.e. chemical reaction between amino acids and reducing sugars) and 
Schiff’s base formation (i.e. the formation of imine products from the reaction 
between amino acids and a reactive carbonyl group of reducing sugars) 
(Castellani, Smith, Richey, & Perry, 1996).  
In brain, glycation of proteins is attributed to sugars like glucose, fructose, 
and reactive dicarbonyls, such as methylglyoxal (MGO), glyoxal (GO) and 3-
deoxy glucosone (Negre-Salvayre, Salvayre, Augé, Pamplona, & Portero-Otín, 
2009). Dicarbonyl molecular species have also been implicated in the production 
of AGEs, which can modify prion proteins and Aβ (Williams, Weinberg, & 
Smith, 2011). Similarly, in vitro glycation of α-syn by D-ribose (ribosylation) 
induced the formation of molten globules, which were toxic to SH-SY5Y cells (L. 




1.7.6  SUMOylation 
SUMOylation is a reversible post-translational modification that covalently 
attaches small ubiquitin-like modifier (SUMO) polypeptides, which are similar to 
Ub, to lysines of proteins. The process is similar to ubiquitination, with the 
difference that SUMOylation does not mark proteins for degradation) (reviewed 
by (Dorval & Fraser, 2007). It is well documented that SUMOylation is 
implicated in the pathogenesis of several neurodegenerative diseases, including 
polyglutamine diseases (Ueda et al., 2002), neuronal intranuclear inclusion 
disease and MSA (Pountney et al., 2003), while a number of proteins involved in 
neurodegeneration e.g. amyloid precursor protein (reviewed by (Sarge & Park-
Sarge, 2011), huntingtin (Steffan et al., 2004), tau (Dorval & Fraser, 2006), DJ-1 
(Shinbo et al., 2006) also undergo SUMOylation. 
α-Syn has also been shown to be SUMOylated in cells co-expressing α-syn 
and SUMO proteins (SUMO 1-3) (Dorval & Fraser, 2006) and it was recently 
reported that SUMO1 co-localises with α-syn in LBs of PD and DLB brains (Y. 
M. Kim et al., 2011).  
1.2  Cross-linking and Tissue Tranglutaminase 
Transglutaminases (TG) constitute a family of Ca
2+
-dependent enzymes that 
catalyse the intermolecular and/or, more rarely, the intramolecular cross-linking 
of intracellular proteins by forming isopeptide bonds between lysines and 
glutamines (Folk & Chung, 1985; Konno et al., 2005). Tissue transglutaminase or 
transglutaminase 2, that possesses GTPase, ATPase and transamidating activities 
(Achyuthan & Greenberg, 1987), has been reported to play a role in a number of 
diseases, including neurodegenerative diseases (A. J. Cooper, Jeitner, & Blass, 




protein (G. J. Ho, Gregory, Smirnova, Zoubine, & Festoff, 1994), the NAC 
fragment of α-syn (Jensen, et al., 1995) and α-syn (Junn, Ronchetti, Quezado, 
Kim, & Mouradian, 2003) are all substrates of tTG in vitro and/or in vivo.   
1.8 α-Synuclein as a target for PD treatment 
Conventional treatment of PD can only treat the symptoms; therefore, it can 
only be beneficial if the disease is diagnosed at an early stage. Unfortunately, with 
the progression of the disease, the treatment can gradually lose its effectiveness, 
as it is believed that treatment fails to prevent the ongoing cell death of 
dopaminergic neurons in SN. As discussed above dopaminergic neurons death is 
believed to be due to the development of LBs, which is composed mainly of α-syn 
aggregates. α-Syn changes from random coil to -sheet conformation to form 
prefilbrillar oligomers and then transient protofibrils before maturing into amyloid 
fibrils and finally LBs (Park, Lasiene, Chou, Horner, & Pun, 2007). Several 
strategies have now focused on the prevention of α-syn aggregation and toxicity 
as a novel treatment strategy for PD (Amer, et al., 2006). As we learn more about 
the role of α-syn in PD, it becomes clear that preventing the aggregation or may 
be silencing SNCA can be a possible therapeutic strategy.   
1.9 Inhibiting α-synuclein aggregation and toxicity as a novel 
therapeutic approach for PD 
1.9.1 Small peptides 
El-Agnaf and colleagues were the first to design peptide inhibitors for α-syn 
aggregation and toxicity (Hosia et al., 2004). A peptide library was synthesized 
from overlapping 7-mer peptides spanning the whole α-syn sequence. By means 




identified (residues 69-72 of α-syn). This sequence was used as the basis for the 
design of various peptide inhibitors of α-syn aggregation and toxicity (El-Agnaf et 
al., 2004). Prompting a focus on developing peptidomimetics and identifying 
small molecule inhibitors for α-syn aggregation (Amer, et al., 2006), Hosia et al 
followed it up by designing several hairpin peptides and investigating their effect 
on amyloid formation including α-syn aggregation (Hosia, et al., 2004). A group 
of hairpin peptides showed to induce non amyloidogenic α-syn aggregates (non-
toxic) suggested an inhibitory effect (Hosia, et al., 2004).  
1.9.2 Dopamine and catecholamines 
Many studies of dopamine (DA), DA metabolites, DA analogous and 
catecholamine in general have shown an effect on α-syn aggregation. In a recent 
study, Lee et al showed that DA can promote the production and secretion of α-
syn oligomers (H. J. Lee et al., 2011). An increased formation of α-syn oligomers 
was found in the vesicles in the presence of DA. The oligomers were shown to be 
SDS resistant, non-fibrillar yet β-sheets-rich. Similar findings were seen with DA 
metabolites, where cell death is induced (Shaltiel-Karyo et al., 2010). However, it 
was shown that catechol o-metheltransferase inhibitors could prevent the toxicity 
of α-syn fibrils (Shaltiel-Karyo, et al., 2010). 
1.9.3 Heat shock proteins 
Heat shock proteins (HSP) are a class of functionally related proteins that 
act as molecular chaperones up-regulated by the cell under stress (Di Giovanni et 
al., 2010) . Hsp70 confers thermotolerance and protects against apoptosis, 
endotoxins, reactive oxygen species, radiations and ischemia (Norris, et al., 2003). 




Hsp70 and Hsp40 can bind and inhibit α-syn aggregation in vitro (Latawiec et al., 
2010). A recent study showed that Hsp104 can reduce the phosphorylated form of 
α-syn and the nigrostriatal dopaminergic loss in a PD animal model (Arawaka, 
Machiya, & Kato, 2010). More recently, a compound termed SNX-0723 (2-
fluoro-6-[(3S)-tetrahydrofuran-3-ylamino]-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-
tetrahydro-1H-indol-1-yl)benzamide) a Hsp90 inhibitor, significantly increased 
striatal dopamine content in rats, suggesting a positive neuromodulatory effect on 
striatal terminals (McFarland et al., 2014). Taken together all these findings 
regarding Hsp inhibitors also represents an exciting new therapeutic strategy for 
PD.  
1.9.4 Anti-Parkinsonian agents and other drugs 
One class of drugs that was identified to ameliorate α-syn fibril formation in 
PD was sirtuin inhibitors (SIRT2) (Grünblatt et al., 2004). It was shown that 
SIRT2 inhibitors rescue α-syn mediated toxicity in a drosophila model of PD 
(Auluck, Chan, Trojanowski, Lee, & Bonini, 2002). Li et al., demonstrated the 
inhibitory effect of the antibiotic rifampicin on α-syn fibrillation that 
disaggregated α-syn amyloid fibrils in a concentration-dependent manner (J. Li, 
Zhu, Rajamani, Uversky, & Fink, 2004). Furthermore, rifampicin was also shown 
to reduce α-syn deposition in a transgenic mouse model of MSA (Putcha et al., 
2010). Gangliosides (lipids that contain saccharides) have shown to interact with 
the helical structure of α-syn thus preventing its aggregation (Putcha, et al., 2010). 
Similar molecules like glycosphingolipids have been shown to behave as 
gangliosides, which indicate the structural importance of sialic acid and 
carbohydrate moieties in these molecules (Alcaín & Villalba, 2009). Selegiline is 




nucleation stage of the wild type and mutant forms of α-syn oligomers (Braga et 
al., 2011). Interestingly, selegiline is a monoamino oxidase B (MAO-B) inhibitor, 
which increases the dopamine levels. The combine effect of selegiline by 
inhibiting MAO-B and delaying the nucleation of α-syn aggregation seems to 
favour the formation of non-toxic aggregates of α-syn (J. Li, et al., 2004). 
1.9.5 Herbal and plant extracts 
Herbal and plant extracts have been used as remedies for thousands of years 
for a variety of diseases including neurodegenerative diseases such as PD. Recent 
work has highlighted a few herbal and plant extract as potential drug such as 
Anemopaegma mirandum (Catuaba), Fructus Psoraleae, Turmeric, Pueraria 
Thomsonii and Bacopa Monnieri. However, only few of these extracts have been 
investigated for their effect on α-syn aggregation and toxicity. 
Research showed that Baicalein (an herbal extract) has the two anti-
oligomeric and anti-amyloidogenic properties that make it a potential drug for PD 
(Frydman-Marom, Shaltiel-Karyo, Moshe, & Gazit, 2011). Moreover, entacapone 
and tolcapone were also shown to prevent α-syn oligomerization (Di Giovanni, et 
al., 2010). Poly-acromatic scaffolds (polyphenols, flavonoids and 
phthalocyanines) have also shown anti-amyloidogenic qualities, this quality can 
be enhanced by an addition of metals into the heterocycle centre (Lu et al., 2011). 
Studies screened natural polyphenols have shown that (−)-epigallocatechin-3-
gallate (EGCG) from green tea can also prevent α-syn aggregation. It was shown 
that EGCG could bind non-covalently to unfolded α-syn resulting in non-toxic 
SDS-stable oligomers. Thus, preventing the formation of the toxic amyloid fibrils. 
In vivo work has yet to determine and test its effectiveness in PD animal models, 




(Ehrnhoefer, 2006; Dagmar E. Ehrnhoefer et al., 2008; D. E. Ehrnhoefer et al., 
2008; Lamberto et al., 2011). 
1.10 Immunotherapy for neurodegenerative diseases 
Immunotherapy is considered the best disease-modifying treatment for 
neurodegenerative diseases. AD has been the focus of many immunotherapeutic 
studies, while less attention has been paid to PD and other neurodegenerative 
disorders. The reason for this difference is that the (Aβ) protein in AD is an 
extracellular molecule (Glenner & Wong, 1984) that circulates in the blood and is 
reading recognized by antibodies. In contrast, deposits of α-syn have been 
considered to be exclusively intracellular in nature (Spillantini, et al., 1997) . 
However, the recent discovery that toxic oligomeric versions of α-syn accumulate 
in the membrane and can be excreted to the extracellular environment (Desplats, 
et al., 2009; El-Agnaf, et al., 2006; Mollenhauer, et al., 2008) has provided a 
rationale for the development of immunotherapeutic approaches for PD, dementia 
with Lewy bodies, frontotemporal dementia, and other neurodegenerative 
disorders characterized by the abnormal accumulation of these proteins. Active 
immunization, passive immunization, and T cell-mediated cellular 
immunotherapeutic approaches have been developed targeting Aβ, α-syn and tau. 
1.10.1  α-Synuclein as immunotherapeutic target 
Several neurodegenerative diseases are characterized by the accumulation of 
misfolded proteins and different approaches using active or passive immunization 
are being explored as potential therapies. Recently, immunotherapy has been 
evaluated as an approach to treat α-syn pathology. Animals vaccinated with 




syn, showed fewer pathologic aggregates in the striatum versus control animals 
that received a mock vaccine. This shows that a protective vaccination strategy 
results in induction of regulatory T cells and activated microglia. This can induce 
immune tolerance against α-syn (Romero-Ramos, von Euler Chelpin, & Sanchez-
Guajardo, 2014). While antibodies against α-syn specifically target and aid in 
clearance of extracellular α-syn by microglia, thereby preventing their actions on 
neighbouring cells (Bae et al., 2012). It was reported that passive immunization 
with α-syn antibody reduced neuronal and glial accumulation of α-syn and 
ameliorated neurodegeneration and behavioral deficits associated with α-syn 
overexpression (Bae, et al., 2012). Targeting the C-terminal of α-syn with specific 
antibodies, found to attenuate synaptic and axonal pathology, reduced the 
accumulation of  C-terminal truncated α-syn in axon, and improved motor and 
memory deficit in mouse PD model (Games et al., 2014). When transgenic α-syn 
mice were treated with anti-human α-syn antibodies, an improvement in 
behavioural deficits as well as decreased accumulation of α-syn aggregates, was 
observed and in addition the antibodies appear to enhance the phagocytosis and 
autophagy of α-syn (Masliah et al., 2011). In another study by the same group 
(Masliah et al., 2005), the active immunization of transgenic α-syn mice with 
human α-syn lead to the production of relatively high-affinity antibodies and 
reduced the accumulation of aggregated human α-syn in neuronal bodies and 
synapses. It was also proposed that immunization was found to degrade α-syn via 
the lysosomal pathway (Masliah, et al., 2005). It is possible that antibodies may 
recognize abnormal α-syn accumulation in the neuronal surface or even secreted 




Using intracellular antibody fragments (intrabodies) is another 
immunotherapy approach that could potentially find application in the treatment 
of PD, that can recognize α-syn and alter its folding. For that, human single-chain 
antibody fragments (scFv) bind to oligomeric α-syn and block extracellular α-syn 
toxicity in human neuroblastoma cells (Emadi, Barkhordarian, Wang, Schulz, & 
Sierks, 2007; Emadi, Kasturirangan, Wang, Schulz, & Sierks, 2009). In a similar 
study,  intrabodies transfected into a cell line that overexpresses wild-type α-syn, 
stabilized detergent-soluble monomeric α-syn and inhibited the formation of 
detergent-insoluble high-molecular-weight α-syn species (C. Zhou, Emadi, Sierks, 
& Messer, 2004).  
1.11 Aim of project 
There are numerous studies suggesting a seminal role for -syn 
aggregation in neurodegenerative diseases. Although the molecular basis of α-syn 
toxicity has not been precisely elucidated, recent studies indicate that α-syn 
toxicity is mediated by a nucleation-dependent polymerization process. Screening 
small compounds that can block, slow down or reverse -syn aggregation and 
inhibit the seeded nucleation-dependent polymerization process, therefore, 
provides an attractive approach for targeting the progression of the PD and related 
disorders. The aim of the project was to elucidate the mechanism and structural 
basis of α-syn mediated toxicity, and to screen small compounds that are capable 
of inhibiting the aggregation and the mediated -syn cytotoxicity. The idea behind 
screening compounds extracted from Chinese medicinal herbs and plants (CMH), 
that have been used for the treatment of a wide range of diseases for over a 




In the first results chapter (Chapter 3) various aggregated α-syn preparations 
are prepared. The effect of these species on -syn mediated cytotoxicity and the 
addition of the monomeric wt or p-S129 α-syn effect on the mediated toxicity was 
investigated by cell viability assay (MTT), Thioflavin S (Th-S), congo red 
bunding assay (CR) and immunoblotting assays. In the second results chapter 
(Chapter 4) the effect of the phenolic compound, GA and its derivatives on -syn 
fibril formation and α-syn mediated toxicity is investigated. The methods used in 
this chapter include ELISA, Th-S assay, TEM, MTT, CR and NMR. In the third 
and fourth chapter of results (Chapter 5 and 6), CMH compounds were examined 
for their effect on -syn oligomerization and aggregation and mediated cell 







2 Chapter 2: Materials and Methods 
2.1 Suppliers 
Details of the suppliers for chemicals and equipment are summarized in  
Table 2.1. Name and location of Suppliers of Chemicals and Equipment 
Short Name Full name and Location 
Aldrich/Sigma Sigma-Aldrich Co. Ltd., Dorset, UK. 
BD Biosciencese 
Becton, Dickinson and Company, Franklin Lakes, 
USA. 
Invitrogen 
Invitrogen Corporation, 5791 Van Allen Way  
Carlsbad, CA 92008, USA 
New England Biolabs New England Biolabs, Ipswich, MA, USA 
Nunc 




Santa Cruz Biotechnology, Delaware Avenue, Santa 
Cruz, CA, U.S.A. 
Gilson 
Gilson, Inc.3000 Parmenter Street, Middleton, WI, 
USA. 
Sterilin Sterilin Limited, Aberbargoed, Bargoed, UK. 
Panreac Panreac. Ltd. Barcelona, Spain. 
Amersham GE Healthcare ,Uppsala Sweden 
Bio-Rad 
Bio-Rad Laboratories, Alfred Nobel Drive 
Hercules, CA, USA. 
Pierce 
Thermo Scientific Life Science Research Products, 
Rockford, IL, USA. 
Hyclone 
Thermo Scientific Life Science Research Products, 
Rockford, IL, USA 






2.2 Materials and equipment 
Table 2.2. Summary of Materials and Suppliers. 
Materials/Equipment Company 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Dulbsecco’s Modified Eagle Medium Invitrogen 
Tissue Culture Flask 75CM X75CM Nunc 
Ethanol Panreac 
Ethidium bromide Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Fetal bovine serum (heat activated) Invitrogen 
Hydrogen chloride (HCl) Sigma-Aldrich 
IPTG Sigma 
Methanol Panreac 




Nitrocellulose membrane filter paper sandwich, 
0.45m pore size 
Invitrogen 
OPTI-MEM Medium Invitrogen 
Penicilin-Streptomycin solution (100 ml 
solution/ 10,000 units penicillin, 10,000 units 
streptomycin) 
Invitrogen 
Nitrocellulose membranes Whattman 
Phosphate buffered saline (PBS) tablets Sigma-Aldrich 
Sodium Azide (NaN3) Sigma-Aldrich 
Sodium dodecylsulphate (SDS) Sigma-Aldrich 
Tris Sigma-Aldrich 
NP-40 Sigma 
Triton X-100 Sigma-Aldrich 
BCA Protein assay reagent kit Pierce 
Cell dissociation solution, non-enzymatic Sigma-Aldrich 




Thioflavine T Sigma 
Thioflavin S Sigma 
SuperSignal ELISA Femto Maximum 
Sensitivity Substrate 
Thermo Scientific 
Microcentrifuge tube 1.5 ml Rose Scientic 
Tissue Culture Plates 96 Well Nunc 
Agarose Ultra Pure Electrophoesis Grade Invitrogen 
Bovine Serum Albumin Sigma-Aldrich 
TEMED Sigma 
Ammonium persulphate Bio-Rad 
Protein MW marker Invitrogen 
Loading buffer Sigma-Aldrich 
Glutathion sepharose beads 4B slurry Amersham 
Thrombin Sigma 
Tissue Culture Flask 25 cm Nunc 
Tissue Culture Flask 75 cm   Nunc 
SuperSignal West Pico Substrate Thermo Scientific 
SuperSignal West Femto Substrate Thermo Scientific 
Paraformaldehyde Sigma-Aldrich 
Geneticin Sigma-Aldrich 
FL-140 rabbit polyclonal antibody Santa Cruz 
211 mouse monoclonal antibody Santa Cruz 
HRP-conjugated goat anti-rabbit DAKO 
Protease inhibitor Pierce 
HRP-conjugated goat anti-mouse DAKO 
Uranyl acetate Agar 
Sulfo-NHS-LC-Biotin   Pierce 
Zeba desalting columns Pierce 





2.3 Cell lines 
Table 2.3. List of Cell lines used in this study 





Dulbecco’s MEM/Nutrient Mix F-12 (1:1) 







Dulbecco’s MEM/High Glucose containing 10% 
fetal bovine serum, 1% penicillin-streptomycin 





Dulbecco’s MEM/Nutrient Mix F-12 (1:1) 
containing 15% fetal bovine serum,  1% 
penicillin-streptomycin, and supplemented with 
1% non-essential MEM amino acid supplement 






Dulbecco’s MEM/Nutrient Mix F-12 (1:1) 
containing 15% fetal bovine serum,  1% 
penicillin-streptomycin, and supplemented with 
1% non-essential MEM amino acid supplement 




Table 2.4. List of compounds tested in this study as inhibitors of α-syn 
aggregation and toxicity. 
Compound Name M.W 
CMC1 Salvianolic acid B 718 
CMC2 Ginsenoside Rg1 800 
CMC3 Ginsenoside Rg3 785 
CMC4 Ginsenoside Rb1 1109 
CMC5 AmmoniµM Glycyrrhizinate 840 
CMC6 Puerarin 416.4 
CMC7 Sinomenine 329.4 
CMC8 Paeoniflorin 480.45 
CMC9 Gamma-schisandrin 400.46 
CMC10 Dihydromyricetin 320 
CMC11 Magnolol 266.32 
CMC12 Honokiol 266.34 
CMC13 Geniposide 388.37 
CMC14 Bilobalide 326.3 




CMC16 Tetrahydropalmatine 355.42 
CMC17 Protopine 353.37 
CMC18 Sipeimine 429.64 
CMC19 Synephrine 167.21 
CMC20 Peinine 429.64 
CMC21 Rhynchophylline 384.47 
CMC22 Isorhynchophylline 384.47 
CMC23 Berberine 336.1 
CMC24 Gallic acid 170.12 
CMC25 Praeruptorin 386.4 
CMC26 Icariin 677.66 
CMC27 Schisandrol B 416.464 
CMC28 (+)-Tetrandrine 622.76 
CMC29 Neohesperidin 610.56 
PA1 3,4,5-trihydroxybenzoic acid 170.12 
PA2 2,4,6-trihydroxybenzoic acid 188.13 
PA3 2,3-dihydroxybenzoic acid 154.12 
PA4 2,4-dihydroxybenzoic acid 154.12 
PA5 2,5-dihydroxybenzoic acid 154.12 
PA6 2,6-dihydroxybenzoic acid 154.12 
PA7 3,4-dihydroxybenzoic acid 154.12 
PA8 3,5-dihydroxybenzoic acid 154.12 
PA9 2-hydroxybenzoic acid  138.12 
PA10 3-Hydroxybenzoic acid 138.12 
PA11 4-Hydroxybenzoic acid 138.12 
PA12 Benzoic acid 122.12 
PA13 4-methoxybenzoic acid 212.20 
PA14 3,4,5-trimethoxybenzoic acid 152.15 
PA15 3,4,5-trifluorobenzoic acid 176.09 
 
2.5 Solutions and buffers 
2.5.1 Phosphate Buffered Saline (PBS), pH 7.4 
One PBS tablet was dissolved in 200 ml d.H2O. The buffer was filtered 
through a 0.2 m filter and stored at 4C.  
2.5.2 Phosphate Buffered Saline with 0.05% Tween-20 (PBST) 





2.5.3 Blocking buffer for western blotting 
5% of dried skimmed milk dissolved in PBST. 
2.5.4 Stacking gel buffer 
0.5M Tris-HCL: 6g of Tris-base were dissolved in 75ml d.H2O and the pH 
was adjusted to 6.8. The volume was then made up to 100ml with d.H2O. 
2.5.5 30% acrylamide 
29.2g acrylamide and 0.8g of bis-acrylamide was dissolved in 100ml of 
d.H2O. 
2.5.6 20% sodium dodecyl sulfate (SDS) 
20g lauryl sodium dodecyl sulphate was dissolved in 100ml d.H2O. 
2.5.7 10% ammonium persulfate (APS) 
0.1g APS was dissolved in 1 ml of d.H2O. 
2.5.8 Transfer buffer 
3g of Tris-base and 14.4g Glycine were dissolved in 800ml d.H2O to which 
200ml of methanol was added. 
2.5.9 Ethlenediamin Tetra Acetic acid (EDTA) 
93.05g EDTA disodium salt was dissolved in 400 ml d.H2O and pH was 





2.5.10 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
solution 
60 g of MTT was dissolved in 10ml of PBS. 
2.5.11 Lysis solution for MTT assay 
20% (v/v) SDS dissolved in warm water containing 50% (v/v) 
dimethylformamide. The pH was then adjusted to 4.7 using a solution of 80% 
acetic acid and 2.5% 1 M HCI. 
2.5.11 Column washing buffer  
50mM Tris-HCL, 150mM NaCl, 10mM EDTA, 1% Triton X-100, the pH 
adjusted to 8.0 
2.5.12 Thioflavin-T solution 
20M Th-T in PBS 
2.5.13 Thioflavin-S solution 
20M Th-T in PBS 
2.5.14 SDS-PAGE sample loading buffer  
250 mM TrisHCl pH6.8, 10% SDS, 30% Glycerol, 5% β-mercapitalethanol, 






3 Chapter 3: Alpha-synuclein neurotoxicity is mediated 
by ongoing seeded polymerization process and is 
inhibited by α-syn S129 phosphorylation. 
3.1 Introduction 
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder, the 
clinical features of which include bradykinesia, rigidity, resting tremor and 
postural instability (Dunnett & Björklund, 1999). These motor symptoms are 
linked to the degeneration of the dopaminergic neurons in an area of the brain 
known as substantia nigra, which appears to be selectively affected in PD (Dauer 
& Przedborski, 2003; Fearnley & Lees, 1991). Similarly to several other 
neurodegenerative diseases, including Alzheimer’s disease (AD) and Prion 
diseases. PD is referred to as a proteinopathy indicating that the disease is 
associated with the accumulation and deposition of a misfolded protein (Chiti & 
Dobson, 2006; Forman, Trojanowski, & Lee, 2004; Ross & Poirier, 2004). 
Indeed, the neuropathological hallmarks of PD are neuronal inclusions either in 
neuronal perikarya or in cell processes, known as Lewy bodies (LBs) and Lewy 
neurites (LNs), respectively (Dickson, 2012), the main component of which is 
fibrillar α-synuclein (α-syn) (Arai et al., 1999; V. M. Lee & Trojanowski, 2006; 
Spillantini, et al., 1997).  
α-Syn is a small, heat-resistant, acidic protein composed of 140 amino acid 
residues (Jakes, et al., 1994), expressed predominantly in certain regions of the 
brain, such as neocortex, hippocampus, olfactory bulb, striatum, thalamus, and 
cerebellum (Iwai et al., 1995). α-Syn can be detected in great abundance at 




Rueter, Trojanowski, & Lee, 2000) and is found in both soluble and membrane-
associated fractions of the brain (Iwai, et al., 1995). In terms of structure, 
monomeric α-syn is soluble, possessing an extended structure of random coils 
(Eliezer, et al., 2001b). However, this protein is characterized by the intrinsic 
propensity to aggregate, forming fibrils both in vitro (Conway, Harper, et al., 
2000b; El-Agnaf, Jakes, Curran, & Wallace, 1998; Hashimoto, et al., 1998b) and 
in vivo (Spillantini, et al., 1997).  
Although the precise mechanism of α-syn aggregation in the brain remains 
to be elucidated, in vitro studies have shown that α-syn fibrillation is a nucleation-
dependent process (S. J. Wood, et al., 1999), which proceeds through a nucleation 
(lag-phase), an elongation (growth-phase) and a steady-state phase (Conway, Lee, 
et al., 2000a; S. J. Wood, et al., 1999). In agreement with this nucleated assembly 
model of fibrillation, it has been shown that the addition of exogenous, preformed 
nuclei, referred to as ‘seeds’, results in the reduction of the lag phase and the 
immediate aggregation of α-syn (Conway, Lee, et al., 2000a; S. J. Wood, et al., 
1999) in a dose dependent manner (S. J. Wood, et al., 1999). Similar results have 
also been reported for -amyloid (A), which is implicated in the pathogenesis of 
AD. More specifically, it has been shown that the absence of the pre-aggregated 
seeds increases the lag time needed for the formation of Aβ fibrils (Jarrett & 
Lansbury, 1993), while seeding of monomeric Aβ aggregation with fibrillar Aβ 
induces neuronal cell death (Wogulis et al., 2005). Furthermore, it has been 
reported that the toxicity of Aβ42, is not linked to specific prefibrillar 
aggregate(s), but to the ability of these species to grow and form fibrils which can 
be achieved by the presence of Aβ42 monomers (Jan et al., 2011). The impact of 




indicating that α-syn aggregation can be induced and accelerated by the addition 
of exogenous oligomers and fibrils both in cultured cells (Danzer, et al., 2007; 
Nonaka, Watanabe, Iwatsubo, & Hasegawa, 2010; Volpicelli-Daley et al., 2011) 
and in mouse brains (Luk et al., 2012; Masuda-Suzukake et al., 2013), supporting 
the hypothesis that the aggregation of the native protein is directly seeded by 
exogenous aggregates. Overall, these studies support the notion that amyloid 
toxicity is mediated by a nucleation-dependent polymerization process. 
Over the years numerous factors have emerged as potent modulators of α-
syn aggregation in vitro and/or in vivo, with α-syn phosphorylation at S129 being 
the most controversial. Given that the α-syn deposited in the LBs of many α-
synucleinopathies is phosphorylated at S129 and that this finding is also 
recapitulated in many animal models (reviewed by (Paleologou & El-Agnaf, 
2012), it can be argued that this post-translational modification of α-syn has a 
pathological role. However, despite the systematic effort put into elucidating the 
impact of phosphorylation on α-syn aggregation and toxicity, it remains unclear 
whether α-syn phosphorylation promotes or inhibits the aggregation and toxicity 
of the protein, as the results of these studies are rather contradictory and 
inconclusive. Indeed, while there are many studies indicating that phosphorylation 
at S129 (either by employing certain kinases and/or the phosphorylation mimics 
S129D/E and the non-phosphorylatable mutant S129A) promotes α-syn 
aggregation and inclusion formation (Arawaka, et al., 2006; Fujiwara, et al., 2002; 
Gorbatyuk, et al., 2008; Kragh et al., 2009; M. Takahashi, et al., 2007; B. Wu et 
al., 2011; Zabrocki, et al., 2008). There are equally as many studies showing that 
phosphorylation at S129 inhibits α-syn accumulation (Oueslati, Schneider, 




& Giasson, 2008), with the phosphorylation-blocking S129A α-syn actually being 
more prone to aggregation and inclusion formation (Azeredo da Silveira, et al., 
2009; L. Chen, et al., 2009; Gonçalves & Outeiro, 2013; Paleologou, et al., 2008; 
Sancenon et al., 2012; Tenreiro et al., 2014). There are also reports indicating that 
phosphorylation either has no effect on inclusion formation (L. Chen, et al., 2009; 
Schreurs et al., 2014) or that aggregation of α-syn is independent of 
phosphorylation (Basso et al., 2013; Waxman & Giasson, 2011). As far as the p-
S129 α-syn-related toxicity is concerned, the results of the various studies are 
equally contradictory and inconclusive. Whereas studies on yeast, oligodendrial 
cells and a drosophila model of PD have show that α-syn phosphorylated at S129 
(p-S129 α-syn) by various kinases (casein kinase 1 (CK1), CK1, Polo-like kinases 
(PLKs), G-protein-coupled kinases (GRKs)) correlates with α-syn toxicity (L. 
Chen, et al., 2009; Kragh, et al., 2009; Zabrocki, et al., 2008), studies employing 
the phosphomutants S129D and S129A are particularly contradictory. In studies, 
S129D α-syn appears to be toxic (Chau, et al., 2009), while there are also reports 
supporting that the phosphomimic S129D α-syn plays a rather protective role 
(Gorbatyuk, et al., 2008; Kuwahara, Tonegawa, Ito, Mitani, & Iwatsubo, 2012; B. 
Wu, et al., 2011) or has no effect on the toxicity of the protein (Azeredo da 
Silveira, et al., 2009; Fischer et al., 2009). Similarly, blocking of α-syn 
phosphorylation at S129 by employing the mutant S129A α-syn has been shown 
to be toxic by some studies (Azeredo da Silveira, et al., 2009; Gorbatyuk, et al., 
2008; Kuwahara, et al., 2012; Sancenon, et al., 2012; Tenreiro, et al., 2014) and 
protective (L. Chen, et al., 2009; Kragh, et al., 2009) or without any effect (Chau, 




The discrepancies observed by the aforementioned studies may be explained 
by the fact that the kinases phosphorylating α-syn in the brain remain unknown, 
and by the findings that phosphomimics do not recapitulate all aspects of 
phosphorylation (Paleologou, et al., 2008) and that α-syn phosphorylation at S129 
may occur after the accumulation and deposition of fibrillar α-syn, given that 
fibrillar α-syn has been shown to be a good substrate for many kinases (Mbefo, et 
al., 2010; Paleologou, et al., 2010; Waxman & Giasson, 2008, 2011). However, 
there is an immediate need to investigate further the correlation between the 
aggregation and toxicity of α-syn and the phosphorylation at S129, especially in 
the light of the recent findings supporting the idea that α-syn mediated toxicity is 





3.2 Experimental procedure 
3.2.1 Expression and purification of recombinant human α-syn.  
A GST-α-syn fusion construct in the pGEX-4T1 vector (kindly provided by 
Dr. Hyangshuk Rhim of the Catholic University College of Medicine, Seoul, 
Korea) was inserted into BL21 E.coli bacteria by heat shock. The transformed 
bacteria were grown in an LB medium supplemented with 0.1 mg/ml ampicillin at 
37°C in an orbital shaker to an OD600 of 0.5. Expression was then induced by 
adding 0.5 mM IPTG (Sigma-Aldrich Chemie GmbH, Germany), and the culture 
was incubated for 2 hours at 37°C. The cells were harvested by a 15 minute 
centrifugation at 9000 x g, and the resulting pellet was resuspended in a lysis 
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% 
DTT) and shaken for 10 mins at room temperature. To improve the efficiency of 
cell lysis, the resuspended pellet was subjected to 6 freeze-thaw cycles in liquid 
nitrogen and a 37°C water bath. The lysate was then centrifuged at 27,000 x g for 
15 mins, and the resulting supernatant was retained for purification by affinity 
chromatography using sepharose beads conjugated to glutathione, which has a 
high affinity for the GST tag. The cell lysate was mixed with glutathione 
sepharose beads and incubated for 1 hour at room temperature, followed by 
centrifugation at 500 x g at 4°C for 8 mins. The beads were then washed twice 
with wash buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, 1% Triton X-
100, pH 8.0), twice with 50 mM Tris-HCl, pH 8.0, and once with 1X PBS. The 
washed beads were resuspended in 5 ml of 1X PBS, and the GST tag was cleaved 
with human plasma thrombin (1 unit/µl), (Sigma-Aldrich, USA). The thrombin-
catalyzed cleavage reaction was incubated overnight at room temperature with 




mixture was then centrifuged for 8 mins at 500 x g at 4°C, and benzamidine 
sepharose beads (Amersham, Sweden) were used to ‘fish out’ thrombin. Pure α-
syn was collected by centrifugation at 500 x g for 8 mins at 4°C. The α-syn 
concentration was estimated using a BCA assay (Pierce Biotechnology, Rockford, 
IL).  
3.2.2 α-Syn purification and characterization.  
Crude α-syn protein after GST tag cleavage was purified using reversed 
phase HPLC. The columns used were an analytical Phenomenex Jupiter C4 (250 3 
4.6 mm) and a preparative Phenomenex Jupiter C4 (250 3 10 mm). α-Syn was 
loaded into the column and eluted with a linear gradient (30-80%) of acetonitrile 
(70% acetonitrile, 0.1% trifluoroacetic acid,) versus water (0.1% trifluoracetic 
acid) for 38 mins at a flow rate of 0.5 ml/minute. (Scheme 3.1). The homogeneity 
of α-syn protein was ascertained by using analytical HPLC and SDS-page 
(Scheme 3.1 A-C). 
 
Scheme 3.1. HPLC analysis and characterization of crude α-syn. A. HPLC 
analysis was done using phenomenex Jupiter C4 (250 3 4.6 mm) column, with a 
gradient of 30%-80% solvent B in solvent A at 0.5 ml/minute over 38 mins. B. 
Coomassie blue staining of 15% SDS-PAGE for HPLC purified recombinant α-







3.2.3 Aggregation of α-syn in vitro. 
The purity of the α-syn employed in this assay was >95% as estimated by 
SDS gels  The α-syn samples placed in 1.5 ml sterile polypropylene tubes, topped 
with drops of mineral oil to prevent sample evaporation, and sealed with parafilm 
were incubated at 37°C for several days with continuous shaking at 800 rpm in a 
Thermomixer (Eppendorf). The samples were collected at certain points, while the 
aggregation of α-syn was monitored by the Thioflavin assay. The samples were 
stored at -80°C until required for further analyses.  
3.2.4 Seeded polymerization assay.  
The aggregation of monomeric wt or p-S129 α-syn with or without seeding 
was performed as described elsewhere (Di Giovanni, et al., 2010). The wt or p-
S129 seeds were prepared by fragmenting the mature -syn fibrils by sonication 
resulting in short fibrils. Monomeric α-syn at a concentration of 100 μM was 
seeded with different concentrations of seeds and incubated at 37°C with 
continuous shaking. The fibrillization was monitored by the Th-S binding assay as 
described above. 
3.2.5 Thioflavin-S (Th-S) assay.  
α-Syn fibril formation was monitored by Th-S binding assay. Th-S is a 
fluorescent dye that interacts with fibrils containing a β-sheet structure. For this 
assay, a total of 10 µl of the sample was diluted in 40 µl of Th-S in PBS (20 µM 
final concentration) and the mixture was dispensed in a 384-well, untreated black 
plate (Nunc, Denmark). The fluorescence was measured by a microplate reader 




at 450 and 510 nm, respectively. To allow for background fluorescence, the 
fluorescence intensity of a blank PBS sample was subtracted from all readings. 
3.2.6 Preparation of α-syn crude seeds, oligomers and fibrils.  
100 µM of monomeric α-syn was aggregated as described above (see 
Aggregation of α-syn  in vitro) either for 2 or 7 days, leading to the α-syn  
samples referred to herein as ‘crude oligomers’ and ‘crude fibrils’, respectively. 
For the preparation of crude seeds, the crude fibrils were fragmented by 
ultrasonication while kept on ice using a sonic ruptor 250, equipped with a fine tip 
(5second pulses, output of 40 watts for 5 mins).  
3.2.7 Preparation of α-syn pure fibrils and pure seeds.  
100 µM of monomeric α-syn was aggregated as described above for 7 days. 
To prepare pure fibrils, the crude α-syn fibril sample was spun at 10,000 xg for 10 
mins at 4°C in a refrigerated microfuge (Eppendorf). The supernatant was then 
discarded, and the pellet was washed twice with ultra-pure water, before 
resuspending in 1x PBS. For the preparation of pure seeds, the pure fibrils were 
fragmented by ultrasonication while kept on ice using a sonic ruptor 250, 
equipped with a fine tip (5 second pulses, output of 40 watts for 5 mins). For the 
estimation of α-syn concentration of the fibrils and seeds, the samples were 
denatured by 6M Guanidine-HCl and BCA assay which were used according to 
manufacturer’s instructions.  
3.2.8  Transmission electron microscopy (TEM). 
Electron images were produced from aged α-syn either alone or in the 
presence of various percentages of p-S129 α-syn. The samples (5 µL) were 




briefly with 0.5% glutaraldehyde (5 µl), negatively stained with 2% uranyl acetate 
(Sigma–Aldrich, USA) and examined in a Philips CM-10 TEM electron 
microscope. 
3.2.9 Immunoblotting. 
Samples of -syn (20 ng) incubated alone or with various percentages of p-
S129  were mixed with 1X sample buffer (250 mM Tris-HCl, pH 6.8, 30% 
glycerol, 0.02% bromophenol blue) and separated in 1 mm 15% SDS-PAGE gels. 
The separated proteins were transferred to 0.45 μm nitrocellulose membranes 
(Whatman Gmbh-Germany) at 90 V for 80 mins. The membranes were boiled for 
5 min in PBS and then blocked for 1 hour with 5% non-fat milk prepared in PBS-
Tween-20 (0.05%; PBST). The membranes were incubated overnight at 4°C with 
the primary mouse monoclonal anti--syn (211) antibody, which recognizes 
human -syn (121-125) (Santa Cruz Biotechnology, USA), at a dilution of 
1:1000. The membranes were then washed several times with PBST, followed by 
incubation with an HRP-conjugated goat anti-mouse antibody (Dako Ltd., Ely, 
UK) at a dilution of 1:70,000 for 60 mins at room temperature with gentle 
agitation. The membranes were then extensively washed for 25 mins, and 
immunoreactive bands were visualized with the Super Signal West Femto 
Chemiluminescent Substrate Kit (Pierce, Rockford, USA) according to the 
manufacturer’s instructions. The amount of monomeric -syn in the samples of -
syn aged alone or with various percentages of p-S129 α-syn was evaluated by 
densitometric analysis using ImageJ software and by comparing the monomeric 
bands of all samples with the band generated by a fresh α-syn sample containing 





3.2.10 Tissue culture of wt BE(2)-M-17  human neuroblastoma cells.  
wt BE(2)-M-17 human neuroblastoma cells were routinely cultured in 
Dulbecco’s MEM/Nutrient Mix F-12 (1:1) (Hyclone) containing 10% fetal bovine 
serum (Hyclone) and 1% penicillin-streptomycin (P/S; 100 U/ml penicillin, 100 
mg/ml streptomycin-Sigma). The cells overexpressing wt α-syn were cultured in 
Dulbecco’s MEM (Hyclone) containing 10% fetal bovine serum (Hyclone) and 
1% penicillin-streptomycin. To maintain the cells overexpressing α-syn, 250 
µg/ml of G418 antibiotic was added to the culturing media for plasmid selection. 
The cells were maintained at 37°C in a humidified incubator with 5% CO2/95% 
air. 
3.2.11 Tissue culture of BE(2)-M-17  human neuroblastoma cells 
overexpressing wt-α-syn.  
BE(2)-M-17 human neuroblastoma cells overexpressing wt-α-syn were 
routinely cultured in Dulbecco’s MEM/High Glucose (Hyclone) containing 10% 
fetal bovine serum (Hyclone), 1% penicillin-streptomycin (P/S; 100 U/ml 
penicillin, 100 mg/ml streptomycin-Sigma) and 250 µg/ml of G418 antibiotic was 
added to the culturing media. The cells were maintained at 37°C in a humidified 
incubator with 5% CO2/95% air. 
3.2.12 Tissue culture of SHSY-5Y human dopaminergic neuroblastoma cells.  
SHSY-5Y human dopaminergic neuroblastoma wt or overexpressing wt-α-
syn cells were routinely cultured in Dulbecco’s MEM/Nutrient Mix F-12 (1:1) 
(Hyclone) containing 15% fetal bovine serum (Hyclone), 1% penicillin-
streptomycin (P/S; 100 U/ml penicillin, 100 mg/ml streptomycin-Sigma), and 




mM freshly prepared glutamine. The cells were maintained at 37°C in a 
humidified incubator with 5% CO2/95% air. 
3.2.13 Measurement of cell viability.  
The MTT assay was employed for the assessment of the cytotoxic effect of 
the different α-syn species, cells suspended in a culturing medium were plated at a 
density of 15,000 cells (100 µl /well) in a 96-well plate. After 24 hours, the 
medium was replaced with 100 μl of MEM-RS (Hyclone) serum-free medium 
containing the different solutions of α-syn species diluted in serum-free media to 
obtain the desired concentrations. The cells were then allowed to grow for 24 or 
48 hours. A total of 20 μl of MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Sigma-Aldrich, USA) (6 mg/ml) in PBS was 
dispensed into each well, and the plate was incubated at 37°C for 4.5 hours. The 
MTT-containing medium was carefully removed, and replaced with 100 μl/well of 
lysis buffer (15% SDS, 50% N,N-dimethylformamide, pH 4.7). The lysis buffer 
was incubated at 37°C overnight. The absorbance values at 590 nm were 
measured in a microplate reader (Perkin Elmer). For the experiments assessing the 
toxic effect of seeded polymerization, the cells were prepared as mentioned 
above. The cells were then incubated at 37°C in 5% CO2 for 1 hour and 
monomeric α-syn was then added to the cells treated with a different species, then  
the cells were incubated again for another 48 hours.  
3.2.14 In vitro phosphorylation of α-syn. 
Monomeric α-syn (wt) was phosphorylated by PLK2 (Invitrogen) at a 
concentration of 1.44 mg/ml (100 µM). The phosphorylation reaction was carried 




HEPES, 10 mM MgCl2, 2 mM DDT, pH 7.4), and 1 µg of PLK2 at 30 °C for 24 
hours without shaking. The reaction volume was 100 µl. 
3.1.1. Wt α-syn gene SNCA small interfering RNA (siRNA) silencing. 
The pre-designed siRNA sequence 5’-AGAGGGUGUUCUCUAUGUAtt-3’ 
targeting human wt α-syn, as well as non-targeting scrambled siRNA were 
purchased from Ambion (Life technologies). BE(2)-M-17  human neuroblastoma 
cells grown in MEM serum-free media were plated either in 6-well or 96-well 
plates at a density of 3x10
5
 or 4,000cells /well respectively. The next day, the 
cells in the 6-well plates were transfected with a 200 pmol siRNA/well for 
immunoblotting, while the cells in the 96-well plates were transfected with 8 pmol 
siRNA/well for use in MTT assay. The siRNA was transfected using a 
transfection reagent (Santa Cruz Biotechnology, USA). After 6 hours of 
incubation, 1 ml of a normal growth medium containing 2 times the amount of 
bovine serum was added without removing the transfection mixture. The cells 
then incubated for 72 hours before applying the appropriate protocols (WB, 
MTT). For the MTT assay the cells were treated with pure fibrils, pure seeds or 
monomers. 
3.1.2. Aggregation of p-S129 α-syn in vitro.  
Recombinant α-syn was mixed with different percentages of in vitro 
prepared p-S129 α-syn (100, 50, 20 and 5%) in 1.5 ml sterile polypropylene tubes, 
topped with drops of mineral oil to prevent sample evaporation, and incubated at 
37°C for several days with continuous shaking at 800 rpm in a Thermomixer 
(Eppendorf). Samples were then collected at certain points and a thioflavin-S 






3.3.1 Morphological and structural requirements for α-syn-mediated 
neuronal cell death 
Several lines of evidence support the idea that toxic Aβ contains a mixture 
of high molecular weight aggregates with different sizes and structures (Jan, 
Hartley, & Lashuel, 2010; Lashuel et al., 2003; Walsh et al., 1999). To investigate 
whether this also applies to α-syn-mediated toxicity, we sought to determine the 
structural features of the most toxic species of α-syn. For this purpose we assessed 
the toxic effect of different species of α-syn on neuroblastoma BE(2)-M-17 and 
SHSY-5Y wt cells. The α-syn species employed for these studies ranged from 
monomeric to oligomeric/intermediate and fibrillar forms. The oligomeric and 
fibrillar species, which are referred to herein as ‘crude oligomers’ and ‘crude 
fibrils’, respectively, were prepared by aggregating 100 µM of monomeric α-syn 
at 37º C with continuous mixing for 2 and 7 days, respectively. The samples 
referred to as ‘crude seeds’ were in turn prepared by subjecting the crude fibrils to 
brief sonication as described above.  The structure and the β-sheet content of these 
samples were evaluated by TEM and Th-S assay, respectively (Fig. 3.1 A, B). To 
assess the effect of the prepared species on the viability of neuronal cells an MTT 
assay was carried out employing wt SHSY-5Y and BE(2)-M-17 - human 
neuroblastoma cells, The total amount of α-syn expressed in these cells was 
estimated by immunoblotting as shown in (Fig. 3.1 C). For the MTT assay, the 
cells were treated with solutions of α-syn monomers and the various α-syn species 
















Figure 3.1. Characterization of the α-syn species and evaluation of the α-syn 
expression in the various neuroblastoma cells. A. The fibril content of the various 
α-syn species, namely crude oligomers, crude seeds, crude fibrils and monomers 
(5 μM) was evaluated by Th-S fluorescence. The assay was performed in 
triplicate, and the means ± standard deviations are shown. B. Electron microscopy 
images of negatively stained samples of α-syn species (100 μM). Scale bar 500 
nm. C. The lysate (20 ng) of both the wt and the α-syn stably transfected 
neuroblastoma cells BE(2)-M-17  and SHSY-5Y were separated by 
electrophoresis in a 15% SDS-PAGE gel and transferred to nitrocellulose 
membrane, which was probed with anti-α-syn (211) and anti β-actin antibodies. 
 
 
As shown in Fig. 3.1, A and B, treatment of BE(2)-M-17 -wt α-syn cells 
(i.e. the cells expressing only endogenous α-syn) with monomers had no effect on 
cell viability, while the treatment with the rest of the α-syn species (crude 
oligomers, seeds, fibrils) had a mild impact on both cell lines. This mild effect on 
the cell viability was comparable for all these three α-syn species, but was more 
prominent in the cells treated with the highest concentration of α-syn species (20 
μM) and for a longer period (48 hours) (Fig. 3.2 B). Comparable results were 



























Figure 3.2. The effect of the various α-syn species on the viability of BE(2)-M-17  
and SHSY-5Y wt neuroblastoma cells. The viability of BE(2)-M-17  human 
neuroblastoma cells was estimated by the MTT assay. The results are expressed as 
the percentage of the control average (i.e., untreated cells). The cells were treated 
with different concentration of α-syn species either 24 or 48 hours prior to MTT 
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addition (average of 3 wells ± standard deviation). A. BE(2)-M-17 -wt cells 
incubated for 24 hours. B. BE(2)-M-17 -wt cells incubated for 48 hours. C. 
SHSY-5Y wt cells incubated for 24 hours. D. SHSY-5Y wt cells incubated for 48 
hours. Statistical analysis was performed using one way anova, followed by 
Tukey's multiple comparison test using the GraphPad Prism 5 software. (***, p< 
0.001; **, p< 0.01, *, p< 0.05). 
 
The results obtained from the wt cells used in the above experiment, 
prompted us to use the same cells overexpressing wt-α-syn to distinguish any 
difference. However, in the case of the BE(2)-M-17  cells overexpressing wt α-
syn (i.e. expressing α-syn in excess), α-syn monomers had no effect on cell 
viability. Treatment with α-syn oligomers, especially in higher concentrations (20 
µM) reduced cell viability by approximately 50% and 65% after 24 hours and 48 
hours of incubation, respectively (Fig. 3.3 A, B). At 20 µM, α-syn crude seeds and 
fibrils had a comparable effect on cell viability, reducing it by approximately 20% 
and 30% after 24 hours and 48 hours of incubation, respectively (Fig. 3.3 A, B). 
Overall, the impact of α-syn crude oligomers, seeds and fibrils on the viability of 
the BE(2)-M-17 cells overexpressing wt α-syn showed a dose-dependent relation 
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Figure 3.3. The effect of the various α-syn species on the viability of BE(2)-M-17  
and SHSY-5Y neuroblastoma cells overexpressing α-syn . The viability of SHSY-
5Y human neuroblastoma cells was estimated by the MTT assay. The results are 
expressed as the percentage of the control average (i.e., untreated cells). The cells 
were treated with different concentration of α-syn species either 24 or 48 hours 
prior to MTT addition (average of 3 wells ± standard deviation). A. BE(2)-M-17  
overexpressing wt-α-syn cells incubated for 24 hours. B. BE(2)-M-17  
overexpressing wt-α-syn cells incubated for 48 hours. C. SHSY-5Y cells over 
expressing wt α-syn incubated for 24 hours. D. SHSY-5Y cells over expressing wt 
α-syn incubated for 48 hours. Statistical analysis was performed using one way 
anova, followed by Tukey's multiple comparison test using the GraphPad Prism 5 
software. (***, p< 0.001; **, p< 0.01, *, p< 0.05). 
 
 
Taken together, the above results indicate that the different forms of 
aggregated α-syn species and especially the crude oligomers, can be more toxic in 
the presence of excess amounts of monomeric α-syn.  
To further confirm these findings, this experiment was carried out using 
another SHSY-5Y cell over expressing wt α-syn. In (Figure 3.3 C and D) it is 
shown that treatment of SHSY-5Y cells (overexpressing wt α-syn) with the 
various α-syn species had an effect analogous to the one produced by the 
treatment of BE(2)-M-17  cells with the same α-syn species.  
3.3.2 Addition of α-syn monomers to pre-treated with preformed 
aggregates cells enhances the α-syn-mediated toxicity 
Given that α-syn crude oligomers had a stronger effect on cell viability 
compared to crude seeds and fibrils and taking into account that the crude 
oligomeric α-syn samples contain both monomers and protofibrils (Fig. 3.4 B), we 
assumed that the toxic effect of the oligomeric α-syn may be linked to its ability to 
seed the aggregation of monomeric α-syn. To investigate this hypothesis, we 
prepared α-syn species so that they contained the minimum number of monomers, 




viability of neuroblastoma cells. For this purpose, both BE(2)-M-17  and SHSY-
5Y wt cells were treated with three different concentration (2, 5 and 10 µM) of 










Figure 3.4. Characterization of α-syn pure fibrils and pure seeds. A. The fibril 
content of pure fibrils, pure seeds, and monomeric α-syn (5 μM) was evaluated by 
Th-S fluorescence. The assay was performed in triplicate, and the means ± 
standard deviations are shown. B. Electron microscopy images of negatively 
stained samples of α-syn species (100 μM). Scale bar 500 nm. 
 
 
To assess the effect of these α-syn species in the presence of α-syn 
monomers, monomeric α-syn was added to the cells 1 hour later at a final 
concentration of 10µM. While both pure seeds and fibrils had an effect on the 
viability of the cells (both BE(2)-M-17 and SHSY-5Y) at all concentrations (Fig. 
3.5), with seeds being more toxic than fibrils, the addition of monomeric α-syn 


















Figure 3.5. The effect of α-syn seeding on the viability of neuroblastoma cells. 
The viability of A. BE(2)-M-17 -wt cells, B. SHSY-5Y -  human neuroblastoma 
wt cells was estimated by the MTT assay. The results are expressed as the 
percentage of the control average (i.e., untreated cells). The cells were treated 
with different concentration of α-syn pure fibrils or pure seeds and one hour after 
treatment, monomeric α-syn to a final concentration of 10 µM was added. The 
cells were then incubated for 48 hours prior to MTT addition. (average of 3 wells 
± standard deviation). Statistical analysis was performed using one way anova, 
followed by Tukey's multiple comparison test using the GraphPad Prism 5 
software. (***, p< 0.001; **, p< 0.01, *, p< 0.05). 
 
  As the effect was independent of the concentration of the pure seeds and 
fibrils, we attempted to evaluate the toxicity of the cells varying both the 
concentration of seeds and fibrils (at a lower concentration scale, i.e. 0.0001-10 
µM) in the presence of a constant concentration of α-syn monomers and vice 
versa. The results of this series of experiments are illustrated in Fig. 3.6. As 
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shown in Fig. 3.6 A and C, pure seeds and fibrils decrease cell viability in a 
concentration-dependent fashion, but they exert a more toxic effect in the 
presence of monomeric α-syn (final concentration of 10 μM), with seeds being 
once again more toxic than fibrils. Indeed, even at a concentration as low as 0.1 
nM, pure seeds produced a strong toxic effect reducing cell viability by 
approximately 40%.  
To investigate the effect of varying concentrations of monomeric α-syn (1-
20 μM) on cell viability, the cells were first treated with a constant concentration 
(2 µM) of either pure fibrils or pure seeds. As shown in Fig. 3.6 B and D, the 
addition of monomers appears to be a prerequisite for cell toxicity when cells are 
pre-treated with pure fibrils and seeds (Fig. 3.6 B) as α-syn monomers alone had 
no effect on cell viability. 
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Figure 3.6. The effect of α-syn seeding on the viability of neuroblastoma cells. 
The viability of BE(2)-M-17  and SHSY-5Y human neuroblastoma wt cells was 
estimated by the MTT assay. The results are expressed as the percentage of the 
control average (i.e., untreated cells). A. The BE(2)-M-17 -wt cells were treated 
with different concentration of α-syn pure fibrils or pure seeds (0.0001-10 µM) 
and one hour after treatment, monomeric α-syn to a final concentration of 10 µM 
of was added. B. The BE(2)-M-17 -wt  cells were treated with 2 µM (final 
concentration) of α-syn pure fibrils or pure seeds and one hour after treatment, 
monomeric α-syn was added to a final concentration ranging between 1-20 µM. 
C. The SHSY-5Y-wt cells were treated with different concentration of α-syn pure 
fibrils or pure seeds (0.0001-10 µM) and one hour after treatment, monomeric α-
syn was added to a final concentration of 10 µM. D. The BE(2)-M-17  wt cells 
were treated with 2 µM final concentration of α-syn pure fibrils or pure seeds and 
one hour after treatment, monomeric α-syn was added to a final concentration 
ranging between 1-20 µM. The cells were then incubated for 48 hours prior to 
MTT addition. (average of 3 wells ± standard deviation). 
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3.3.3 The effect of pure seeds and fibrils on the cell viability of BE(2)-M-17  
cells, whose endogenous α-syn has been knocked down 
To investigate further the role of monomeric α-syn in inducing the 
nucleation polymerization process of α-syn, we assessed the effect of pure seeds 
and fibrils on the viability of BE(2)-M-17 -wt cells whose endogenous α-syn was 
knocked down by siRNA silencing. The silencing was evaluated by 
immunoblotting and the expression level of α-syn was quantified by the image 
processing program ImageJ (Fig. 3.7 A, B). The siRNA transfected BE(2)-M-17  
wt cells were treated with pure fibrils and pure seeds at four different 
concentrations (1, 5, 10 and 20 µM), while monomeric α-syn was employed as a 
control at the same concentrations. According to the MTT results (Fig. 3.7 C-E), 
the cells whose endogenous α-syn was knocked down were less susceptible to the 
toxic effects of pure fibrils (Fig. 3.7 C) and seeds (Fig. 3.7 D). However, the 
treatment of the cells with monomeric α-syn at any given concentration had a 
comparable impact on the viability of both the siRNA-transfected and the control 
cells (Fig. 3.7 E). These results confirm further the role of monomeric α-syn in the 



















Figure 3.7. The effect of pure seeds and fibrils on the cell viability of BE(2)-M-17  
cells,  whose endogenous α-syn has been knocked down. Pre-designed siRNA 
sequence targeting human wt α-syn was used to silence the expression of α-syn, 
and non-targeting scrambled siRNA was used as negative control. A. 
Immunoblotting for cell lysate to detect total α-syn using the mouse monoclonal 
anti-α-syn (211) antibody  and anti β-actin for loading control, lane 1: 
recombinant α-syn, lane 2: non- transfected cell lysate, lane 3: scambled siRNA 
transfected cell lyste, lane 4: R-12 peptide transfected cell lysate, lane 5: siRNA 
transfected cell lysate. B. Quantification of α-syn expression levels by 
densitometric analysis  using the ImageJ software. C-E. The viability of BE(2)-M-
17  human neuroblastoma wt cells was estimated by the MTT assay. The results 
are expressed as the percentage of the control average (i.e., untreated cells). C. 
The BE(2)-M-17  wt cells were treated with different concentrations of wt-α-syn 
pure fibrils D. wt-α-syn puree seeds. E. Monomeric α-syn. The cells were then 
incubated for 48 hours prior to MTT addition, (average of 3 wells ± standard 
deviation). Statistical analysis was performed using one way anova, followed by 


















































































































3.3.4 Addition of p-S129 α-syn monomers to pre-treated with preformed 
aggregates cells does not promote the α-syn-mediated toxicity. 
The finding that the majority of α-syn present in LBs is phosphorylated at 
S129, while the same modification appears only in 4% of the protein in the 
normal brain (Anderson, et al., 2006; Fujiwara, et al., 2002; Hirai, Fujita, 
Iwatsubo, & Hasegawa, 2004) indicates that the phosphorylation of α-syn at S129 
plays a major role in PD. Despite the huge effort put into elucidating the role of p-
S129 α-syn in the pathogenesis of PD, it remains unknown whether 
phosphorylation takes place before or after α-syn is deposited in the brain, while it 
is still debatable whether α-syn phosphorylation at S129 promotes or inhibits the 
aggregation and toxicity of the protein. To better understand the impact of 
phosphorylation on α-syn aggregation and toxicity, we sought to unravel the role 
of α-syn phosphorylation at S129 in the seeded polymerization and toxicity. 
Our findings prompted us to investigate whether adding monomeric p-S129 
α-syn to the cells pre-treated with either pure fibrils or pure seeds would have an 
effect on their toxicity. For this purpose, in vitro phosphorylated monomeric and 
aggregated recombinant α-syn (characterized by immunoblotting and Th-S 
binding Fig. 3.8 A and B) were used to assess the ability of various p-S129 α-syn 
species to seed the aggregation process. The phosphorylation of α-syn was 
assessed by immunoblotting employing a p-S129 α-syn-specific antibody (Fig. 3.8 
C). Both wt and p-S129 α-syn pure seeds were characterized by EM and Th-S 












Figure 3.8. Characterisation of in vitro prepared p-S129 α-syn. A. 
Characterization of monomeric and aggregated α-syn by immunoblotting. B. Th-S 
fluorescence readings of the monomeric and aggregated α-syn samples. C. 
Immunobloting for the samples of α-syn incubated with PLK2 at different time 
points. Phosphorylation at S129 was detected by an p-S129 α-syn-specific 
antibody. Total a-syn was detected by anti-α-syn (211) antibody. D. Estimation of 
the fibril content in the p-S129 seeds, wt seeds and aged α-syn by Th-S 
fluorescnce. The assay was performed in triplicate and, the means ± standard 
deviations are shown. E. Electron microscopy images of negatively stained 
samples of p-S129 seeds, wt seeds and aged α-syn (100 μM). Scale bar 500 nm. 
 
 
Prior to any toxicity experiment incorporating various species of α-syn, the 
effect of monomeric p-S129 α-syn alone compared with wt α-syn was assessed in 
both BE(2)-M-17 and SHSY-5Y wt cells. Monomeric p-S129 α-syn employed at 
a range of concentrations (0.31-20 μM) was not toxic to neither BE(2)-M-17  cells 




For the experiments assessing the effect of monomeric p-S129 α-syn on 
the viability of the cells pre-treated with pure seeds or fibrils, BE(2)-M-17 and 
SHSY-5Y-wt cells were treated with different concentrations of either pure fibrils 
or pure seeds (10, 5 and 2 µM) and after one hour incubation, monomeric p-S129 
α-syn was added to the cells at a final concentration of 10 µM. Surprisingly, as 
shown in Fig. 3.9 C and D, in contrast to the wt monomeric α-syn (Fig. 3.5), the 
p-S129 monomers  had no effect on cell viability when pre-treated with any 
concentration of pure fibrils or pure seeds. Indeed, the toxicity levels observed 
after treatment with the monomeric p-S129 α-syn following treatment with pure 
seeds or fibrils were comparable (and statistically non-significant) to the ones 






































































































































Figure 3.9. The effect of p-S129 α-syn seeding on the viability of neuroblastoma 
cells. The effect of monomeric wt and p-S129 α-syn on the viability of A. BE(2)-
M-17 -wt cells, B. SHSY-5Y - human neuroblastoma wt cells was estimated by 
the MTT assay. The results are expressed as the percentage of the control average 
(i.e., untreated cells). C. The BE(2)-M-17  and D. SHSY-5Y cells were treated 
with different concentration of α-syn pure fibrils or pure seeds and one hour after 
treatment, monomeric p-S129 α-syn was added to a final concentration of 10 µM. 
The cells were then incubated for 48 hours prior to MTT addition. (average of 3 
wells ± standard deviation). Statistical analysis was performed using one way 
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3.3.5 Assessing the ability of p-S129 to seed the aggregation of α-syn 
To assess the ability of p-S129 α-syn to seed the aggregation of the protein, 
100 µM of monomeric α-syn was incubated alone or in the presence of 2 µM 
(final concentration) wt or p-S129 α-syn seeds for 5 hours. Considering that α-syn 
aggregation is a nucleation-dependent process, the addition of exogenous 
preformed nuclei, namely the seeds, is expected to reduce the nucleation phase of 
the process, resulting in an immediate aggregation of the protein (Wood, et al., 
1999; Conway, et al.,2000b). Indeed, as illustrated in Fig. 3.11, the addition of wt 
and p-S129 α-syn seeds accelerated the aggregation of monomeric α-syn as 
compared to the control, which showed comparable Th-S fluorescence readings 
throughout the 5-hour incubation process. It is noteworthy, that the wt α-syn seeds 
had a greater impact on the aggregation of monomeric α-syn compared to the p-
S129 α-syn ones (Fig. 3.10), but since this effect was not statistically significant 
the experiment was repeated employing a lower concentration of seeds (0.1 µM) 












Figure 3.10. Assessing the ability of pS129 α-syn to seed the 
polymerization/aggregation of α-syn. Samples of monomeric α-syn (100 μM) 
were incubated for 5 hours at 37°C with continuous shaking in the presence or 
absence of 2 μM of wt or pS129 α-syn seeds. Fibril formation was measured by 
Th-S fluorescence. The assay was performed in triplicate, and the means ± 





The results of this series of experiments are shown in Fig. 3.11 A and B. 
As shown in Fig. 3.11 A, even after 48 hours of incubation, the seeding effect of 2 
μM wt was statistically significant while 2 μM p-S129 α-syn seeds were not 
significant. However, at 0.1 µM, the impact of p-S129 α-syn seeding as compared 
to wt seeding was prominent. As shown in Fig. 3.11 B, at 0.1 µM, wt α-syn seeds 
accelerated the aggregation of α-syn, with the trend becoming apparent after 8-12 
hours of incubation and increasing in a time-dependent manner thereafter. In 
contrast, at 0.1 µM, p-S129 α-syn seeds not only did not accelerate the 
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Figure 3.11. The ability of p-S129 α-syn to seed the on 
polymerization/aggregation of α-syn. A. Monomeric α-syn (100 µM) was 
incubated alone or with 2 µM or B. 0.1 µM (final concentration) of p-S129 or wt 
seeds for 48 hours. C. Samples of p-S129 monomeric α-syn (100 µM) was 
incubated alone or with 2 µM or D. 0.1 µM (final concentration) of p-S129 or wt 
seeds for 48 hours. The fibrillation was evaluated by Th-S fluorescence. The assay 
was performed in triplicate, and the means ± standard deviations are shown. 
Statistical analysis was performed using one way anova, followed by Tukey's 
multiple comparison test using the GraphPad Prism 5 software.  (**, p< 0.01, *, 
p< 0.05). 
 
To further investigate this rather unexpected finding, we assessed the 
ability of wt or p-S129 α-syn seeds to seed p-S129 α-syn monomers instead of wt. 
The monomeric p-S129 α-syn was incubated in the presence or absence of wt or 
p-S129 α-syn seeds at two different final concentrations (2 and 0.1 µM) for 48 
hours. As shown in Fig. 3.11 C and D, regardless of the type or the concentration 
of the seeds, p-S129 α-syn failed to aggregate even after 48 hours of incubation, 
















p-S129 α-syn monomers + p-S129 α-syn seeds 
p-S129 α-syn monomers + wt-α-syn seeds 
C 
















p-S129 α-syn monomers + p-S129 α-syn seeds 





indicating that phosphorylation at S129 has an inhibitory effect on the aggregation 
of the protein.  
  
3.3.6 Assessing the effect of p-S129 α-syn on the aggregation of α-syn  
To further explore the impact of phosphorylation at S129 on the aggregation 
of the protein, and considering that only 5% of α-syn is phosphorylated at S129 
under physiological conditions (Hirai, et al., 2004), we investigated the effect of 
various amounts of p-S129 α-syn on the aggregation of α-syn. For this purpose, 
pure monomeric p-S129 α-syn was mixed with different concentrations non-
phosphorylated α-syn to obtain the desired percentages of p-S129 α-syn 
monomers (0-100 % p-S129). These samples were incubated for up to 20 days, 
and the aggregation was assessed at different time points by Th-S assay. As 
shown in Fig. 3.12, the non-phosphorylated α-syn gradually aggregated reaching 
approximately 35,000 Th-S counts after 20 days of incubation. The sample 
containing 5% p-S129 α-syn exhibited a similar tendency to aggregate to the non-
phosphorylated sample, with the only difference in the aggregation pattern of the 
two samples being the slightly slower rate of aggregation observed for the 5% p-
S129 sample during the incubation period of between 3-12 days (Fig. 3.12). 
However, the sample containing 20% p-S129 α-syn showed a marked inability to 
aggregate, given that the reduction in Th-S fluorescence readings was more than 
50%. In the case of the samples containing 50% and 100% p-S129 α-syn, the 
fibrillation was almost completely inhibited, with the Th-S fluorescence readings 
reaching approximately 2,000 counts after 20 days of incubation. Interestingly, 




incubation (Fig. 3.12). These results further confirm that phosphorylation at S129 











Figure 3.12. The effect of p-S129 on α-syn aggregation. Monomeric α-syn (100 
µM) was incubated in the presence of various percentages (0, 5, 20 ,50 and 100%) 
of p-S129 monomeric α-syn for 20 days at 37°C with continuous shaking. The 
fibrillation was evaluated by Th-S fluorescence.The assay was performed in 
triplicate, and the means ± standard deviations are shown. 
 
 
Collectively, the above results advocate a protective role for p-S129 α-syn, 
since it has been shown (i) not to be toxic to cells (Fig. 3.9 A and B) , (ii) not to 
promote the seeding-mediated toxicity (Fig. 3.9 C and D), (iii) not to aggregate 
(Fig. 3.11 C and D), (iv) to inhibit the seeded polymerisation of wt α-syn 
monomers (Fig. 3.11 A, B) and (v) to inhibit the aggregation of monomeric α-syn 











































































Identifying the toxic species of α-syn together with the mechanism of their 
formation plays a central role in elucidating the α-syn-induced toxicity associated 
with PD and related disorders. Several lines of evidence indicate that the α-syn 
species driving neurodegeneration are the early aggregates, referred to as soluble 
oligomers, rather than mature amyloid fibrils (El-Agnaf, et al., 2003; Winner, et 
al., 2011). In order to identify specific toxic α-syn species, which contribute to the 
toxicity of the protein, we prepared various α-syn species (referred to as crude 
oligomers, crude seeds and crude fibrils) following a well-characterized in vitro 
aggregation protocol varying the incubation times from 2-7 days. The morphology 
and distribution of the aggregates present in the various preparations of α-syn 
were characterized by EM (Fig. 3.1). The toxic effect of these α-syn preparations 
was evaluated in two different neuroblastoma cell lines, BE(2)-M-17 and SHSH-
5Y, either expressing only endogenous α-syn or overexpressing wt α-syn. The 
toxicity of the various α-syn species was first assessed in the cell lines expressing 
only endogenous α-syn. As shown in Fig. 3.2, the majority of the α-syn species 
employed in this experiment did not have a significant impact on the viability of 
the cells, with the crude oligomers being slightly toxic. However, when the same 
α-syn species were used for the treatment of the cell lines overexpressing wt α-
syn, it became apparent that crude oligomeric preparation of α-syn, which is a 
heterogeneous mixture of monomeric and oligomeric α-syn (Fig. 3.1) was more 
toxic compared to crude seeds and fibrils (Fig. 3.3). Considering that the latter 
two preparations contain less or no monomeric or protofibrillar α-syn, and since 
they were more toxic in the cells overexpressing wt α-syn, we hypothesized that 




reflect their  inability to grow. To support this finding, a previous study has shown 
that the toxicity of Aβ42 is not linked to specific prefibrillar aggregate(s), but to 
their ability to grow in the presence of Aβ42 monomers (Jan, et al., 2011; 
Wogulis, et al., 2005). To further investigate the impact of monomeric α-syn on 
the aggregation-induced toxicity of the protein, we assessed the effect of α-syn 
monomer-free preparations, namely pure fibrils and pure seeds (Fig. 3.4), on the 
viability of the wt BE(2) M-17 and SHSY-5Y cells expressing only endogenous 
α-syn in the presence or absence of exogenously added monomeric α-syn (10 μM 
final concentration). As illustrated in Fig. 3.5, the addition of monomeric α-syn to 
the cells pre-treated with pure seeds and fibrils increased the levels of toxicity 
when compared to the cells treated only with the pure seeds and fibrils. It is worth 
mentioning that, in the presence of α-syn monomers, pure seeds and fibrils 
induced a good level of toxicity, even at concentrations as low as 100 nM (Fig. 
3.6 A and C).   
The significance of α-syn monomers toxicity associated with the 
polymerisation/aggregation process was further confirmed with a series of 
experiments, during which the BE(2)-M-17 cells, whose endogenous α-syn was 
knocked down, were treated with pure fibrils and pure seeds.  Compared to the wt 
cells, a significant level of protection against the seed and fibril growth-induced 
toxicity was achieved when the expression of endogenous α-syn was silenced 
(Fig. 3.7).  
As the aim of the present study was to unravel the structural prerequisites of 
the seeding process and its relation to toxicity, we sought to unravel the role of p-
S129  α-syn monomers in seeding the α-syn polymerisation/aggregation and to 




3.9, addition of p-S129 α-syn monomers to the cells pre-treated with pure seeds or 
pure fibrils has no effect on cell viability. By comparing these findings with the 
corresponding data for the wt α-syn monomers (Fig. 3.5), which were shown to 
promote the toxicity of pure seeds and fibrils when added to the cells, it becomes 
apparent that p-S129 α-syn monomers behave differently from the wt α-syn 
monomers, suggesting a potential role of p-S129 α-syn in inhibiting the seeded 
polymerization process. It is still debatable whether α-syn phosphorylation at 
S129 promotes or inhibits the aggregation and toxicity of the protein, as far as the 
p-S129 α-syn-related toxicity is concerned, the results of the various studies are 
equally contradictory and inconclusive. Whereas studies on yeast, oligodendrial 
cells and a Drosophila model of PD have shown that α-syn phosphorylated at 
S129 (p-S129 α-syn) by various kinases [casein kinase 1 (CK1), CK1, Polo-like 
kinases (PLKs), G-protein-coupled kinases (GRKs)] correlates with α-syn toxicity 
(L. Chen & Feany, 2005; L. Chen, et al., 2009; Kragh, et al., 2009; Zabrocki, et 
al., 2008), studies employing the phosphomutants S129D and S129A are 
particularly contradictory. In some studies, S129D α-syn appears to be toxic 
(Chau, et al., 2009; L. Chen & Feany, 2005), while there are also reports 
supporting that the phosphomimic S129D α-syn plays a rather protective role 
(Gorbatyuk, et al., 2008; Kuwahara, et al., 2012; B. Wu, et al., 2011) or has no 
effect on the toxicity of the protein (Azeredo da Silveira, et al., 2009; Fischer, et 
al., 2009). 
The findings above prompted us to further investigate the implications of p-
S129 α-syn in the seeding of the aggregation process and according to the data 
obtained (Fig. 3.10 and Fig 3.12), monomeric p-S129 α-syn failed to seed the 




time. Moreover, prolonged incubation of wt α-syn with various percentages of p-
S129 α-syn also resulted in a strong inhibitory effect, which was dependent on the 
percentage of p-S129 α-syn present in the samples (Fig. 3.12). These findings are 
in accordance with previous studies indicating that phosphorylation at S129 has a 
rather inhibitory effect on the aggregation of α-syn (Paleologou, et al., 2008; 
Waxman & Giasson, 2008). 
Our data suggest that phosphorylation of α-syn at S129 may play a 
protective role against the toxic effect of α-syn by inhibiting the seeding 
polymerization process which was shown to underlie the α-syn-induced toxicity.  
  A deeper understanding of the role of p-S129 α-syn on cellular responses 
to nucleation dependent polymerization may provide a promising novel approach 





4 Chapter 4: Structure activity relationship of phenolic 
acid inhibitors of alpha-synuclein fibril formation and 
toxicity 
4.1 Introduction 
α-Syn aggregation proceeds through several key intermediate stages, with 
monomeric α-syn first assembling into oligomeric forms that gradually generate 
insoluble amyloid fibrils. Because α-syn aggregation plays a crucial role in PD 
pathogenesis and related synucleinopathies, intensive effort has been put into 
identifying compounds that could block or even reverse the aggregation process. 
Over the years, polyphenols, a set of more than 8000 compounds that contain one 
or more phenolic rings, have emerged as potent amyloid inhibitors, interfering 
with the in vitro fibril assembly of many amyloidogenic proteins including α-syn, 
β-amyloid (Aβ), tau-protein and prions (reviewed by Porat, et al., 2006). 
Gallic Acid (GA) is a phenolic acid. Phenolic acids constitute a group of 
compounds, which are derived from benzoic acid and cinnamic acid, giving rise to 
hydroxybenzoic acids and hydrocinnamicacids, respectively. GA (3,4,5-
trihydroxybenzoic acid) is a benzoic acid derivative that can be found in almost 
all plants, with the highest GA contents detected in gallnuts, witch hazel, 
pomegranate, berries such as blackberries and raspberries, sumac, tea leaves and 
oak bark. GA can also be isolated from the roots of Radix Paeoniae (white-
flowered peony), which is commonly used to treat vascular and liver diseases in 
traditional Chinese medicine (J. H. Ho & Hong, 2011). It has been reported that 




Berg, Quarles van Ufford, van Dijk, & Labadie, 1992) and anti-viral (Kreis, 
Kaplan, Freeman, Sun, & Sarin, 1990) properties, and a well-documented anti-
cancer effect (H. H. Ho et al., 2013; K. C. Liu et al., 2011; C. S. Yang et al., 
2000). Recently, GA has been reported to act as a potent anti-oxidant and free 
radical scavenger in a rat PD model (Sameri, Sarkaki, Farbood, & Mansouri, 
2011). Additionally, GA was shown to efficiently inhibit α-syn and β-amyloid 
(Aβ) aggregation and toxicity in vitro (Bastianetto, Yao, Papadopoulos, & 
Quirion, 2006; Di Giovanni, et al., 2010). 
The aim of the present chapter was to systematically assess the ability of 
GA to (a) inhibit α-syn oligomerization and fibrillation, (b) block α-syn-induced 
toxicity and (c) disaggregate preformed α-syn fibrils. To gain insight of the 
mechanism of action of GA against α-syn aggregation and toxicity and to 
establish a structure-activity relationship, we assessed the anti-fibrillogenic effect 
of eleven different hydroxybenzoic acid derivatives with chemical structures 
similar to GA. The selection of phenolic acids was based on the number of the 
hydroxyl moieties attached to the phenyl ring. To further investigate the role of 
hydroxyl groups in the inhibitory activity of phenolic acids, we also included and 
assessed the effect of three different benzoic acid derivatives that have fluorides 





4.2 Experimental procedure 
4.2.1 Expression and purification of recombinant human α-syn 
As described in the experimental procedure 3.2.1 
4.2.2 α-syn purification and characterization 
As described in the experimental procedure 3.2.2 
4.2.3 Aggregation of α-syn in vitro 
Stock solutions of the compounds tested (10 mM) were prepared in DMSO. 
Solutions of lower concentrations were prepared by diluting the stock solutions to 
final concentration of 25-100µM. The amount of DMSO in the final samples was 
1%. Samples of 25 µM (unless otherwise stated) α-syn in PBS were aged either 
alone or with phenolic acid at various molar ratios (phenolic acids to protein 
molar ratios of 4:1, 2:1 and 1:1). The samples were placed in 1.5ml sterile 
polypropylene tubes, sealed with parafilm and incubated at 37°C for 5 days with 
continuous shaking at 800 rpm in a thermomixer (Eppendorf). Samples were 
collected at regular intervals. The thioflavin-S (Th-S) fluorescence was measured 
immediately, while the rest of the samples were stored at -80°C until required for 
further analysis. 
4.2.4 Thioflavin-S (Th-S) fluorescence assay 
As described in the experimental procedure 3.2.5 
4.2.5 Transmission Electron Microscopy (TEM) 
Electron microscopy images were produced from α-syn aged in the presence 
or absence of GA. The samples (5 µL) were deposited on formvar-coated 400 




stained with 2% uranyl acetate (Sigma-Aldrich) and examined in a Philips CM-10 
TEM electron microscope. 
4.2.6 Immunoblotting 
Samples (20 ng) of α-syn incubated alone or with GA were mixed with a 
loading sample buffer (250 mM Tris-HCl, pH 6.8, 30% glycerol, 0.02% 
bromophenol blue) without SDS or boiling and then separated on 1 mm 15% 
SDS-PAGE gels. The separated proteins were transferred to nitrocellulose 
membranes (0.45 μm, Whatman Gmbh-Germany) at 90 V for 80 mins. The 
membranes were boiled for 5 mins in PBS and then blocked for 1 hour with 5% 
non-fat milk prepared in PBS-Tween-20 (0.05% PBST). The membranes were 
incubated overnight at 4°C with the primary antibody, namely the mouse 
monoclonal anti-α-syn (211) that recognizes human α-syn (121-125) (Santa Cruz 
Biotechnology, USA), at a dilution of 1:1000. The membranes were then washed 
several times with PBST, followed by incubation with HRP-conjugated goat anti-
mouse antibody (Dako Ltd., Ely, UK) at a dilution of 1:70,000 for 60 mins at 
room temperature and with gentle agitation. The membranes were then 
extensively washed for 25 mins. The immunoreactive bands were visualized with 
a SuperSignal West Femto Chemiluminescent Substrate Kit (Pierce, Rockford, 
USA) according to the manufacturer’s instructions. 
4.2.7 Immunoassay for measuring oligomeric α-syn 
A 384-well ELISA plate (Nunc Maxisorb, Nunc, Denmark) was coated with 
1 µg/ml of non-biotinylated mouse monoclonal anti-α-syn antibody [mAb, 211 - 
recognizes amino acid residues 121-125 of human α-syn (Santa Cruz 




µl/well) and incubated overnight at 4°C. The plate was then washed 4 times with 
PBST and blocked with 100 µl/well of blocking buffer (5% gelatin from cold 
water fish skin, 0.05% Tween 20 in 1X PBS pH 7.4) for 2 hours at 37°C. After 
being washed 4 times with PBST, 50 µl of the samples were dispensed in each 
well, and each sample was tested in duplicate. The plates were then incubated at 
37°C for another 3 hours. After washing 4 times with PBST, 50 µl of biotinylated 
211 antibody diluted in blocking buffer to a concentration of 0.4 µg/ml was added 
and incubated at 37°C for 2 hours. The wells were washed 4 times with PBST and 
incubated with 50 µl/well of extravidin-peroxidase (Sigma-Aldrich, GmbH- 
Germany) diluted 1:7,500 in blocking buffer and incubated for 1 hour at 37°C. 
The wells were then washed 4 times with PBST before adding SuperSignal 
ELISA Femto Maximum Sensitivity Substrate (Pierce Biotechnology, Rockford, 
USA) (50 µL/well).The chemiluminescence in relative light units was measured 
immediately using a microplate reader (Perkin Elmer).  
4.2.8 Culture of BE(2)-M-17 human neuroblastoma cells 
As described in the experimental procedure 3.2.10 
4.2.9 Measurement of cell viability  
As described in the experimental procedure 3.2.13 
4.2.10 Congo red binding assay 
Congo red (20µM) was dissolved in PBS (pH 7.4) and filtered through a 
0.45 µm filter. Samples of α-syn (5 µM), aged alone or with GA at different molar 
ratios, were mixed with Congo red (final concentration 5 µM), and the reaction 
samples were thoroughly mixed. The UV absorbance spectrum was recorded from 




mm quartz cuvettes (Hellma Analytics-Germany). Monomeric α-syn and Congo 
red alone were used as negative controls. 
4.2.11 α-Syn disaggregation assay 
Recombinant α-syn dissolved in sterilized PBS (pH 7.4) was aggregated at a 
concentration of 25 μM as indicated above. The resulting aggregated α-syn was 
incubated either alone or with GA at various molar ratios (GA: α-syn molar ratios 
6:1, 4:1 and 2:1). It should be noted that for the purpose of the experiment, the 
concentration of α-syn was assumed to be the same as that of the fresh α-syn. The 
samples were incubated at 37°C for 3 days on a thermomixer with continuous 
shaking at 800 rpm. Samples were collected at regular intervals, and the Th-S 
fluorescence was measured immediately. 
4.2.12 Seeding polymerization assay 
The aggregation of monomeric α-syn with or without seeding was carried 
out as described elsewhere (Di Giovanni, et al., 2010). Mature α-syn fibrils were 
fragmented by sonication to obtain short fibrils, which were employed as ‘seeds’. 
100 μM monomeric α-syn was seeded with 2 μM seeds and incubated in the 
presence or absence of GA (10 μM and 50 μM) at 37°C for 6 hours with 
continuous shaking. Fibrillation was monitored by Th-S binding as described 
above. 
4.2.13 Size Exclusion Chromatography (SEC) for separating α-syn oligomers 
and monomers 
SEC was carried out using an AKTA FPLC system (GE Healthcare-
Sweden) and a superdex 200 column  at 4 °C, in order to separate the oligomers 




Monomeric α-syn at a concentration of 100 µM was aggregated in the presence of 
GA for 5 days as described above. At the end of the aggregation process, the 
sample was centrifuged for 45 mins at 14,000 x g at 4°C generating a supernatant 
free from insoluble material. Prior to injecting 80% of the supernatant generated, 
the column was thoroughly equilibrated with an SEC running buffer (1x PBS, pH 
7.4) and the flow rate was set to 0.1 ml/min (0.5 ml/fraction). α-Syn elution was 
monitored at absorbance wavelengths of 215 nm, 254 nm, and 280 nm. To 
determine the elution time for monomeric α-syn, molecular weight standards 
(ferritin 440 kDa, aldolase 171 kDa, albumin 68 kDa and chymotrypsinogenA 25 
kDa) and monomeric α-syn were co-injected into the column and eluted to the 
same standards as mentioned above. The fractions eluting between 7-9 ml CV 
were combined and labeled as oligomers (sample P1), whereas the fractions 
eluting in the 13–15ml CV were combined and labeled as monomers (sample P2). 
The P1 and P2 fractions were further characterized by western blotting and TEM. 
4.2.14 UV scanning 
The P1 and P2 samples, representing the oligomeric and monomeric 
fractions of SEC, respectively, were concentrated using a speed vac (CentriVap, 
Labconco). The content concentration of protein was estimated by using BCA 
assay. The UV absorbance spectrum was recorded from 200-600 nm in a 
spectrophotometer (DU-800, Beckman-Coulter) using 10 mm quartz cuvettes 
(Hellma Analytics-Germany) and employing equal concentrations of both P1 and 






For NMR studies, recombinant 15N-labeled α-syn was expressed and 
purified as previously described (Bussell & Eliezer, 2003a; Eliezer, Kutluay, 
Bussell, & Browne, 2001a), resuspended in PBS at pH 6.5. Two-dimensional 
proton-nitrogen correlation spectra were acquired for α-syn at a 200 μM 
concentration in the absence of GA and in the presence of increasing GA: α-syn 
stoichiometries of 0.5:1, 1:1, 2:1, 5:1 and 10:1.  Data were collected on a Varian 
600 MHz Unity Inova Spectrometer equipped with a cold probe. 
 
4.3 Results 
4.3.1 The effect of GA on α-syn fibril formation 
To investigate the effect of GA on α-syn fibrillation, 25µM of α-syn was 
incubated with GA at varying molar ratios of GA: α-syn of 4:1, 2:1 and 1:1 for a 
period of 6 days. GA inhibited the formation of α-syn fibrils in a concentration-
dependent manner as indicated by the Th-S assay (Fig. 4.1 A). Taking into 
account the lack of Th-S signal at the 4:1 ratio, GA exhibited an excellent 
inhibitory effect on α-syn fibrillation, inhibiting it completely during the 6-day 
incubation (Fig. 4.1 A). At a 2:1 ratio, GA also suppressed the formation of fibrils 
to a great extent, and the Th-S signal was detected only after 4 days of incubation, 
while after 6 days, GA reduced the Th-S counts to approximately one fifth of the 
control counts (Fig. 4.1 A). Even at a 1:1 ratio, GA hindered the fibrillation of α-
syn but to a smaller extent than the other ratios (Fig. 4.1 A). The anti-fibrillogenic 
activity of GA was further assessed by using a Congo red binding assay. Congo 




of CR alone (5 µM) was 490 nm, while when incubated with α-syn amyloid 
fibrils, the maximum absorption shifted to 508 nm (Fig. 4.1 B).This shift in the 
peak absorption wavelength represents the binding of CR to the β-sheet-rich 
fibrils. However, this prominent shift was not observed for the fresh α-syn sample 
or when α-syn was aged in the presence of GA (Fig. 4.1 B), indicating that GA 
inhibited the formation of structures with a β-sheet conformation. In fact, GA 
blocked the formation of β-sheets in a dose-dependent manner, similar to the Th-S 
results. It was observed that the lower the GA concentration, the more prominent 
the peak absorbance wavelength shift was (485 nm, 493 nm and 500 nm for 100 
µM, 50 µM and 25 µM GA, respectively). Electron microscopy images also 
confirmed that GA not only affected the extent of fibrillation in a dose-dependent 
fashion but also the morphology of α-syn fibrils. Indeed, instead of forming dense 
meshes of long fibrils (longer than 1 µm) as observed in aged α-syn alone (Fig. 
4.1 C), α-syn aged in the presence of 100 µM (Fig. 4.1 D) and 50 µM of GA (Fig. 
4.1 E) generated thin, sheared fibrils that were approximately 0.1-0.2 µm in 
length. α-Syn aged in the presence of 25 µM GA (Fig. 4.1 F) formed longer fibrils 





Figure 4.1. GA inhibits α-syn fibrillation in a concentration-dependent manner. A. 
Samples of α-syn (25 µM) were incubated alone or in the presence of GA (molar 
ration of GA: α-syn 4:1, 2:1, 1:1) for 6 days with continuous shaking at 37°C. 
Fibril formation was estimated by Th-S fluorescence. The assay was performed in 
triplicate (average of triplicate measurement ± standard deviation).B. Congo red 
binding for samples of α-syn (25 µM) incubated alone or in the presence of GA 
(molar ration of GA: α-syn 4:1, 2:1, 1:1) for 6 days with continuous shaking at 
37°C. Samples of α-syn (5 µM) aged alone or with GA were mixed with Congo 
red at a final concentration of 5 µM. The reaction samples were thoroughly mixed 
and placed in a 10mm quartz cuvette. The UV absorbance spectra were recorded 
from 400 nm to 600 nm. C-F. Electron microscopy images of negatively stained 
samples of α-syn (25 µM) aged alone or in the presence of GA (molar ratio of 
GA: α-syn 4:1, 2:1, 1:1) for 6 days with continuous shaking at 37°C. C. Aged α-
syn alone. D. α-Syn aged in the presence of GA at a molar ratio of GA: α-syn 4:1. 
E. α-Syn aged in the presence of GA at a molar ratio of GA: α-syn 2:1. F. α-Syn 
aged in the presence of GA at a molar ratio of GA: α-syn 1:1. Scale bar, 500 nm. 
 
4.3.2 The effect of GA on α-syn oligomerization (early aggregates) 
To evaluate the effect of GA on α-syn oligomer formation, samples of α-syn 
aged alone or in the presence of GA at different molar ratios were assessed for 
their oligomeric content by oligomer-specific ELISA and immunoblotting. For the 
detection of α-syn oligomeric species in the samples, we employed a novel ELISA 
developed in our laboratory at the UAEU (El-Agnaf, et al., 2006), which 
specifically recognizes the oligomeric species present in the samples. The ELISA 




oligomers when employed at the highest concentration namely 100 M. 
Interestingly, at lower concentrations, GA appeared to enhance α-syn 
oligomerization as compared to the control (Fig. 4.2 A). The samples of α-syn 
aged in the presence of 25 M and 50 M GA exhibited gradually increasing 
oligomeric content, which was much higher than the control (Fig. 4.2 A).  
Similarly, immunoblotting of the same samples (Fig. 4.2 B) indicated a 
decrease in the oligomeric species when α-syn was aged with 100 M GA (Fig. 
4.2 B), while there was a characteristic increase in the band corresponding to 
dimeric α-syn (Fig. 4.2 B). The same sample was also characterized by the 
presence of strong monomeric and trimeric (approximately 50 kDa) bands and the 
absence of the band corresponding to larger α-syn aggregates with a high 
molecular weight. However, in the presence of 50 M and 25 M GA, the bands 
corresponding to the oligomeric species were much stronger, with a 
concentration-dependent decrease in the bands corresponding to the monomeric, 
dimeric and trimeric species. Additionally, the intensity of the band corresponding 
to larger α-syn aggregates increased in a dose-dependent manner. These data 









































Figure 4.2. GA inhibits α-syn oligomerization at a high concentration, but at lower 
concentrations it promotes oligomerization. A. Samples of α-syn (25 M) aged 
alone or in the presence of GA at different molar ratios for 6 days with continuous 
shaking at 37°C were assessed for their ability to inhibit the formation of 
oligomers by the oligomeric ELISA assay. The assay was performed in duplicate 
(average of duplicate measurements ± standard deviations). B. Immunoblot 
analysis of the effect of GA on α-syn oligomerization. Fresh or aged α-syn 
samples alone or in the presence of GA at molar ratios of GA: α-syn 1:1, 2:1 and 
4:1 incubated for 6 days with continuous shaking at 37°C were separated by 
electrophoresis in a15% SDS-PAGE gel. Lane 1: fresh α-syn; lane 2: aged α-syn; 
lane 3: GA: α-syn molar ratio of 4:1, lane 4: GA:α-syn molar ratio 2:1 and lane 5: 





4.3.3 The effect of GA on preformed α-syn amyloid fibrils 
 
Given that GA was shown to be such an effective inhibitor of α-syn 
fibrillation, we investigated whether it could also reverse fibrillation. Therefore, 
25 µM of preformed α-syn fibrils (Fig. 4.3 A) were incubated at 37°C in the 
presence of GA at molar ratios of GA: α-syn of 6:1, 4:1 and 2:1 for a period of 48 
hours. By measuring the Th-S fluorescence counts (Fig. 4.4 A) we estimated the 
fibril content at the indicated time points. At time 0, the Th-S counts were 
approximately 8000 for all samples (Fig. 4.4 A). The α-syn fibrils that were 
incubated alone continued to aggregate further, as indicated by the increase in  
Th-S counts (Fig. 4.4 A). However, the α-syn fibrils that were incubated in the 
presence of GA disaggregated over time as shown by the decrease in the Th-S 
counts (Fig. 4.4 A). It is noteworthy that after 24 hours of incubation, α-syn fibrils 
incubated without GA gave approximately 18,000 Th-S counts, while the fibrils 
incubated with all concentrations of GA tested produced less than 2,000 Th-S 
counts (Fig. 4.4 A). Thus, GA disaggregated preformed α-syn fibrils in a dose-
dependent fashion. Furthermore, similar results were obtained when the 
experiment was performed using α-synuclein fibrils after reaching a plateau in Th-
























Figure 4.3. GA disaggregates preformed α-syn fibrils (after reaching plateau). A. 
Samples of α-syn (25 µM) were incubated alone for 5 days with continuous 
shaking at 37°C. Fibril formation was estimated by Th-S fluorescence. The assay 
was performed in triplicate (average of triplicate measurement ± standard 
deviation). B. Samples of aggregated α-syn were incubated for 48 hours at 37°C 
in the absence or presence of various concentrations of GA (GA: α-syn 6:1, 4:1, 
2:1). The fibril content was then measured by the Th-S binding assay. The assays 









After 48 hours of incubation, the samples were also tested for their CR 
binding (Fig. 4.4 B). As expected, α-syn fibrils incubated in the presence of GA 
produced spectra with a peak absorbance wavelength that was shifted slightly 
compared to the controls, indicating minimal -sheet content. In contrast, the 
fibrils of α-syn that were incubated alone produced a peak absorbance at 550 nm, 
indicating a high -sheet content (Fig. 4.4 B). These finding were confirmed by 
EM (Fig. 4.4 C). All samples at 0 were characterized by the presence of dense 
meshes of fibrils longer than 0.5 µm. However, the α-syn fibrils incubated in the 
presence of GA gradually became thinner and shorter and appeared fragmented, 
isolated and scarce, unlike the control, which continued to demonstrate networks 
of long fibrils (Fig. 4.4 C). 
To assess whether GA disaggregation of α-syn fibrils was accompanied by 
a decrease in α-syn toxicity, we then evaluated the toxicity of the α-syn species 
that resulted from the disaggregation experiment on human neuroblastoma BE(2)-
M-17 cells (Fig. 4.4 D). The samples were diluted to a final α-syn concentrations 
of 0.5 µM, 1 µM and 5 µM. Preformed α-syn fibrils incubated for 6 days in the 
absence of GA decreased cell viability in a dose-dependent manner. However, 
preformed α-syn fibrils incubated with GA for 6 days generated species that were 
less toxic compared to the control. This trend was most prominent for 5 µM α-
syn, which, when incubated in the absence of GA, induced the death of 45% of 






Figure 4.4. GA disaggregates preformed α-syn fibrils in a concentration-
dependent manner. A. Samples of aggregated α-syn were incubated for 48 hours 
at 37°C in the absence or presence of various concentrations of GA (GA: α-syn 
6:1, 4:1, 2:1). The fibril content was then measured by the Th-S binding assay. 
The assays were performed in triplicate (average of triplicate measurements ± 
standard deviations).B. Congo red binding to samples of pre-aged α-syn (25 µM) 
incubated alone or in the presence of GA (molar ratio of GA: α-syn 6:1, 4:1, 1:1) 
for 72 hours with continuous shaking at 37°C. Samples of α-syn (5 µM) incubated 
alone or with GA at different molar ratios were mixed with Congo red, at a final 
concentration of 5µM. The reaction samples were thoroughly mixed and placed in 
a 10mm quartz cuvette. The UV absorbance spectra were recorded from 400 nm 
to 600 nm. C. Electron microscopy images of negatively stained samples of pre-
aged α-syn (25 µM) incubated alone or in the presence of GA for 72 hours with 
continuous shaking at 37°C. 1. α-Syn aged alone. 2. α-Syn aged in the presence of 
GA at a GA:α-syn molar ratio of 6:1. 3. α-Syn aged in the presence of GA at a 
GA:α-syn molar ratio of 4:1. 4. α-Syn aged in the presence of GA at a GA: α-syn 
molar ratio of 2:1. Scale bar, 500 nm. D. The disaggregation of preformed α-syn 
fibrils by GA generated species that were less toxic to the cells. The viability of 
BE(2)-M-17  human neuroblastoma cells was assessed by the MTT assay. The 
results are expressed as percentages of the control average (i.e., untreated cells). 
The α-syn species generated by 72h incubation of preformed α-syn fibrils in the 
presence or absence of GA were added to the cells 48 hours prior to MTT addition 
(average of 3 wells ± SD. Statistical analysis was performed using two tailed 





4.3.4 The effect of GA on the seeding of α-syn aggregation 
It has been previously shown that the process of amyloid fibril formation 
follows a nucleation-dependent polymerization (Jarrett and Lansbury, 1992). 
According to this model, soluble species generated via the nucleation of 
oligomeric species (nucleation or lag time phase), which in turn polymerize 
(polymerization or growth phase) to generate fibrils, thus reaching a final plateau 
known as the equilibrium phase (Harper et al., 1999). Small aggregates or seeds 
have been shown to accelerate the nucleation phase of amyloid formation both in 
vitro and in vivo by a process known as seeding (Jarrett and Lansbury, 1993, Luk 
et al., 2012, Harper and Lansbury, 1997, Volpicelli-Daley et al., 2011). Given that 
GA inhibited both α-syn fibrillation and disaggregated preformed α-syn fibrils; we 
sought to identify the effect of this phenolic acid on the seeding of α-syn 
aggregation. More specifically, mature α-syn fibrils were fragmented by 
sonication to obtain short fibrils, which were employed as ‘seeds’ (Fig. 4.5 B). 
These short fibrillar ‘seeds’ were then added to monomeric α-syn, which was 
allowed to aggregate as described above. As expected, the addition of short 
fibrillar seeds accelerated the fibrillation of α-syn as indicated by the increased 
Th-S counts. Indeed, with seeding, the extent of α-syn fibrillation after 6 hours of 
incubation was comparable to the fibrillation of the protein incubated for 72 hours 
without seeding (Fig. 4.5 B and Fig. 4.1, respectively).  
In order to assess the effect of GA on the seeding of α-syn aggregation, 10 
and 50 µM GA was added to 100 µM monomeric α-syn containing seeds at a final 
concentration of 2 µM, and the mixture was incubated with continuous mixing at 
37°C for 6 hours. GA at 50 µM inhibited the seeded fibrillation of α-syn by 




concentrations (10 μM), GA also had an inhibitory effect on the seeded fibrillation 
of α-syn but to a smaller extent. At 10 µM, GA inhibited seeded fibrillation by 40-
















































Figure 4.5. GA inhibits the seeded fibrillation of α-syn. A. Samples of α-syn 
(100M) seeded with short fibrillar α-syn (2 M) were incubated in the presence 
or absence of GA at different concentrations (10 M and 50 M) for 6 hours with 
continuous shaking at 37°C. The extent of fibrillation was estimated by the Th-S 
binding assay. The assays were performed in triplicate (average of triplicate 
measurements ± standard deviations). B. Electron microscopy images of 
negatively stained samples of seeds alone and α-syn+ seeds incubated alone or in 
the presence of GA (50 M) for 6 hours with continuous shaking at 37°C. Scale 
bar represents 1000 nm. 
 
 
4.3.5 The effect of GA on α-syn aggregates-induced toxicity 
It has been reported that the oligomeric intermediates are the neurotoxic 
species in the amyloid fibrillation pathway (Allsop et al., 2001; Argyriou et al., 
2012; Breydo, Wu, & Uversky, 2012; Colla et al., 2012; El-Agnaf, Nagala, Patel, 
& Austen, 2001; El-Agnaf, et al., 2006; Vendruscolo, Paci, Dobson, & Karplus, 
2001; Walsh et al., 2002). As described above, at high concentration (4:1), GA 
inhibited both early and late aggregate formation, whereas at low concentrations 
(2:1 and 1:1), it stabilized α-syn oligomers         (Fig. 4.2 A). To determine the 
effect of GA on the toxicity conferred by α-syn aggregates, a cell-based toxicity 
assay, the MTT assay, was conducted with human neuroblastoma BE(2)-M-17 
cells. The samples were diluted to final α-syn concentrations of 5 µM and 0.5 µM. 
The MTT assay showed that α-syn aged in the absence of GA decreased cell 
viability in a dose-dependent manner (Fig. 4.6). However, when α-syn was aged 
in the presence of a high concentration of GA (4:1), there was visible 
neuroprotection of the cells observed (Fig. 4.6). At low concentrations (2:1 and 
1:1), GA exhibited a minor protective effect against α-syn toxicity, possibly due 
to the increase in oligomers as demonstrated by the ELISA results and the 
immunoblotting analysis (Fig. 4.2, A and B, respectively). Our results clearly 




µM) by significantly inhibiting the formation of toxic α-syn oligomers. The 
toxicity of the oligomers resulted from α-syn: GA 1:4 was compared with α-syn 
oligomers prepared in the absence of GA as described in the materials and 
methods section by using MTT assay (Fig. 4.6 B). Both samples were 
characterized for the presence of oligomers by using SDS PAGE (Fig. 4.6 C) and 
native PAGE (Fig. 4.6 D). It was clear, that the oligomers resulting from the 
incubation of α-syn with GA were not toxic comparing with oligomers in absence 
of GA. Moreover, these oligomers were stable under denaturing conditions (Fig. 
4.6 C) comparing with those formed in the absence of GA. 
 
Figure 4.6. Effect of GA on the toxicity of aggregated α-syn. A.The viability of 
BE(2)-M-17  human neuroblastoma cells was estimated by the MTT assay. The 
results are expressed as the percentage of the control average (i.e., untreated 
cells). The cells were treated with aggregated α-syn with/without GA for 48 hours 
prior to MTT addition (average of 3 wells ± standard deviation. Statistical 
analysis was performed using two-tailed unpaired t-test, ***, p< 0.001; *, p< 
0.05). B. The viability of BE(2)-M-17  human neuroblastoma cells was estimated 
by the MTT assay. The cells were treated with α-syn oligomers in absence or 
presence of GA for 48 hours prior to MTT addition (average of 3 wells ± standard 
deviation. C. Immunoblot analysis of α-syn oligomers generated in presence or 




Immunoblot analysis of α-syn oligomers generated in presence or absence of GA, 
separated by electrophoresis in a 3-12% Native-PAGE gel. 
4.3.6 GA inhibition of α-syn fibrillation is mediated via binding to the 
intermediate species and forming stable oligomers 
The strong inhibitory effect that GA exerted on fibrillation together with the 
stimulating effect it had on α-syn oligomerization at lower GA concentrations, 
prompted us to investigate further the interaction of GA with α-syn oligomers. For 
this purpose, monomeric α-syn (100 µM) was aggregated in the presence of GA 
(GA: α-syn 4:1). After 5 days of incubation the samples were centrifuged and the 
supernatant was injected in a superdex 200 SE column. The elution volume for 
monomeric α-syn was determined by a molecular weight standard (Fig. 4.7 A), 
and was eluted to a peak corresponding to a column volume of 13-15 mL (Fig. 4.7 
B), while oligomeric α-syn eluted in a peak corresponding to column volume of 
approximately 7-9 ml (Fig. 4.8 A). The fractions corresponding to the oligomeric 
and monomeric α-syn peaks were pooled together giving rise to P1 and P2 
samples, respectively (Fig. 4.8 A), which were concentrated using a speed vac. 
The α-syn species in samples P1 and P2 were characterized by western blotting 
(Fig. 4.8 B). According to the western blotting results, the oligomers generated 
during the incubation of α-syn with GA are stable under denaturing conditions 
(Fig. 4.6 C and 4.8 B). Electron microscopy of the same samples indicates the 
presence of different species of oligomers in P1 (Fig. 4.8 D), which agrees with 
the imunoblotting results (Fig. 4.8 B). In order to detect the incorporated GA in 
the P1 and P2 samples, we exploited the property of GA to produce UV 
absorbance spectra with two peaks, one at 225 nm and one at 260 nm. In the 




oligomeric P1 samples (Fig. 4.8 C). These findings support the hypothesis that 



















Figure 4.7. Size Exclusion Chromatography:A: Gel-filtration profile of MW 
standard containing Ferritin 440 KDa, Aldolase 171 KDa, Albumin 68 KDa and 
Chymotrypsinogen A 25 KDa using Superdex 200 column at 0.1 ml/min flow rate 
(0.5 ml/fraction). B: Gel-filtration profile for monomeric α-syn using Superdex 









Figure 4.8. GA binds to α-syn oligomers (GA: α-syn molar ratio of 4:1). A. Gel 
filtration profile of the 5-day aggregated a-syn in the presence of GA at a GA: α-
syn molar ratio 4:1 (α-syn concentration =100 µM) -using a superdex 200 SE 
column. P1 sample contains the isolated fractions corresponding to the oligomeric 
peak and P2 the isolated fractions corresponding to the monomeric peak. The 
elution was monitored at the absorbance wavelength of 215 nm. B. Immunoblot 
analysis of the samples P1 and P2 separated by electrophoresis in a 15% SDS-
PAGE gel. C. UV absorbance spectra of samples P1 and P2. The UV absorbance 
was recorded between 200-600 nm employing a 10 mm quartz cuvette. D. 
Electron microscopy images of negatively stained samples P1 and P2 of α-syn in 
the presence of GA (molar ratio of GA: α-syn 4:1) purified by SEC. Scale bar 




To further evaluate whether GA interacts with α-syn monomers, we 
monitored a titration of GA into a solution of monomeric α-syn using two-
dimensional NMR spectroscopy, which provides signals covering the entire amino 




observed no significant chemical shift or resonance intensity changes (Fig. 4.10 
A-E), confirming that GA does not interact significantly with monomeric α-syn. 
This result is largely in agreement with NMR studies of related compounds 




























Figure 4.9. Analysis of GA binding to monomeric α-syn by NMR spectroscopy. 
Proton-Nitrogen correlation (HSQC) spectra of monomeric α-syn in the presence 
of increasing ratios of GA: α-syn demonstrating that there are no significant 
changes in the positions of the NMR resonances, indicating the lack of an 



































Figure 4.10. Analysis of GA binding to monomeric α-syn by NMR spectroscopy. 
Ratios of NMR resonance intensities from proton-nitrogen (HSQC) correlation 
spectra in the presence of increasing ratios of GA: α-syn (A - 0.5:1, B - 1:1, C - 
2:1, D - 5:1, E - 10:1) to intensities observed in the absence of GA. The absence 
of any significant intensity changes in the presence of GA again confirms the 








4.3.7 Investigating the structure-activity relationship of GA inhibition of α-
syn fibrillation 
To define the most effective molecular scaffolds against α-syn fibril 
formation and establish a structure-activity relationship for GA, we exploited the 
structural diversity of benzoic acid derivatives (i.e., hydroxybenzoic acids). 
Twelve hydroxybenzoic acids, including GA, salicylic acid and gentisic acid (see 
Table 4.1) were assessed for their anti-fibrillogenic properties by the Th-S binding 
assay (Fig. 4.11).  



















Name of compound MW 
Benzoic acid 122.12 
2-Hydroxybenzoic acid (salicylic acid) 138.12 
3-Hydroxybenzoic acid 138.12 
4-Hydroxybenzoic acid 138.12 
2,3-dihydroxybenzoic acid 154.12 
2,4-dihydroxybenzoic acid 154.12 
2,5-dihydroxybenzoic acid 154.12 
2,6-dihydroxybenzoic acid 154.12 
3,4-dihydroxybenzoic acid 154.12 
3,5-dihydroxybenzoic acid 154.12 
2,4,6-trihydroxybenzoic acid 188.13 
3,4,5-trihydroxybenzoic acid (GA) 170.12 
3,4,5-trihfluorobenzoic acid 176.09 
3,4,5-trimethoxybenzoic acid 212.20 





The structure of the hydroxybenzoic acids tested was characterized by the 
presence of a phenyl ring that has a carboxyl group, and hydroxyl moieties (OH) 
attached to the ring at different positions. The selection of the compounds 
examined in the present study was based on the number (between 0-3) and 
position of the hydroxyl groups attached to the phenyl ring (see Table 4.2). 
 
Table 4.2. The compounds were divided into four groups based on the number of 






The kinetics of α-syn fibrillation was studied over a period of 5 days in the 
presence or absence of the phenolic acids. Based on the Th-S assay results (Fig. 
4.11 and Table 4.3), the effect of the twelve phenolic acids on α-syn fibrillation 
varied greatly. The extent of the inhibition of α-syn fibrillation was ~ 99% for 
GA, ~ 72% for 2,4,6-trihydroxybenzoic acid, ~ 60% for 3,4-dihydroxybenzoic 
acid  30% for five compounds including 2,6-dihydroxybenzoic acid and 4-
hydroxybenzoic acid and only 5% for benzoic acid (see Fig. 4.11 and Table 4.3).  
 
Table 4.3. Summary of  Th-S results showing the percentage of inhibition of fibril  
formation comparing with number of OH groups around the phenyl ring. 
 
 
Moreover, three compounds, 2-hydroxybenzoic acid (salicylic acid), 3-
hydroxybenzoic acid and 3,5-dihydroxybenzoic acid, failed to inhibit α-syn 
fibrillation, with salicylic acid appearing to enhance the aggregation of α-syn 





Inhibition% of -syn 
aggregation 
PA1 3,4,5-trihydroxybenzoic acid 3 99% 
PA2 2,4,6-trihydroxybenzoic acid 3 72% 
PA3 2,3-dihydroxybenzoic acid 2 44% 
PA4 2,4-dihydroxybenzoic acid 2 35% 
PA5 2,5-dihydroxybenzoic acid 2 30% 
PA6 2,6-dihydroxybenzoic acid 2 16% 
PA7 3,4-dihydroxybenzoic acid 2 60% 
PA8 3,5-dihydroxybenzoic acid 2 0% 
PA9 2-hydroxybenzoic acid  1 0% 
PA10 3-Hydroxybenzoic acid 1 0% 
PA11 4-Hydroxybenzoic acid 1 9% 
PA12 Benzoic acid 0 5% 
PA13 4-methoxybenzoic acid 0 0% 
PA14 3,4,5-trimethoxybenzoic acid 0 0% 




Figure 4.11. Effect of different benzoic acid derivatives (phenolic acids, PA) and 
the effect of methoxy and fluoro groups in benzoic acid derivatives on α-syn 
fibrillogenesis. Samples of α-syn (25 µM) were incubated alone or in the presence 
of different benzoic acid derivatives (PA: α-syn molar ratios of 4:1, 2:1, 1:1) for 6 
days with continuous shaking at 37°C. The fibril formation was measured by the 
Th-S binding assay and expressed as a percentage of the fibril content of α-syn 
aged alone. The assay was performed in triplicate (average of triplicate 









The formation of amyloid aggregates has long been considered responsible 
for the pathogenesis of several neurodegenerative disorders (Dorval & Fraser, 
2007; Taylor, Hardy, & Fischbeck, 2002; Vekrellis, Xilouri, Emmanouilidou, 
Rideout, & Stefanis, 2011). Although amyloidogenic proteins, such as α-syn, ar e 
usually found unfolded in their native state (Fauvet et al., 2012; Uversky, 2008), 
in which they are soluble and non-toxic, they can undergo misfolding resulting in 
the formation of insoluble aggregates (Irvine, et al., 2008; Kahle, 2008; Seidler et 
al., 1996; Stefanis, 2012; Veldman, Wijn, Knoers, Praamstra, & Horstink, 1998). 
These aggregates deposit in various regions of the brain, constituting the main 
neuropathological feature of several neurodegenerative diseases such as PD, DLB, 
MSA and approximately 50% of Alzheimer’s cases. In the case of α-syn, 
pathological, biochemical, genetic and animal modeling studies provide 
compelling evidence that α-syn aggregation plays a pivotal role in the 
pathogenesis of PD and related synucleinopathies. As a consequence, the 
identification of compounds that can block or reverse the aggregation process of 
α-syn is considered a vital therapeutic strategy against these diseases. 
To this end, we assessed the effect of the phenolic compound GA (3,4,5-
trihydroxybenzoic acid) on α-syn aggregation and toxicity, and we established a 
structure-activity relationship for GA. By employing an array of biophysical and 
biochemical techniques, we showed that at a high concentration (100 Μ, 
represented by the molar ratio of 4:1), GA exerts significant inhibitory effect on 
both α-syn fibrillation (Fig. 4.1, A and B) and oligomerization (Fig. 4.2, A and B), 
as well as seeded fibrillation of α-syn (Fig. 4.5 A). In accordance with these 




concentration only formed a few short, thin fibrils that had a fragmented 
appearance (Fig. 4.1 D) accounting for the low Th-S counts (Fig. 4.1 A) and a 
minor wavelength shift in the CR binding assay (Fig. 4.1 B). At lower GA 
concentrations (especially at 1:1 molar ratio), however, the ability of the GA to 
inhibit α-syn fibrillation was less dramatic and accompanied by a striking increase 
in the oligomeric content (Fig. 4.2 A), indicating GA may stabilize the oligomeric 
structure. Size exclusion chromatography combined with UV spectroscopy for 
detection of the GA incorporated in α-syn confirmed that GA binds to α-syn 
oligomers (Fig. 4.8 C). Furthermore, GA was able to disaggregate preformed α-
syn fibrils (Fig. 4.4, A-C), generating species that possessed a decreased -sheet 
content (Fig. 4.4 B) and were less toxic to cells (Fig. 4.4 D). Previous studies have 
also shown that the phenolic flavonoid compound baicalein, as well as other 
antioxidant compounds inhibit α-syn fibrillation and disaggregate pre-aggregated 
fibrils (Ono & Yamada, 2006; Zhu et al., 2004).  GA was also shown to alleviate 
α-syn aggregates associated-toxicity in neuroblastoma BE(2)-M-17 cells (Fig. 4.6 
A and B).  
These results are in agreement with previous studies indicating that GA possesses 
anti-fibrillation, oligomer-stabilizing and neuroprotective properties against α-syn 
and A cytotoxicity (Di Giovanni, et al., 2010). Indeed, GA was shown to 
stabilize biotinylated A1-42 oligomers (LeVine, Lampe, Abdelmoti, & Augelli-
Szafran, 2012) and to inhibit the in vitro conversion of low molecular weight A1-
42 protofibrils into fibrils by 50% (Di Giovanni, et al., 2010). Additionally, GA 
was reported to block the fibrillation of α-syn in vitro and to suppress the ability 
of short α-syn fibrils to seed the aggregation of monomeric α-syn (Di Giovanni, et 




cytotoxicity of α-syn and A1-42 (Di Giovanni, et al., 2010), possibly due to the 
inhibition of the amyloid aggregation but potentially also due to the anti-
inflammatory (D. H. Kim et al., 2011), anti-oxidant (Ban et al., 2008; S. Y. Hong, 
Jeong, & Jun, 2012) and anti-apoptotic properties it possesses (S. Y. Hong, et al., 
2012). 
Based on our findings using both SEC and NMR, as well as previous reports, GA 
inhibits α-syn fibrillation not by interacting with the monomeric α-syn - similar to 
many other phenolic compounds (reviewed by (Porat, et al., 2006), and preventing 
it from polymerizing but rather by stabilizing the structure of oligomeric α-syn 
(Fig. 4.2 B, 4.8 C) which appears to be non-toxic (Fig. 4.6). These findings are in 
accordance with previous studies indicating that polyphenolic compounds, such as 
baicalein, curcumin and epigallocatechin gallate (EGCG) induce the formation of 
soluble, non-toxic oligomers (Masuda et al., 2006; Zhu, et al., 2004). From a 
therapeutic point of view, this represents a major advantage, as GA may not 
interfere with the physiological function of the monomeric α-syn (Wagner et al., 
2013). It has been reported that phenolic compounds such as curcumin inhibit A 
aggregation due to conformation-dependent binding (F. Yang et al., 2005). 
Consistent with this model of inhibition, GA also inhibited the seeding ability of 
short fibrillar α-syn. Although the presence of oligomers can be transient as they 
assemble into fibrils (Fink, 2006; Kaylor et al., 2005a), there are studies revealing 
that in the presence of the polyphenolic compound EGCG, they can shift off-
pathway from fibrillation (D. E. Ehrnhoefer, et al., 2008). Indeed, EGCG was 
shown to promote the formation of less toxic oligomers that were exceedingly 
stable and incapable of contributing to the aggregation process (D. E. Ehrnhoefer, 




oligomers by a mechanism similar to that of EGCG, accelerating the formation of 
off-pathway oligomers and leading to the accumulation of non-toxic oligomers 
and the interruption of the fibrillation process.  
To gain insight into the mechanism of action of GA and to establish a 
structure-function relationship for this phenolic acid, we evaluated the effect of 
various structurally similar phenolic acids on α-syn fibrillation. The results 
generated from this approach point towards a structure-related effect on α-syn 
fibrillation in which the better inhibitors were observed to have a greater number 
of -OH groups attached to the phenyl ring that were directly conjugated to the 
carboxylic acid arm (see Fig. 4.11). In fact, the ranking of the anti-fibrillogenic 
potency of all the phenolic compounds tested could be represented as follows: 
trihydroxybenzoic acid>dihydroxybenzoic acid>monohydroxybenzoic acid = 
benzoic acid. This finding is in accordance with previous studies indicating that 
the potency of certain polyphenolic compounds to inhibit and disaggregate α-syn 
oligomers correlates with the number of vicinal - OH groups present on a single 
phenyl ring (Caruana et al., 2011; Masuda, et al., 2006). The significance of the 
presence of the hydroxyl group on the phenyl ring was further stressed by the fact 
that the compounds that possess appendages other than hydroxyl groups on the 
phenyl rings failed to inhibit α-syn aggregation. At this point, it is more than idle 
speculation to suggest that the inhibition capacity of the phenolic compounds is 
not only dependent on the number of hydroxyl moieties but also on their position 
and conjugation with respect to the benzoic acid appendage. Comparison of the 
two trihydroxybenzoic acids tested in this study, GA (3,4,5-trihydroxybenzoic 
acid) and 2,4,6-trihydroxybenzoic acid, indicates that although both compounds 




syn fibrillation compared to the latter, strongly suggesting that it is not only the 
total number of -OH groups present in the molecule but also their position that is 
important. Additionally, comparison of the dihydroxybenzoic acids employed in 
the present study reveals that the presence of -OH groups in two consecutive 
positions and conjugated with the carboxyl group (e.g., 3,4-dihydroxybenzoic acid 
(60% inhibition) and 2,3-dihydroxybenzoic acid (44% inhibition)) renders the 
compounds more active compared to those that have hydroxyl groups in non-
consecutive positions (e.g., 2,5-dihydroxybenzoic acid (30% inhibition) and 3,5-
dihydroxybenzoic acid (0% inhibition) (see Fig. 4.11 and Table 4.3).The 
importance of the 4 - OH moiety is emphasized by the fact that of the three 
hydroxybenzoic acids tested, only 4-hydroxybenzoic acid could partially inhibit 
α-syn fibrillation. Among the dihydroxybenzoic acids, 3,4-dihydroxybenzoic acid 
was the most potent of all, inhibiting fibrillation by 60% (Table 4.3). Taken as a 
whole, these data show that the total number of - OH groups present in the 
molecule is important for the compound activity and that the position of the 
overall -OH groups also affects activity, with a hydroxyl group at position 4 
appearing to play a significant role. Thus, the presence of three vicinal hydroxyl 
groups, as in 3,4,5-trihydroxy benzoic acid (GA), or the three homo-vicinal 
groups, as in 2,4,6-trihydroxy benzoic acid, with one - OH group at position 4, 
enhances the compounds able to inhibit α-syn fibrillation to a great extent.  
 
Given that all the compounds tested in this study have a phenyl ring in 
their structures, the phenyl structure itself is clearly not sufficient to inhibit α-syn 
aggregation. Consequently, the inhibition ability of such compounds must be 




The conjugated hydroxyl groups with the carboxylic acid appendage can easily 
form quinone structures (see Fig. 4.12). It is worth mentioning that quinone 
formation has been previously reported as the potential mechanism for the 
inhibition of α-syn fibrillation by the phenolic compound (Zhu, et al., 2004). The 
formation of such oxidized derivatives can increase the stability of the compound 
binding to the α-syn fibrils (Taniguchi et al., 2005), possibly accounting for the 
increased inhibitory potency of the compounds with more - OH groups present in 
their structures. Quinones are likely to interact with the aromatic residues of α-
syn, interfering with their π−π stacking (Ebrahimi & Schluesener, 2012; Hamley, 
2012; Porat, et al., 2006). Moreover, quinones have a planar orientation that 
allows them to align with the hydrophobic groove of α-syn fibrils, which possess 
an in-register organization of side chains in the regular cross-β-sheet structure 
(Ebrahimi & Schluesener, 2012; Hamley, 2012; Porat, et al., 2006). Therefore, the 
inhibition of α-syn fibrillation by GA and 2,4,6-trihydroxybenzoic acid could be 
attributed to the combined properties of their three -OH groups and quinone-
forming structures. Based on these results, we propose a plausible model to 
interpret the inhibitory and disassembling effects of GA. Two dominant ligand-
protein interactions contribute to inhibitor potency, (a) the dipole-dipole 
interactions of the quinone and (b) the dipole-dipole interactions of the diquinone 
group. The most potent inhibitors, with 3,4,5-trihydroxy and 2,4,6-trihydroxy 
substitution patterns (GA and 2,4,6-trihydroxy benzoic acid, respectively), (see 
Fig. 4.12 c), enable both hydrophobic and dipole-dipole interactions. The π−π 
stacking is known to play a role in the binding affinity of inhibitors to aggregates; 
increasing the potential for quinone formation of each compound generally leads 




Consistent with this interpretation, ortho- and meta-hydroxybenzoic acid, as well 
as benzoic acid (see Fig. 4.12 f) showed no inhibition compared to their para- and 
ortho-paradihydroxy (Fig. 4.12 a) counterparts due to the inability of the former to 
















Figure 4.12. Mechanistic insight for the mechanism of quinone formation. 
 
 
Although monocyclic compounds such as phenolic acids were previously 
shown to be very poor inhibitors of aggregation (Reinke & Gestwicki, 2007), later 
studies revealed that monocyclic compounds could suppress amyloid assembly by 





inhibiting the transition to -sheet structures (Levy-Sakin, Shreberk, Daniel, & 
Gazit, 2009). It is therefore likely that phenolic acids, especially GA, act in a 
similar way, interacting with oligomers and stabilizing their structure through the 
- OH groups, preventing the transition to -sheet-rich structures. This may explain 
the increased oligomeric content detected at low GA concentrations and the low 
-sheet content of α-syn species generated in the presence of GA. 
In summary, we conducted a systematic study of the effect of GA on α-syn 
fibrillation, oligomerization and toxicity, and we conclude that GA inhibits α-syn 
fibrillation and toxicity by stabilizing the non-toxic oligomeric structure of α-syn 
through oligomer binding. Our study points toward a structure-related inhibition, 
with the number of - OH moieties and their position around the phenyl ring 
playing a fundamental role. Based on the above experimental results, we propose 
a model to interpret the inhibitory and disassembling effects of GA derivatives on 
α-syn aggregation (see Fig. 4.12). α-Syn aggregation is a sequential process in 
which unstructured α-syn monomers undergo conformational transition and re-
ordering to form oligomers and then finally amyloid fibrils (routes a → b → c → 
d, Fig. 4.12). The analysis of the results obtained from this study shows that GA 
derivatives can prolong the nucleation process, suggesting that these scaffolds can 
bind to unstructured α-syn oligomers and prevent protein association (Fig. 4.12, 
route a → f) and/or slow down the conformational transition to structured 
oligomers, the precursors of amyloid fibrils. GA derivatives interact with α-syn 
monomers and/or oligomers through π-π stacking, leading to the formation of an 
energy barrier that prevents the association of α-syn molecules. Meanwhile, GA 
derivatives through their respective quinone oxidation products could induce 




β-sheet groove regions of α-syn fibrils, leading to fibril disaggregation (d → e). It 
should be noted that, due to the hydrophobic aromatic nature and planar structure 
of quinones, they might interact with α-syn fibrils by relatively nonspecific 
dipole-dipole interactions with β-sheet-rich side chains. This binding mode 
implies that quinones could have a general inhibitory effect on the aggregation of 
α-syn. A Schematic model for the anti-aggregation and disassembly effect of GA 
derivatives on α-syn is shown in (Fig. 4.13). 
Figure 4.13. Schematic model for the antiaggregation and disassembly effect of 
GA derivatives on α-syn. 
 
 
By comparing the structures of the most effective and least effective 
compounds, we concluded that better inhibition of fibrillation is observed when 
there are a large number of hydroxyl groups (- OH) attached to the phenyl ring of 
the compound. Moreover, the positions at which the hydroxyl groups are attached 




attached at positions 3, 4 and 5 (see Table 4.2) and is much more effective than 
2,4,6-trihydroxybenzoic acid, which also bears three - OH groups but at different 
positions (Fig. 4.11). Interestingly, 3,4-dihydroxybenzoic acid, which only lacks 
an - OH group at position 5 compared to the very effective GA, is the third best 
inhibitor of α-syn fibrillation (Fig. 4.11). Among all the dihydroxybenzoic acids 
tested, the ones with - OH groups at two consecutive positions, i.e., 3,4-
dihydroxybenzoic acid (60% inhibition) and 2,3-dihydroxybenzoic acid (44% 
inhibition), are more potent inhibitors compared to those that have -OH groups at 
non-consecutive positions, i.e., 2,5-dihydroxybenzoic acid (30% inhibition) and 
3,5-dihydroxybenzoic acid (0% inhibition) (Fig. 4.11). Additionally, all 
compounds with one -OH group, as well as the benzoic acid without an OH 
group, failed to show any inhibitory effect on α-syn aggregation (Fig. 4.11). 
To further investigate the significance of the (-OH) moieties on the 
activity of the GA and the other active phenolic acids, three additional compounds 
with either fluorides or methoxy groups rather than hydroxyl groups attached to 
their phenyl rings (4-methoxybenzoic acid, 3,4,5-trimethoxybenzoic acid and 
3,4,5-trifluorobenzoic acid) (see table 4.2) were tested for their ability to inhibit α-
syn fibril formation. As expected, none of the three tested compounds in any of 
the three molar ratios tested (compound: α-syn 4:1, 2:1 and 1:1) could inhibit α-
syn fibrillation (Fig. 4.11). This finding provides additional support for the 











5 Chapter 5: Ginsenoside Rb1 inhibits fibrillation and 
Toxicity of alpha-synuclein and disaggregates 
preformed fibrils 
5.1 Introduction 
α-Syn aggregation proceeds through the formation of oligomers (early 
aggregates), which ultimately convert into well-ordered fibrils (late aggregates) 
(Uversky, Lee, Li, Fink, & Lee, 2001). Recent studies indicate that early 
aggregates of α-syn, the so-called soluble oligomers, form the pathogenic species 
that drive neurodegeneration and neuronal cell death rather than mature amyloid 
fibrils (Conway et al., 2000b; El-Agnaf, et al., 2003; Winner, et al., 2011). 
The drugs currently available for the treatment of PD provide symptomatic 
relief but do not alter the course of the disease (He et al., 2013). However, the 
effectiveness of these drugs diminishes after several years of treatment. Together 
with the increasing incidence of PD due to an aging population, these facts 
indicate the compelling need for more effective drugs and treatments for PD. 
Although modern therapeutic options that target disease modifications are on the 
rise, the multiple mechanisms involved in the pathogenesis of PD create 
considerable difficulties in producing effective treatments. Hence, the inhibition 
of α-syn aggregation may represent a viable strategy for therapeutic intervention 
in PD and related disorders. It is therefore essential to identify compounds that 




Ginseng is a well-known medicinal herb that has been used for more than 
two thousand years in China, Korea and Japan to promote well-being and alleviate 
fatigue. Although there are eleven different species of ginseng that belong to the 
genus Panax of the Aralliaceae family, the most commonly used species are 
Panax ginseng (Asian or Korean Ginseng), P. quinquefolius (American Ginseng), 
P. japonicus (Japanese Ginseng) and P. notoginseng (Chinese Notoginseng or 
Sanchi) (F. Chen, Eckman, & Eckman, 2006). Named after its ability to treat 
several conditions - panax means panacea in Greek ginseng is now a well-
documented anti-carcinogenic, anti-diabetic, anti-oxidant and vasorelaxing agent 
that exhibits immunomodulatory properties and improves the function of the 
central nervous system (Lü, Yao, & Chen, 2009). The numerous pharmacological 
properties of ginseng are attributed to its biologically active ingredients, the 
ginsenosides (reviewed by (Im & Nah, 2013), which can be extracted from many 
parts of the ginseng plant, including the root, the leaves and the berries (Attele, 
Wu, & Yuan, 1999). Ginsenosides, which are also referred to as ginseng saponins, 
are derivatives of triterpenoid dammarane with a four-ring, steroidal structure 
bearing sugar moieties and an aliphatic side chain (Wee JJ, 2011). The variations 
in the structure of ginsenosides, namely the type of aglycone (triterpene), the type 
of sugar moieties (glucose, maltose, fructose, saccharose etc), their number and 
their site of attachment (Wee JJ, 2011), give rise to three categories of ginseng 
saponins, the panaxadiol group, the panaxatriol group and the oleanolic acid 
group (Kim et al., 2013). More than 100 ginsenosides have been identified so far 
(Nag, et al., 2012), but the most frequently studied ones are Rb1, Rg1, Rg3, Rd, 






Ginsenosides have been shown to affect voltage-gated ion channels, such as 
the Ca2+, Na+, K+ channels, as well as the ligand-gated ion channels, such as the 
5-HT3-, the α7 nicotinic acetylcholine and the N-methyl-d-aspartate (NMDA)-
gated channels (reviewed by (Nag et al., 2012; Radad, Moldzio, & Rausch, 2011). 
This property of ginsenosides appears to underlie many of the pharmacological 
effects of ginseng, including neuroprotection (J. H. Kim et al., 2007), since it has 
a beneficial effect on many neurological conditions, including neurodegenerative 
diseases such as PD (reviewed by (Cho, 2012; H. J. Kim, Kim, & Shin, 2013). 
However, despite numerous studies exploring the effect of various ginsenosides 
on the nervous system, there are no reports on the effect of ginsenosides on the 
aggregation propensity of amyloidogenic proteins such as α-syn. As a 
consequence, we sought to determine the potential of the most frequently used 
and studied ginsenosides, namely Rb1, Rg1 and (20S)-Rg3, i.e. the stereoisomer 

























5.2 Experimental procedure 
5.2.1 Expression and purification of recombinant human α-syn.  
As described the experimental procedure 3.2.1 
5.2.2 α-Syn purification and characterization.  
As described the experimental procedure 3.2.2 
5.2.3  Aggregation of α-syn in vitro.  
Protein purity was estimated to be >95% using an SDS gel. The 
ginsenosides were purchased from the National Institute for the Control of 
Pharmaceutical and Biological Products, China (NICPBP). Ginsenosides stock 
solutions (10 mM) were prepared in 100% DMSO such that the final amount of 
DMSO in the sample solutions was 1%. Samples of 25 µM α-syn in PBS were 
aged alone or with ginsenosides at various molar ratios (ginsenoside: -syn molar 
ratios of 4:1, 2:1 and 1:1). The samples were placed in 1.5 ml sterile 
polypropylene tubes, drops of mineral oil were added to prevent sample 
evaporation, and the tubes were then sealed with parafilm and incubated at 37°C 
for 5 days with continuous shaking at 800 rpm in a thermomixer (Eppendorf). 
Samples were collected at the indicated intervals, and a thioflavin-T assay was 
performed immediately at each time point, while the rest of the samples were 
stored at -80°C until required for further analyses.  
5.2.4 Thioflavin-T (Th-T) assay 
α-Syn fibril formation was monitored by Th-T binding assay. Th-T is a 
fluorescent dye that interacts with fibrils containing a β-sheet structure. A total of 
10 µl of each sample was diluted in 40 µl of Th-T in PBS. Fluorescence was then 
measured in a 384-well, untreated black micro-well plate (Nunc, Denmark) using 




emission wavelengths set at 450 and 486 nm, respectively. To allow for 
background fluorescence, the fluorescence intensity of a blank PBS solution was 
subtracted from all readings. 
5.2.5  Transmission electron microscopy (TEM).  
As described in the experimental procedure 3.2.8 
5.2.6  Immunoblotting. 
As described in the experimental procedure 4.2.6 
5.2.7  Congo red binding assay.  
As described in the experimental procedure 4.2.10 
5.2.8  Proteinase K (PK) digestion.  
Samples of -syn (25 µM), aged alone or with Rb1, Rg1 or Rg3 (-syn: 
compound molar ratio of 1:1) were incubated for 15 mins at 37ºC with PK 
(Sigma-Aldrich, USA) to a 2.5 µg/ml. The reaction was stopped by the addition of 
2x sample loading buffer (250 mM Tris-HCl, pH 6.8, 30% glycerol, 0.02% 
bromophenol blue, 8% SDS, 5% beta-mercaptoethanol), and then heated for 10 
mins at 95ºC. The samples were loaded and run into 15% SDS-PAGE gels which 
were then silver stained. 
5.2.9  Tissue culture of BE(2)-M-17  human neuroblastoma cells.  
As described the experimental procedure 3.2.10 
5.2.10  Measurement of cell viability.  
As described in the experimental procedure 3.2.13 
5.2.11  Immunocytochemistry staining.  
BE(2)-M-17 cells expressing wt- α-syn were plated on 12-mm coverslips in 
24-well plate for 24 hours. The cells were then washed twice with PBS and fixed 




washes (5 mins each with PBS) the cells were permeabilized by incubating for 10 
mins at room temperature with PBS-1% Triton and then incubated in a blocking 
buffer [5% normal goat serum (NGS) in PBS + 1% Triton] for 1 hour at room 
temperature. Fixed cells were incubated with anti α-syn 211 Ab for 3 hours at 
room temperature and then washed three times with PBS. FITC conjugated goat 
anti-mouse secondary Ab (Sigma) was added to the cells for 1 hour at room 
temperature, and after three washes with PBS the cells were counterstained with 
DAPI to reveal nuclei, and mounted in Shandon immu-mount (Thermo 
Scientific). Fluorescent images were taken with an inverted Axiovert 40 CFL 
fluorescence microscope (Carl Zeiss), equipped with AxioCam HRc (Carl Zeiss) 
using the 63x oil objective. 
5.2.12 -Syn disaggregation assay.  
α-Syn solution in PBS (pH 7.4) was aggregated at a concentration of 25 μM 
as indicated above. The resulting aggregated -syn was incubated either alone or 
with Gn Rb1 at various molar ratios (Gn Rb1: -syn molar ratios of 6:1, 4:1 and 
2:1). It should be noted that for the purpose of the experiment, the concentration 
of -syn taken into account was the concentration of fresh -syn. The samples 
were incubated at 37°C for 48 hours on a thermomixer with continuous shaking at 
800 rpm. Samples were collected at regular time points, and Th-T fluorescence 
was measured immediately. 
5.2.13  Seeding polymerization assay.  
The aggregation of monomeric α-syn with or without seeding was 
performed as described elsewhere (Di Giovanni, et al., 2010). The seeds were 
prepared by fragmenting the mature -syn fibrils by sonication to obtain short 
fibrils, which were employed as ‘seeds’. Monomeric α-syn at a concentration of 
100 μM was seeded with 2 μM of seeds and incubated in the presence or absence 
of Gn Rb1 (10 μM or 50 μM) at 37°C for 6 hours with continuous shaking. The 





5.2.14 Size Exclusion Chromatography (SEC) for separating α-syn oligomers 
and monomers.  
As described in the experimental procedure 4.2.13 
5.2.15 UV scanning.  
As described in the experimental procedure 4.2.14 
5.2.16 NMR studies.  
As described in the experimental procedure 4.2.15 
5.3 Results 
5.3.1 The effect of ginsenosides on α-syn fibrillation 
A 25 µM solution of α-syn , which was purified by reverse-phase HPLC 
chromatography and its purity was estimated by SDS-PAGE and immunoblotting 
(Scheme 3.1 B and C) was incubated at 37ºC with continuous shaking for 5 days, 
leading to fibril formation, which was monitored by Th-T fluorescence at regular 
time intervals. α-Syn was incubated with Gn Rg1, Gn (20S)-Rg3 and Gn Rb1 at 
molar ratios of 4:1, 2:1 and 1:1 (molar ratio ginsenosides: α-syn) with a constant 
α-syn concentration of 25 µM. From the three tested compounds, only Gn Rb1 
exhibited a significant inhibitory effect on α-syn fibrillation as indicated by the 





























Figure 5.1. Gn Rb1 inhibits -syn fibrillation. A. Samples of α-syn (25 µM) were 
incubated for 5 days at 37°C with continuous shaking in the presence of various 
concentrations of the ginsenosides Rb1, Rg1 and (20S)-Rg3 (100 µM, 50 µM and 
25 µM). Fibril formation was measured by Th-T binding assay. The assay was 
performed in triplicate, and the means ± standard deviations are shown. B. Congo 
red binding for Gn Rb1, Gn Rg1 and Gn (20S)-Rg3. α-Syn (5 µM) aged alone or 
in the presence of different concentrations of ginsenosides was mixed with Congo 
red (final concentration of 5 µM). The UV absorbance spectrum was recorded 
from 400 to 600 nm in a spectrophotometer. C. Silver staining for 15% SDS gel of 
α-syn monomers, α-syn aged alone or in the presence of Rb1, Rg1 and Rg3 at 
molar ratio 1:1 after 2.5 µg/ml PK digestion. D. Electron microscopy images of 
negatively stained samples of α-syn (25 µM) aged alone or in the presence of the 
ginsenosides (gincenoside: -syn molar ratios of 4:1, 2:1, and 1:1) for 5 days with 




This effect was observed as early as after 2 days of incubation, when the 
inhibition percentage was approximately 90%. After 5 days of incubation, the 
fibrillation of -syn was reduced by approximately 80%. In contrast, Gn Rg3 
showed a partial inhibitory effect, which was most prominent on the third day of 
incubation. After 5 days of incubation, Gn Rg3 inhibited the fibrillation of -syn 
by approximately 25%, (Fig. 5.1 A). The extent of inhibition was comparable for 
all concentrations tested. The third compound tested, Gn Rg1, had no significant 
effect on -syn fibrillation given the comparable Th-T measurements produced by 
the Gn Rg1 containing samples and the control, that is the α-syn solution aged 
alone (Fig. 5.1 A).  
The ability of the three ginsenosides to block α-syn fibril formation was 
further assessed by the Congo red (CR) binding assay. CR is a dye with high 
affinity for amyloid fibrils (Groenning, 2010). Upon binding to -syn fibrils, the 
absorption maximum of CR shifts from 490 to 508 nm. This shift was quite 
pronounced for the -syn sample incubated in the absence of any of the three 
compounds (i.e. control) (Fig. 5.1 B). However, this characteristic shift was not 
observed for -syn samples aged in the presence of Gn Rb1, indicating that this 
compound inhibited the formation of amyloid fibrils (Fig. 5.1 B). Indeed, the 
absorption maximum of CR bound to the -syn samples containing Gn Rb1 (at all 
concentrations tested) only shifted a few nm and did not exceed the wavelength of 
495 nm (Fig. 5.1 B). Interestingly, the CR shift was comparable to the shift 
observed for monomeric α-syn. In contrast, the samples incubated in the presence 
of Gn Rg1 and (20S)-Rg3 behaved similarly to the control sample, exhibiting the 
characteristic shift from 490 nm to approximately 508 nm. To test if the formed α-




in the presence of Gn Rb1, Rg1 and Rg3 at molar ratio of 1:1 were treated with 
2.5 µg/ml PK; the digested samples were then run on 15% SDS-PAGE and the gel 
was silver stained as described in the materials and methods. The α-syn aged in 
the presence of Rb1 was easily digested by PK and behaved exactly as the 
monomeric α-syn (Fig. 5.2 C), while the samples of aged α-syn alone or in the 
presence of Rg1 and Rg3 were resistant to digestion (Fig. 5.2 C) possibly due to 
presence of β-sheets in these samples (Fig. 5.1 A, B). 
These findings were further confirmed by electron microscopy. TEM 
images of α-syn aged in the presence of Gn Rb1 showed that -syn formed thin, 
short, rod-like fibrils, with a fragmented appearance (Fig. 5.1 D), unlike the dense 
meshes of long fibrils formed by α-syn aged alone (Fig.5.1). For both Gn Rg1 and 
Gn (20S)-Rg3, TEM confirmed that there was little or no change in fibril 
morphology compared with the control, consistent with the Th-T fluorescence and 
CR binding findings (Fig. 5.1 D). 
5.3.2 The effect of ginsenosides on α-syn oligomerization  
The effect of the Gn Rg1, Gn (20S)-Rg3 and Gn Rb1 over α-syn 
oligomerization was assessed by western blotting. The samples of α-syn aged 
alone or in the presence of the three ginsenosides were centrifuged (14,000 rpm, 
15 mins, 4ºC) and the supernatants were separated on 15% SDS gels, transferred 
onto nitrocellulose membranes and probed with an antibody that recognizes the 
amino acid residues 121-125 of α-syn (anti-α-syn clone 211). Gn Rb1, which was 
shown to inhibit α-syn fibrillation, was also a potent inhibitor of α-syn 
oligomerization at all molar ratios (Fig. 5.2 A). More specifically, Gn Rb1 
inhibited the formation of larger aggregates (MW >250 kDa) and high MW 




(Fig. 5.2 A). Densitometric analysis of the monomeric bands revealed that Gn 
Rb1 hindered -syn oligomerization to the same extent in all tested 
concentrations, (Fig. 5.2 A). It should be noted that even at the lowest 
concentration, Gn Rb1 was able to inhibit the formation of larger aggregates. 
The other two ginsenosides, Gn Rg1 and Gn (20S)-Rg3, failed to inhibit α-
syn oligomerization, similarly to their effect on α-syn fibrillation. In fact, in the 
presence of Gn Rg1, -syn oligomerization was enhanced compared with the 
control, as indicated by the detection of numerous strong bands corresponding to 
the oligomeric species (Fig. 5.2 B). Densitometric analysis of the monomeric 
bands showed that Gn Rg1 stimulated α-syn oligomerization to the same extent at 
all concentrations tested (Fig. 5.2 B). In the case of Gn (20S)- Rg3, at every 
concentrations tested of the compound, the separation of -syn in the gel 
generated bands comparable with that of the control, indicating that Gn (20S)-Rg3 




















































Figure 5.2. Immunoblot analysis showing the effect of ginsenosides on α-syn 
oligomerization. α-Syn alone or in the presence of ginsenosides at ginsenoside: α-
syn molar ratios of 1:1, 2:1 and 4:1, was incubated for 5 days. Lane 1, 
ginsenoside: α-syn 1:1, lane 2, ginsenoside: α-syn 2:1, lane 3, ginsenoside: α-syn 
4:1, A: aged α-syn and M: fresh α-syn. A. Gn Rb1, B. Gn Rg1, C. Gn Rg3. The 
amount of the monomeric α-syn in the samples was quantified using ImageJ 





5.3.3 The effect of ginsenosides on α-syn-induced cytotoxicity 
BE(2)-M-17  human neuroblastoma cells were treated with aged α-syn 
solutions at three different concentrations, 0.5 µM, 1 µM and 5 µM, either alone 
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was determined by MTT assay. Prior to the experiments with α-syn and 
ginsenosides, we assessed the effect of the ginsenosides alone on cell viability 
(Fig. 5.3 left panel), employing the same non-toxic ginsenoside concentrations 
that were later employed for the experiments with aged α-syn. 
  As shown in Fig. 5.3 A-C, aged α-syn inhibited the reduction of MTT in a 
dose-dependent fashion. Given that MTT reduction is directly proportional to the 
number of surviving cells, it becomes apparent that fewer cells survived at higher 




















Figure 5.3. The effect of the ginsenosides on the toxicity induced by the 
aggregates of α-syn. The viability of BE(2)-M-17  human cells was evaluated by 
MTT assay. The results are expressed as percentages of the average of the control 
(i.e. untreated cells). The cells were treated with either -syn aged with or without 
the A. Rb1, B. Rg1, and C. Rg3 for 48 hours prior to the addition of MTT. The 
graphs appearing on the left panel illustrate the toxicity of the compounds alone 
(average of 3 wells ± standard deviation). Statistical analysis was performed using 
a two-tailed unpaired t-test. ***, p< 0.001; **, p< 0.01; *, p< 0.05. D. 
Immunocytochemistry against α-syn of BE(2)-M-17  cells. a.The cells were either 
non-treated or treated for 48 hours with 5 µM of b. aged α-syn alone, or with 
ginsenoside c. Rb1, d. Rg1, e. Rg3. at a molar ratio of aged α-syn: compound 1:4. 
Scale bar 30 µm. 
 
   However, the α-syn aged in the presence of Gn Rb1 was less toxic to the 
cells, as indicated by the increase in MTT reduction (Figs. 5.3 A). Indeed, at 5 
µM, the aged α-syn resulted in a decrease in the number of viable cells by almost 
50%, whereas in the presence of all concentrations of Gn Rb1, the viability of the 
cells increased by approximately 30%, with approximately 80% of the cells 
surviving (Fig. 5.3 A). A similar trend was observed in the case of 1 µM aged α-
syn; in all concentrations used, Gn Rb1 improved the viabilty of the cells treated 




(20S)-Rg3, however, did not show any protective effect on neuroblastoma cells 
against the toxicity of aged α-syn (Fig. 5.3 B, C), possibly due to their inability to 
inhibit α-syn fibrillation (Fig. 5.1) and oligomerization (Fig. 5.2). To confirm the 
toxicity effect observed in the MTT assay, BE(2)-M-17 neuroblastoma cells were 
exposed to 5 μM α-syn aged in the presence or absence of the ginsenocide at a 
molar ratio of 1:4 (α-syn: Gn) and subjected to immunostaining for α-syn. 
Fluorescence microscopy revealed that, whereas untreated cells were healthy and 
displayed diffuse cytoplasmic α-syn staining (Fig. 5.3 D a), the cells treated with 
aged α-syn lost their neuronal shape, appearing  rounded and unhealthy, with 
aggregated fibrils accumulating at the cell membranes (Fig. 5.3 D b). This effect 
was dramatically reversed when the cells were treated with α-syn aged in the 
presence of Gn Rb1, with no apparent aggregates detected on the cell membranes 
(Fig. 5.3 D c). In contrast, the cells treated with the α-syn aged in the presence of 
Rg1 and Rg3, which were shown above not to inhibit α-syn aggregation, appeared 
rounded, unhealthy and bearing extracellular, membrane-bound aggregates (Fig. 
5.3 D d, e). 
5.3.4 The effect of Gn Rb1 on preformed -syn amyloid fibrils 
Due to its high efficiency in inhibiting -syn fibrillation, Gn Rb1 was also 
assessed for its effectiveness in reversing fibrillation. Hence, 25 µM of preformed 
-syn fibrils were incubated at 37°C in the presence of Gn Rb1 at molar ratios 
representing Gn Rb1: -syn of 6:1, 4:1 and 2:1 for a period of 48 hours. By 
measuring the Th-T fluorescence counts, the fibril content was estimated at 
different intervals. Even at time 0, the Th-T counts for -syn incubated alone 




Rb1, especially the one with the highest concentration of that particular 
ginsenoside (Fig. 5.4 A). During the course of the experiment, the -syn fibrils 
that were incubated in the absence of Gn Rb1 continued to aggregate further, as 
indicated by the increase in Th-T counts (Fig. 5.4 A), whereas the fibrils 
incubated in the presence of the ginsenoside disaggregated in a dose-dependent 
fashion, given the decrease in Th-T counts (Fig. 5.4 A). This trend was apparent 
after 4 hours of incubation, with the Th-T counts for the Gn Rb1 containing 





Figure 5.4. The effect of Gn Rb1 on preformed -syn fibrils and on the seeded 
polymerization of -syn. A. Samples of aggregated -syn were incubated for 48 
hours at 37°C in the absence or presence of various concentrations of Gn Rb1 (Gn 
Rb1: -syn at 6:1, 4:1, and 2:1). The fibril content was then measured by the Th-T 
binding assay. The assay was performed in triplicate (average of triplicate 
measurements ± standard deviations). B. Electron microscopy images of 
negatively stained samples of the pre-aggregated α-syn incubated alone or in the 
presence of Gn Rb1 (1:4) for 0 and 48 hours with continuous shaking at 37°C. 
Scale bar, 500 nm. C. Samples of -syn monomers (100 M) were seeded with 2 
M sonicated α-syn fibrils, which were incubated in the presence or absence of 
Gn Rb1 at different concentrations (10 and 50 M) for 6 hours with continuous 
shaking at 37°C. The extent of fibrillation was estimated by the Th-T binding 




standard deviations). D. Electron microscopy images of negatively stained 
samples of the α-syn seeds alone and of the seeded α-syn incubated in the absence 
or presence of Gn Rb1 (50 µM) for 6 hours with continuous shaking at 37°C. 
Scale bar, 1,000 nm. 
 
5.3.5 Gn Rb1 inhibition of -syn fibrillation is mediated via binding to the 
intermediate species and formation of stable oligomers.  
The strong inhibitory effect that Gn Rb1 showed on fibrillation, prompted 
us to investigate further the interaction of Gn Rb1 with α-syn oligomers. For this 
purpose, monomeric α-syn (100 µM) was aggregated in the presence of Gn Rb1 
(Gn Rb1: α-syn molar ratio 4:1). After 5 days of incubation, the samples were 
centrifuged and the supernatant was injected in a superdex 200 SE column. The 
elution volume for monomeric α-syn was determined by molecular weight 
standards, and was eluted in a peak corresponding to column volume of 14-16 ml, 
while oligomeric α-syn eluted in a peak corresponding to a column volume of 





Figure 5.5. Gn Rb1 binds to -syn oligomers (Gn Rb1: -syn molar ratio of 4:1). 
A. Gel filtration profile of the 5-day aggregated α-syn in the presence of Gn Rb1 
at a (Gn Rb1: α-syn) molar ratio 4:1 (α-syn concentration =100 µM) using a 
superdex 200 SE column. P1 and P2 samples contain the isolated fractions 
corresponding to the oligomeric peak and P3 the isolated fractions corresponding 
to the monomeric peak. The elution was monitored at the absorbance wavelength 
of 215 nm, immunoblot analysis of the samples P1 P2 and P3 separated by 
electrophoresis in a 15% SDS-PAGE gel. B. Electron microscopy images of 
negatively stained samples P1, P2 and P3 of α-syn in the presence of Gn Rb1 
(molar ratio of Gn Rb1: -syn 4:1) purified by SEC. Scale bar, 500 nm. C. UV 
absorbance spectra of Gn Rb1 alone.  The UV absorbance was recorded between 
200-600 nm employing a 10 mm quartz cuvette. D. UV absorbance spectra P1, P2 
and P3. The UV absorbance was recorded between 200-600 nm employing a 10 
mm quartz cuvette. 
 
 
The fractions corresponding to the oligomeric and monomeric α-syn peaks 
were pooled together giving rise to P1, P2 and P3 samples (Fig. 5.5 A), which 




characterized by western blotting and EM (Fig. 5.5 A, B). In agreement with the 
imunoblotting results (Fig. 5.5 A), electron microscopy of the samples indicated 
the presence of different species of oligomers in P1 and P2 (Fig. 5.5 B). In order 
to detect the incorporated Gn Rb1 in the P1, P2 and P3 samples, we exploited the 
property of Gn Rb1 to produce UV absorbance spectra with three notable peaks 
(Fig. 5.5 C).  
To further evaluate whether Gn Rb1 interacts with α-syn monomers, we 
monitored a titration of Gn Rb1 into a solution of monomeric α-syn using two-
dimensional NMR spectroscopy, which provides signals covering the entire amino 
acid sequence of α-syn (Fig. 5.6). At stoichiometries of up to 6:1 Gn Rb1: α-syn, 
we observed no significant chemical shift or resonance intensity changes (Fig. 5.7 











Figure 5.6. Analysis of Gn Rb1 binding to monomeric α-syn by NMR 
spectroscopy. Proton-Nitrogen correlation (HSQC) spectra of monomeric α-syn in 
the presence of increasing ratios of Gn Rb1: α-syn demonstrating that there are no 
significant changes in the positions of the NMR resonances, indicating the lack of 

















Figure 5.7. Peak intensity ratio plot of 200 µM 15N-labeled wt α-syn FL+ Gn Rb1 
(Gn Rb1: α-syn 1:1, 2:1, 4:1 and 6:1). From the HSQC spectra and the intensity 
plot, there might be no interaction between α-syn monomer and Gn Rb1. A. all; B. 




5.4  Discussion 
PD is a progressive neurodegenerative disorder, the incidence of which is 
expected to rise sharply worldwide by 2030, with PD cases doubling by that time 
(Dorsey et al., 2007). Existing treatments for PD cannot cure the disease and can 
only offer moderate symptom relief, which is moreover accompanied by adverse 
side effects. Hence, there is a definite and imperative need for the development of 
new and more efficient treatments. Although PD pathology is considered to be 
induced by various etiological factors (reviewed by (Di Monte, 2003), there is 




role in the pathogenesis of PD and related disorders (Baba, et al., 1998; 
Spillantini, Crowther, Jakes, Hasegawa, & Goedert, 1998; Spillantini, et al., 
1997). As a result, there is an ongoing endeavor to identify or design molecules 
that can suppress or even reverse -syn aggregation (reviewed by (Findeis, 2000). 
Ginseng and its biologically active components, the ginsenosides, have been 
shown to have a beneficial effect on neurological conditions such as PD, due to 
their neuroprotective properties (Cho, 2012; H. J. Kim, et al., 2013), but their 
potential as anti-amyloidogenic agents have never been assessed. This gap in 
knowledge prompted us to investigate the effect of the most frequently used 
ginsenosides, namely Rb1, Rg1 and Rg3, on the formation of the early aggregates 
(soluble oligomers) and late aggregates (fibrils) of α-syn. For this purpose we 
employed an array of biophysical, biochemical and cell-cultured based 
techniques.  
Among the ginsenosides screened, ginsenoside Rb1 was shown to be the 
only potent inhibitor of -syn fibrillation that adequately blocked -syn-induced 
toxicity; it disaggregated preformed α-syn fibrils and inhibited the seeded 
aggregation of α-syn. More specifically, our results show for the first time that Gn 
Rb1 can disrupt the fibrillation of -syn in vitro (Fig. 5.1 A, B) allowing only the 
formation of small, sheared, rod-like species that are easily digested by PK (Fig. 
5.1 C) and fail to elongate even after an extended aggregation period (Fig. 5.1 D). 
The accumulation of α-syn monomers was first detected by immunoblotting and 
densitometric analysis of the monomeric bands (Fig. 5.2 A) and was further 
confirmed by SEC (Fig. 5.5 A). Furthermore, Gn Rb1 could satisfactorily curb the 




increase in cell survival and exhibiting a neuroprotective effect on neuroblastoma 
cells (Fig. 5.3 A and D). Gn Rb1 also disaggregated preformed α-syn fibrils 
 (Fig. 5.4 A and B) and inhibited the seeded aggregation of α-syn in a 
concentration-dependent manner (Fig. 5.4 C and D),   
These results are in accordance with previous reports that described Gn Rb1 as a 
neurotrophic and anti-inflammatory agent. Gn Rb1 has been previously shown to 
exert cell protective effects against the toxicity induced by A42 (Qian, Han, Hu, 
& Shi, 2009) and A25-35 (X. Xie et al., 2010). In animal models, Gn Rb1 was 
demonstrated to have anti-inflammatory activity (Wang et al., 2011) and to reduce 
soluble A40 in a dose-dependent fashion (Shi et al., 2010). Interestingly, Gn Rb1 
was shown to attenuate the A25-35-induced hyperphosphorylation of tau protein in 
vitro (Y. H. Xie et al., 2007) and A25-35-induced memory impairment, axonal 
atrophy and synaptic loss in vivo (Tohda, Matsumoto, Zou, Meselhy, & Komatsu, 
2004). 
In terms of structure, Gn Rb1is a triterpene saponin, containing a four-ring 
steroidal structure that bears an aliphatic side chain and two disaccharide moieties 
attached to C-3 and C-20 of the triterpene structure (Scheme 5.1). Since one of the 
disaccharides of Rb1 is attached to the 3-position of the dammarane-type 
triterpine, Gn Rb1 is a protopanaxadiol-type of gindenoside, like Gn (20S)-Rg3. 
By comparing the structure of Gn Rb1 with that of Gn (20S)-Rg3 that partially 
inhibited fibrillation but failed to inhibit -syn oligomerisation and toxicity 
(Scheme 5.1), it becomes apparent that the difference between the two 
ginsenosides lies in the presence of two additional sugar rings in Gn Rb1 at C-20 
of the triterpene. As a consequence, Gn Rb1 possesses overall four sugar rings 




triterpene, thus conferring a more symmetrical structure to Gn Rb1 as compared 
to Gn (20S)-Rg3, which has only a disaccharide group attached to C-3 of the 
triterpene. Although structural symmetry is not a prerequisite for the inhibition of 
amyloid aggregation, there are many naturally occurring compounds whose 
structural symmetry renders them potent anti-aggregating agents in vitro 
(Caruana, et al., 2011; Porat, et al., 2006).  
Furthermore, it is well understood that the specific action of each 
ginsenoside may depend on the type of sugar components, their number and their 
position on the aglycone (Z. Q. Liu et al., 2003; Nag, et al., 2012; Popovich & 
Kitts, 2002; Qi, Wang, & Yuan, 2010; Sun, Yang, & Ye, 2006). It is therefore 
likely that the number of sugar moieties may also play an important role in the 
anti-amyloidogenic properties of the ginsenosides. Gn Rb1 that was shown to be 
the most potent inhibitor possesses four sugar rings, while Gn (20S)-Rg3, which 
partially inhibited α-syn fibrillation but failed to exhibit any inhibitory effect in 
the rest of the assays, and possesses two sugar moieties. Although both Gn (20S)-
Rg3 and Gn Rg1 (which failed to inhibit fibrillation and stimulated the 
oligomerisation of α-syn) contain two sugar rings, there is a major difference 
between the two ginsenosides. Gn (20)-Rg3 belongs to the protopanaxadiol group 
of gindenosides, whereas Gn Rg1 belongs to the protopanaxatriol group, which is 
characterized by the presence of an OH or a sugar group at C-6 of the triterpene. 
Gn Rg1 bears a sugar moiety at C-6 (Scheme 5.1). It has been reported before that 
the sugar linkage at C-6 is associated with a decreased ginsenoside anticancer 
activity compared to the linkages at C-3 or C-20 (R. J. Chen, Chung, Li, Lin, & 
Tzen, 2009).  Also, the sugar linkage at C-6 has been shown to confer an 




possibility that the C-6 linkage also renders the ginsenosides poor anti-
amyloidogenic agents. Based on our findings using both NMR and SEC combined 
with UV spectroscopy, Gn Rb1 inhibits α-syn fibrillation not by interacting with 
the monomeric α-syn and preventing it from fibrillation, but rather by stabilizing 
the structure of soluble oligomeric α-syn without any β-sheet content (Fig. 5.2 A 
and 5.5 A), which appears to be non-toxic (Fig. 5.3 A and D). Since some 
interactions between α-syn and binding partners are not revealed in chemical shift 
changes, we also analyzed for changes to resonance intensities, which can 
sometimes reveal interactions that are otherwise missed. In this case, neither 
chemical shifts nor intensities changed. Nevertheless, it remains possible that a 
very weak interaction occurs that is missed by both measures, as indeed was the 
case in the analysis of Hsp70 binding by Dedmon et al. (Dedmon, Christodoulou, 
Wilson, & Dobson, 2005). The NMR data suggests that if any interaction is 
present with monomeric α-syn, it is a very weak and transient one. When 
combined with the size exclusion data, we conclude that the *predominant* 
interaction of Rb1 is with oligomeric α-syn rather than with the monomeric 
protein. These findings are in accordance with previous studies indicating that 
some polyphenolic compounds, such as baicalein, curcumin and epigallocatechin 
gallate induce the formation of soluble, non-toxic oligomers of α-syn or Aβ 
(Porat, et al., 2006). 
Amyloid fibrils formed by aged α-syn are rich in -sheet content and binding of 
these aggregates to the cell membrane results in membrane permeabilization and a 
resultant alteration in calcium homeostasis, which can cause cytotoxicity (El-
Agnaf, Jakes, Curran, Middleton, et al., 1998; Pieri, Madiona, Bousset, & Melki, 




that we observed in cultured BE(2)-M-17 cells exposed to aggregated α-syn alone 
is suggestive of the localization of these aggregates to the plasma membrane, 
while the cells lost their characteristic neuronal shape as they appeared rounded 
and unhealthy. Treatment of the cells with α-syn aged in the presence of Gn Rb1, 
which did not result in α-syn fibrillation, appeared healthy without the 
accumulation of α-syn at the cell membranes, whereas exposure to α-syn aged in 
the presence of Rg1 or Rg3, which were poor inhibitors of α-syn fibrillation, led 
to the formation of membrane-bound aggregates, and the cells appeared unhealthy 
and rounded. This observation is in accordance with the results obtained from the 
MTT assay, wherein cells treated with aged α-syn alone or in the presence of Rg1 
or Rg3 displayed cytotoxicity, which was not observed when the cells were 
exposed to α-syn aged in the presence of Rb1. Since Rb1 was found to inhibit α-
syn fibrillation and stabilize soluble, non-toxic oligomers  without a -sheet 
content (Fig. 5.1), we hypothesize that the neuroprotective role of Rb1 stems from 
its ability to inhibit the formation of mature amyloid fibrils containing -sheet 
structures and thereby prevent plasma membrane disruption in neuroblastoma 
cells. However, we cannot exclude the possibility that the anti-oxidant properties 
(Y. H. Xie, et al., 2007) and the anti-inflammatory activity (Wang, et al., 2011) of 
Gn Rb1 may also contribute to its neuroprotective effect. Interestingly, Gn Rb1 
has previously been shown to be a much more potent anti-oxidant than Rg1, while 
Rg3 was shown to promote the free radical-induced heamolysis in human red 
blood cells (Z. Q. Liu, et al., 2003).  
 
In conclusion, from the three tested ginsenosides, Rb1 was shown for the first 




preformed fibrils and block the α-syn seeded polymerization possibly by binding 
and stabilizing non-toxic α-syn oligomers without β-sheet content. The next step 
is to assess its effect on PD animal models. Gn Rb1 could thus represent the 
starting point for designing new molecules that in turn could be used as new drugs 
for the treatment of PD and related disorders.  
6 Chapter 6: Salvianolic acid b and Dihydromyricetin, 
inhibit the formation and toxicity of early and late 
alpha-synuclein aggregates. 
6.1 Introduction 
Drugs Currently available for the treatment of PD provide symptomatic 
treatment but do not alter the course of the disease (He, et al., 2013). However, the 
effectiveness of these drugs diminishes after several years of treatment. Together 
with the increasing incidence of PD due to an aging population, these facts indicate 
the compelling need for more effective drugs and treatment for PD. Modern 
therapeutic options that target disease modification are on the rise. However, the 
multiple mechanisms involved in the pathogenesis of PD create considerable 
difficulty in producing effective treatments. Hence, the inhibition of α-syn 
aggregation may represent a viable strategy for therapeutic intervention in PD and 
related disorders. It is therefore essential to identify compounds that can serve as 
potent inhibitors and interrupt the early stages of aggregation.  
Chinese medicinal compounds (CMCs) extracted from medicinal herbs and 
plants have been used for the treatment of a wide range of diseases for over a 
millennium. Indeed, traditional Chinese medicine has employed various CMCs as 




disorders (Kum et al., 2011), cardiovascular diseases (Ceylan-Isik, Fliethman, Wold, 
& Ren, 2008) and even cancer (reviewed by (X. Li et al., 2013). As a consequence, 
traditional Chinese medicine is considered a good resource for the treatment of 
several diseases, including PD. In fact, a lot of effort has been invested into 
unraveling the molecular basis of several CMCs employed in traditional Chinese 
medicine. Baicalein, the main component of the traditional Chinese herbal medicine 
Scutellaria baicalensis, has been reported to inhibit the fibrillation of wild-type (Zhu, 
et al., 2004) and E46K α-syn (Jiang et al., 2010) and to disaggregate preformed 
fibrils in vitro (Zhu, et al., 2004). Baicalein was also shown to alleviate the toxicity 
induced by E46K α-syn in a PD cell model (Jiang, et al., 2010). Additionally, 
curcumin, the main component of the traditional Chinese herbal medicine turmeric, 
isolated from the roots of Curcuma longa, has been shown to inhibit the aggregation 
and toxicity of β-amyloid peptide (F. Yang, et al., 2005). 
The aim of this study was to assess the effects of a small library of CMCs on 
the oligomerization, fibrillation and toxicity of -syn to identify potential inhibitors 
of α-syn aggregation. Eleven CMCs, which were extracted from Chinese herbal 
medicines (CHMs) including ginseng, gardenia, ginkgo biloba, Japanese raisin tree, 
Japanese arrowroot, peony, licorice, and danshen, were systematically tested using 
biophysical, biochemical and cell-culture techniques.  
We found that among the 11 CMCs, salvianolic acid B (CMC1) significantly 
inhibited α-syn oligomerization and fibril formation and protected against α-syn-
induced toxicity, while dihydromyricetin (CMC7), was shown to inhibit α-syn 





6.2 Experimental procedure 
6.2.1 Expression and purification of recombinant human α-syn 
As described in the experimental procedure 3.2.1 
6.2.2 α-syn purification and characterization 
As described in the experimental procedure 3.2.2 
6.2.3 Aggregation of α-syn in vitro.  
As described in the experimental procedure 3.2.3 
6.2.4 Thioflavin-T (Th-T) assay 
α-Syn fibril formation was monitored by Th-T binding assay. Th-T is a 
fluorescent dye that interacts with fibrils containing a β-sheet structure. A total of 10 
µl of each sample was diluted in 40 µl of Th-T in PBS. Fluorescence was then 
measured in a 384-well, untreated black micro-well plate (Nunc, Denmark) using a 
microplate reader (Victor X3 2030, Perkin Elmer) with the excitation and emission 
wavelengths set at 450 and 486 nm, respectively. To allow for background 
fluorescence, the fluorescence intensity of a blank PBS solution was subtracted from 
all readings. 
6.2.5 Transmission electron microscopy (TEM) 
As described in the experimental procedure 3.2.8 
6.2.6 Immunoblotting 
As described in the experimental procedure 4.2.6 
6.2.7 Congo red binding assay 
As described in the experimental procedure 4.2.10 
6.2.8 Tissue culture of BE(2)-M-17  human neuroblastoma cells 




6.2.9 Measurement of cell viability 
As described in the experimental procedure 3.2.13 
6.2.10 Seeding polymerization assay 
As described in the experimental procedure 5.2.13 
6.2.11 -Syn disaggregation assay 
As described in the experimental procedure 5.2.12 
6.2.12 Size Exclusion Chromatography (SEC) for separating α-syn oligomers 
and monomers 
As described in the experimental procedure 5.2.14 
6.2.13 UV scanning.  
As described in the experimental procedure 5.2.15 
 
6.3 Results 
6.3.1 The effect of salvianolic acid B and dihydromyricetin on α-syn 
fibrillation 
α-Syn solution at a concentration of 25 µM was incubated at 37ºC with 
continuous shaking for 5 days, leading to fibril formation, which was monitored by 
Th-T fluorescence at regular time intervals. α-Syn was incubated with each of the 
eleven CMCs (see Table. 6.1 and Scheme 6.1) at molar ratios of 4:1, 2:1 and 1:1 



















Scheme 6.1: Chemical structure for the tested compounds. Salvianolic acid B, 
Ammonium Glycyrrhizinate, Puerarin, Sinomenine, Paenoflorin, Gamma-
Schisandrin, Dihydromyricetin, Magnolol, Honokiol, Geniposide, Bilobalide.  
 
Table 6.1. The small compounds from Chinese herbal medicines and their effect on 



















Inhibition of α-syn fibril formation was tested by Th-T assay as described in the materials and methods. 
2
Inhibition of α-syn 
oligomer formation was tested by immunoblotting as described in the materials and methods. 
3
Inhibition of α-syn fibril toxicity 
toward M-17 - neuroblastoma cells was tested by MTT assay as described in the materials and methods. (+ + +, very potent; + 























- - - 
CMC3 Puerarin - - - 
CMC4 Sinomenine - - - 
CMC5 Paenoflorin - - - 
CMC6 Gamma-Schisandrin - - - 
CMC7 Dihydromyricetin + + + 
CMC8 Magnolol - - - 
CMC9 Honokiol - - - 
CMC10 Geniposide - - - 




Two compounds, salvianolic acid B (CMC1) and dihydromyricetin (CMC7), 
inhibited α-syn fibrillation as indicated by reduced Th-T fluorescence (Fig. 6.1). 
More specifically, at concentrations of 100 and 50 M, CMC1 exhibited a complete 
inhibitory effect, which was prominent on the third day of incubation. After 5 days of 
incubation, CMC1 at 100 M completely abolished the fibrillation of -syn, while at 
50 M; it inhibited fibrillation by almost 80%. At a lower concentration (i.e., 25 
M), CMC1 also induced the inhibition of -syn fibrillation, the percentage of which 
was reduced by approximately 35% after 5 days of incubation (Fig. 6.1). These 
results indicate that CMC1 inhibited the formation of fibrils in a concentration-
dependent manner. CMC7 was observed as a good inhibitor of fibrillation, although 
its inhibitory effect was not comparable with of CMC1. Indeed, after 5 days of 
incubation, CMC10 inhibited -syn fibrillation by 80 and 40% at 100 and 50 M, 

















Figure 6.1. Th-T assay for CMCs. CMCs inhibit -syn fibrillation in a concentration-
dependent fashion. Samples of α-syn (25 µM) were incubated for 5 days at 37°C 
with continuous shaking in the presence of various concentrations of CMCs (100, 50 
and 25 µM) Salvianolic acid B (CMC1), Dihydromyricetin (CMC7), Geniposide 
(CMC10) and Bilobalide (CMC11). Fibril formation was then measured by Th-T 
binding assay. The assays were performed in triplicate, and the means ± standard 
deviations are shown. 















































































In contrast, the compounds ammonium glycyrrhizinate (CMC2), puerarin 
(CMC3), sinomenine (CMC4), paeoniflorin (CMC5), gamma-schisandrin (CMC6), 
magnolol (CMC8), honokiol (CMC9),and bilobalide (CMC11) had no significant 
effect on -syn fibrillation because Th-T measurements indicated that the α-syn fibril 
formation was comparable to that for the control α-syn solution aged alone, (see 
Table 6.1). Geniposide (CMC10) had a slight stimulating effect on fibrillation with 
increased Th-T measurements (Fig. 6.1). 
The ability of CMC1 and CMC7 to block α-syn fibril formation was further 
explored using the Congo red (CR) binding assay. CR is a dye with high affinity for 
amyloid fibrils (Groenning, 2010). Upon binding to -syn fibrils, the absorption 
maximum of CR shifts from 490 to 508 nm, and this shift is quite pronounced for -
syn samples incubated in the absence of CMCs (Fig. 6.2). However, this 
characteristic shift was not observed for -syn samples aged in the presence of 
CMC1 or CMC7, indicating that these compounds inhibited the formation of 
amyloid fibrils (Fig. 6.2), comparing with CMC10 and CMC11 which did not inhibit 
the fibril formation (Fig. 6.2). Indeed, the absorption maximum of CR bound to the 
-syn samples containing CMC1 and CMC7 (at all tested concentrations) only 

























Figure 6.2. Congo red binding assay assay for CMCs.  Congo red binding for CMCs. 
α-Syn solution samples (5 µM) either aged alone or with different molar ratios of 
CMCs were mixed with a final concentration of 5 µM Congo red. The UV 
absorbance spectrum was recorded from 400 to 600 nm in a spectrophotometer 
 
Then the α-syn formed aggregates were tested to see if they were resistant to 
PK digestion, samples of α-syn aggregated alone or in the presence of CMC1, 
CMC7, CMC10 and CMC11 at molar ratio of 1:1 were treated with 2.5 µg/ml PK; 
the digested samples were then run on 15% SDS-PAGE and the gel was silver 
stained. The α-syn aged in the presence of CMC1 and CMC7 was easily digested by 
PK and behaved exactly as monomeric α-syn (Fig. 6.3), while the samples of aged α-
syn alone or in the presence of CMC10 and CMC11 were resistant to digestion (Fig. 

















Figure 6.3. Proteinase K digestion assay.  Silver staining for 15% SDS gel of α-syn 
monomers, α-syn aged alone or in the presence of CMC1, CMC7, CMC10 and 
CMC11at molar ratio 1:1 after 2.5 µg/ml PK digestion. 
 
 
These findings were further confirmed by electron microscopy. TEM images 
of α-syn aged in the presence of CMC1 and CMC10 showed that -syn formed thin, 
short rod-like fibrils, with a fragmented appearance (Fig. 6.4), which was unlike the 
dense meshes of long fibrils formed by α-syn aged alone (Fig. 6.4). For the rest of 
the compounds, TEM images confirmed that there were few or no changes in fibril 
morphology compared with the control, which is consistent with the Th-T 
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Figure 6.4. Electron microscopy images  for CMCs. Electron microscopy 
images of negatively stained samples of α-syn (25 µM) aged alone or in the 
presence of CMCs (CMC: -syn molar ratios of 4:1, 2:1, and 1:1) for 5 days 
with continuous shaking at 37°C. Scale bar, 500 nm. 
 
 
6.3.2 The effect of salvianolic acid B and dihydromyricetin on α-syn 
oligomerization 
The effect of the compounds on α-syn oligomerization was also assessed by 
immunoblot analysis. The same fresh and aged solutions of α-syn alone or with 
CMCs were analyzed, and the majority of freshly prepared α-syn migrated as a band 
at ~16 KDa, corresponding to α-syn monomers (Figs. 6.5 A-D). CMC1 and CMC10, 
which were shown to inhibit α-syn fibrillation, were also observed as potent 
inhibitors of α-syn oligomerization. In fact, similar to their effect on -syn 
fibrillation, CMC1 and CMC7 inhibited -syn oligomerization in a dose-dependent 




More specifically, CMC1 inhibited the formation of larger aggregates (MW 
>250 kDa) and high MW oligomers bands corresponding to monomeric and dimeric 
-syn were the most prominent species, and a band corresponding to trimeric -syn 
was faint (Fig. 6.5 A). With decreasing CMC1 concentration, the dimeric, trimeric 
and oligomeric bands were increasingly stronger, indicating that CMC1 inhibited -
syn oligomerization in a dose-dependent fashion (Fig. 6.5 A). It should be noted that 
even at the lowest concentration, CMC1 still induced the inhibition of larger 
aggregates. CMC7 also suppressed the formation of oligomeric forms in a 
concentration-dependent manner; the highest concentration was the most potent of 
the three concentrations tested (Fig. 6.5 B). At the highest concentration of CMC7, 
-syn produced faint dimeric and trimeric bands (Fig. 6.5 B). However, these bands 
were progressively stronger with decreasing CMC7 concentration, consistent with 
dose-dependent inhibition (Fig. 6.5 B).  
The rest of the compounds tested had an effect on -syn oligomerization 
analogous to their effect on fibrillation. These compounds either had no effect on α-
syn oligomerization or they stimulated it. For the sake of simplicity, we will only 
refer to two compounds: CMC10, which represents the group of CMCs that induced 
oligomerization (Fig. 6.5 C), and CMC11, which represents the group of CMCs had 
no effect on oligomerization (Fig. 6.5 D). Thus, In the presence of CMC10, -syn 
oligomerization was enhanced compared to the control, as indicated by the detection 
of numerous strong bands corresponding to the oligomeric species (Fig. 6.5 C), in the 
presence of all CMC11 concentrations, separation of -syn in the gel generated 
bands comparable with that of the control, indicating that CMC11 failed to inhibit -
syn oligomerization (Fig. 6.5 D), which is similar to its observed effect on 






the presence of CMCs was quantified against a fresh -syn sample that contained 



























Figure. 6.5. Immunoblot analysis of the effect of CMCs on α-syn oligomerization. α-
Syn alone or in the presence of CMCs at CMC: α-syn molar ratios of 1:1, 2:1 and 
4:1, incubated for 5 days. Lane 1, CMC: α-syn 1:1, lane 2, CMC: α-syn 2:1, lane 3, 
CMC: α-syn 4:1, A: aged α-syn and M: monomeric α-syn. A. Salvianolic acid B 
(CMC1), B. Dihydromyricetin (CMC7), C. Geniposide (CMC10), D. Bilobalide 
(CMC11). The amount of the monomeric α-syn was quantified for α-syn samples 






6.3.3 The effect of salvianolic acid B and dihydromyricetin on α-syn-induced 
cytotoxicity  
BE(2)-M-17  human neuroblastoma cells were treated with aged α-syn 
solutions at three different concentrations, 0.5, 1 and 5 µM, either alone or in the 
presence of CMCs. The CMCs tested included CMC1, CMC7, CMC10 and CMC11. 
The last two compounds CMC10 and CMC11 were included as negative controls 
because they failed to inhibit or even stimulate the formation of α-syn aggregation.  
The viability of cells treated with α-syn solution aged in the presence or 
absence of CMCs was determined with an MTT assay. Prior to experiments, the 
effect of CMCs alone on cell viability was assessed, employing the same non-toxic 
CMCs concentrations that were later employed for experiments with aged α-syn 
solutions (Figs. 6.6 left panel) 
Aged α-syn inhibited the reduction in MTT in a dose-dependent fashion (Fig. 
6.6). Because a reduction in MTT is directly proportional to the number of surviving 
cells, it is apparent that fewer cells survived at higher concentrations of aged α-syn 
(Fig. 6.6). However, aged α-syn solutions in the presence of CMC1 and CMC7 were 
less toxic to cells, as indicated by the increase in MTT reduction (Fig. 6.6), which 
was directly proportional to the number of living cells. Indeed, 5 µM of α-syn aged 
alone induced the reduction in viable cells by almost 50%, whereas in the presence of 
CMC1, cell survival dramatically improved, reaching 95% for the molar ratios of 4:1 
and 2:1 (Fig. 6.6). Interestingly, at these molar ratios, CMC1 proved to be a good 
inhibitor for fibril formation, as indicated by the reduction in the Th-T counts (Fig. 
6.1). CMC7 also reduced the α-syn toxicity, but it was not as potent as CMC1 (Fig. 
6.6). CMC7 exhibited slight protection for cells at the highest concentration, which is 




10%. These findings are in accordance with the Th-T fluorescence measurements 
(Fig. 6.1) and immunoblotting analyses (Fig. 6.5). 
As expected, the rest of the tested compounds, CMC10 and CMC11, did not 
show any protective effect for neuroblastoma cells against the toxicity of aged α-syn 

































Figure 6.6. The effect of the CMCs on the toxicity induced by the aggregates of α-
syn. The viability of BE(2)-M-17 human cells was evaluated by MTT assay. The 
results are expressed as percentages of the average of the control (i.e. untreated 
cells). The cells were treated with either α-syn aged with or without the CMC1, 
CMC7, CMC10, and CMC11 for 48 hours prior to the addition of MTT. The graphs 
appearing on the left panel illustrate the toxicity of the compounds alone (average of 
3 wells ± standard deviation). Statistical analysis was performed using a two-tailed 




  To confirm the toxicity effect observed in the MTT assay, BE(2)-M-17 
neuroblastoma cells were exposed to 5 μM α-syn aged in the presence or absence of 
the CMC1, CMC7, CMC10, and CMC11 at a molar ratio of 1:4 (α-syn: CMC) and 
subjected to immunostaining for α-syn. Fluorescence microscopy revealed that, 
whereas untreated cells were healthy and displayed diffuse cytoplasmic α-syn 
staining (Fig. 6.7 A), the cells treated with aged α-syn lost their neuronal shape, 
appearing rounded and unhealthy, with aggregated fibrils being accumulate at the 
cell membranes (Fig. 6.7 B). This effect was dramatically reversed when the cells 
were treated with α-syn aged in the presence of CMC1 and CMC7, with no apparent 
aggregates detected on the cell membranes (Fig. 6.7 C and D respectively). In 
contrast, the cells treated with the α-syn aged in the presence of CMC10 and 
CMC11, which were shown above not to inhibit α-syn aggregation, appeared 
rounded, unhealthy and bearing extracellular, membrane-bound aggregates (Fig. 6.7 















Figure 6.7. Immunocytochemistry against α-syn of BE(2)-M-17  cells. A.The cells 
were either non-treated or treated for 48 hours with 5 µM of B. aged α-syn alone, or 
with ginsenoside C. CMC1, D. CMC7, E. CMC10, F. CMC11. At a molar ratio of 
aged α-syn: compound 1:4. Scale bar 30 µm. 
 
6.3.4 The effect of salvianolic acid B and dihydromyricetin on preformed       
-syn amyloid fibrils 
Because CMC1 and CMC7 were shown to be effective inhibitors of -syn 
fibrillation, we wondered whether they could also reverse fibrillation. Hence, 25 µM 
of preformed -syn fibrils was incubated at 37°C in the presence of the above 
mentioned CMCs at CMC: -syn molar ratios of 6:1, 4:1 and 2:1 for a period of 48 
hours. By measuring the Th-T fluorescence counts (Figs. 6.8 A and B), we estimated 
the fibril content at the different points. At 0, the Th-T counts were approximately 
20,000 for -syn incubated alone or with CMC1, while in the presence of CMC7, the 
Th-T count was less at that time point (Fig. 6.8 A and  B). The -syn fibrils that were 
incubated alone continued to aggregate further, as indicated by the increase in Th-T 
counts (Fig. 6.8 A and B). However, while -syn fibrils incubated in the presence of 





the other hand, CMC1 failed to disaggregate the preformed -syn fibrils (Fig. 6.8 A). 























Figure 6.8. Effect of CMC1 and CMC7 on performed -syn fibrils. A and B. 
Samples of aggregated -syn were incubated for 48 hours at 37°C in the absence or 
presence of various concentrations of CMC1 and CMC7 (CMC: -syn at 6:1, 4:1, 
and 2:1). The fibril content was then measured by a Th-T binding assay. The assays 
were performed in triplicate (average of triplicate measurements ± standard 
deviations). C. Electron microscopy images of negatively stained samples of aged α-
syn incubated with alone or in the presence of CMC1 and CMC7  CMC: -syn at 
6:1) for 0 or 48  hours with continuous shaking at 37°C. Scale bar, 500 nm. 
 
 
6.3.5 The effect of salvianolic acid B and dihydromyricetin on the seeding of -
syn monomers 
It has been previously shown that the process of amyloid fibril formation 
follows a nucleation-dependent polymerization model (Jarrett & Lansbury, 1992). 
According to this model, soluble species generate via nucleation oligomeric species 




phase) to generate fibrils, thus reaching a final plateau known as the equilibrium 
phase (Harper, Wong, Lieber, & Lansbury, 1999). Small aggregates or seeds have 
been shown to accelerate the nucleation phase of amyloid formation in vitro and in 
vivo via a process known as seeding (Harper & Lansbury, 1997; Jarrett & Lansbury, 
1993; Luk, et al., 2012; Volpicelli-Daley, et al., 2011). Given that CMC1 and CMC7 
inhibited -syn fibrillation and that only CMC7 disaggregated preformed -syn 
fibrils, we sought to identify the effect of those compounds on the seeding of -syn 
aggregation. More specifically, mature -syn fibrils were fragmented by sonication 
to obtain short fibrils, which were employed as ‘seeds’ (Fig. 6.9 C). These short 
fibrillar seeds were then added to monomeric α-syn, which was allowed to aggregate 
as described above. As expected, the addition of the short fibrillar seeds accelerated 
the fibrillation process of -syn monomers, as indicated by an increase in Th-T 
counts. Indeed, with seeding, the extent of -syn fibrillation after 6 hours of 
incubation was comparable with the extent of fibrillation of protein incubated for 24 
hours without seeding (Figs. 6.9 D, B and Fig. 6.1).  
To assess the effect of CMC1 and CMC7 on the seeding of -syn aggregation, 
the compounds were added at concentrations of 10 or 50 µM to 100 µM monomeric 
-syn containing seeds at a final concentration of 2 µM, and the mixture was then 
incubated with continuous mixing at 37°C for 6 hours. The tested CMCs at a 
concentration of 50 µM inhibited the seeding process by approximately 90%, as 
indicated by the low Th-T counts (Fig. 6.9 A and B). In contrast, at a lower 
concentration (10 μM), only CMC7 showed an inhibitory effect on the seeding of -
syn monomers, but to a lesser extent in the case of CMC1 (Fig. 6.9 A). These 












Figure 6.9. Effect of CMC1 and CMC7 on the seeding of -syn monomers with 
fibrils. A and B. Samples of -syn monomers (100 M) were seeded with 2 M 
sonicated α-syn fibrils, which were incubated in the presence or absence of CMC1 
and CMC7 at different concentrations (10 and 50 M) for 6 hours with continuous 
shaking at 37°C. The extent of fibrillation was estimated by Th-T binding assay. The 
assays were performed in triplicate (average of triplicate measurements ± standard 
deviations). C, Electron microscopy images of negatively stained samples of seeds 
alone and α-syn incubated with seeds alone or in the presence of CMCs (50 µM) for 




6.3.6 Salvianolic acid B and dihydromyricetin inhibition of -syn fibrillation is 
mediated via binding to the intermediate species and forming stable 
oligomers  
Monomeric α-syn (100 µM) was aggregated in the presence of CMC1 and 
CMC7 and after 5 days of incubation the samples were centrifuged and the 
supernatant was injected in a superdex 200 SE column. The elution volume for 
monomeric α-syn was determined by a molecular weight standard (Fig. 4.7 A), and 
was eluted in a peak corresponding to a column volume of 14-16 mL (Fig. 4.7 B), 




approximately 7-8 and 12-14 ml for P1 and P2 respectively (Fig. 6.10 A and 6.11 A). 
The fractions corresponding to the oligomeric and monomeric α-syn peaks were 
separately pooled together giving rise to P1, P2 and P3 samples (Fig. 6.10 A and 6.11 









Figure 6.10. CMC1 
binding activity to -syn oligomers (CMC1: -syn 4:1). A. Gel filtration profile of  
100 µM -syn sample incubated with CMC1 at 4:1 molar ratio (CMC1: -syn) for 5 
days as described before using superdex 200 SE column, P1and P2 represent the 
oligomeric species while P3 represents the monomeric species, the elution was 
monitored at absorbance wavelengths of  A215.TEM images represent the resulted 
peaks in the top of A . B. Immunoblot analysis of the pooled fractions represent P, P2 
AND P3 resulted from the presence of CMC1 at molar ratios of CMC1: -syn 4:1 
incubated for 5 days with continuous shaking at 37°C were separated by 
electrophoresis in a 15% SDS-PAGE gel. C. P1, P2 and P3 samples of -syn resulted 
from the SE chromatography were placed in a10mm quartz cuvette and the UV 
absorbance spectra were recorded from 200 nm to 600 nm. D. The UV absorbance 





The α-syn species in the samples were characterized by western blotting and 
EM (Fig. 6.10 and 6.11 A and B). According to the western blotting results, the 
oligomers generated during the incubation of α-syn with both CMC1 and CMC7 are 
stable under denaturing conditions (Fig. 6.10 B and 6.11 B). Electron microscopy of 
the same samples indicates the presence of different species of oligomers in P1 and 
P2 (Fig. 6.10 A and 6.11 A), in agreement with the imunoblotting results (Fig. 6.10 B 













Figure 6.11. CMC7 binding activity to -syn oligomers (CMC7: -syn 4:1). A. Gel 
filtration profile of  100 µM -syn sample incubated with CMC7 at 4:1 molar ratio 
(CMC7: -syn) for 5 days as described before using superdex 200 SE column, P1, 
P2 represent the oligomeric species and P3 represent the monomeric species, the 
elution was monitored at absorbance wavelengths of  A215. TEM images represent the 
resulted peaks in the top of A.  B. Immunoblot analysis of the pooled fractions 
represent P1, P2 and P3 resulted from the presence of CMC7 at molar ratios of 
CMC7: -syn 4:1 incubated for 5 days with continuous shaking at 37°C were 
separated by electrophoresis in a15% SDS-PAGE gel. C. P1, P2 and P3 samples of 
-syn resulted from the SE chromatography were placed in a 10mm quartz cuvette 
and the UV absorbance spectra were recorded from 200 nm to 600 nm. D. The UV 




  In order to detect the incorporated CMC1 and CMC7 in the P1, P2 and P3 
samples, we exploited the property of both compounds to produce UV absorbance 
spectra with three notable peaks (Fig. 6.10 D and 6.11 D). In the sample containing 
CMC1: α-syn at 4:1 molar ratio, we detected CMC1 only in the oligomeric P2 
samples (Fig. 6.10 C) while in the sample containing CMC7: α-syn at 4:1 we 
detected CMC7 in both P2 and P3 which represent the oligomeric and monomeric 
species respectively. 
To further evaluate whether CMC1 and CMC7 interact with α-syn 
monomers, we monitored a titration of both compounds into a solution of monomeric 
α-syn using two-dimensional NMR spectroscopy, which provides signals covering 
the entire amino acid sequence of α-syn (Fig. 6.12 and Fig. 6.13 respectively). At 
stoichiometries of up to 6:1 CMC1: α-syn, and 10:1 CMC7: α-syn, we observed no 
significant chemical shifts or resonance intensity changes (Fig. 6.12 A and Fig. 6.13 
A respectively), and the peak intensity ratio plots of (wt α-syn + CMC1 or CMC7) 
(Fig. 6.12 B and Fig. 6.13 B respectively) indicate that there is no sign of interaction 
between α-syn and CMC1 or CMC7, confirming that CMC1 and CMC7, does not 












































Figure 6.12. Analysis of CMC1 binding to monomeric α-syn by NMR spectroscopy. 
A. Proton-Nitrogen correlation (HSQC) spectra of monomeric α-syn in the presence 
of increasing ratios of Salvianolic acid B CMC1: α-syn. B. Peak intensity ratio plot 
of 200 µM 
15
N-labeled wt α-syn FL+ CMC1 (CMC1: α-syn 1:1, 2:1, 4:1 and 6:1). 
From the HSQC spectra and the intensity plot, there might be interaction between α-
syn monomer and CMC1. A. 1:1/0:1 and 0:1/0:1; B. 2:1/0:1 and 0:1/0:1; C. 4:1/0:1 



































Figure 6.13. Analysis of CMC7 binding to monomeric α-syn by NMR spectroscopy. 
A. Proton-Nitrogen correlation (HSQC) spectra of monomeric α-syn in the presence 
of increasing ratios of Dihydromeryricetin CMC7. B. Peak intensity ratio plot of 200 
µM 15N-labeled wt α-syn FL+ CMC7 (CMC7: α-syn 1:1, 2:1, 4:1, 6:1 and 10:1). 
From the HSQC spectra and the intensity plot, there is no interaction between α-syn 
monomer and CMC7. a. 1:1/0:1 and 0:1/0:1; b. 2:1/0:1 and 0:1/0:1; c. 4:1/0:1 and 






In this study, a total of eleven CMCs were assessed for their effect on the 
formation of early aggregates (soluble oligomers) and late aggregates (fibrils). 
Among the compounds screened, salvianolic acid B and dihydromyricetin (CMC7) 
were shown to be the most potent inhibitors of -syn oligomerization and 
fibrillation. These compounds were also able to protect neuroblastoma cells from the 
toxic effects of aged α-syn.  
Salvianolic acid B (CMC1) is one of the most abundant compounds extracted 
from Radix Salvia miltiorrhiza (Danshen). For centuries, traditional Chinese 
medicine has exploited the medicinal properties of danshen, employing it as a 
remedy against cardiovascular disorders. The medicinal properties of salvianolic acid 
B rely on its anti-oxidative ability, which is attributed to it by its polyphenolic 
structure. Dihydromyricetin (CMC7) is a flavonoid that can be extracted from the 
Japanese raisin tree (Hovenia dulcis) and is employed as a hangover cure. 
Our results show for the first time that salvianolic acid B and dihydromyricetin 
disrupt the oligomer and fibril formation of -syn in vitro. Salvianolic acid B and 
dihydromyricetin blocked α-syn oligomerization and fibrillation in a concentration-
dependent manner. Salvianolic acid B also protected neuroblastoma cells against -
syn toxicity in vitro, demonstrating a marked increase in cell survival, while 
dihydromyricetin exhibited weak neuroprotection at the highest concentration. 
Electron microscopy of -syn aged solutions with salvianolic acid B and 
dihydromyricetin showed that the protein forms small non-toxic, sheared, rod-like 




These results are in accordance with previous reports that described salvianolic 
acid B as an anti-fibrillogenic and neuroprotective compound. Indeed, salvianolic 
acid B has been previously reported to inhibit the fibril formation of certain 
amyloidogenic compounds [-amyloid (A), human islet amyloid polypeptide 
(hIAPP)] and to protect cells from their toxic effects. In fact, salvianolic acid B not 
only blocks the fibrillation of A (Tang & Zhang, 2001) but also disaggregates 
preformed A fibrils (Durairajan et al., 2008). Furthermore, salvianolic acid B was 
shown to have neurotrophic properties, protecting cells from the toxic effects of A42 
(Durairajan, et al., 2008) and A25-35 (Lin et al., 2006; Tang & Zhang, 2001). Recent 
reports indicate that the neurotrophic properties of salvianolic acid B also extend to 
animals (D. H. Kim, et al., 2011; Y. W. Lee et al., 2013). A recent study also 
demonstrated that salvianolic acid B inhibits the fibrillation of hIAPP, disaggregates 
preformed hIAPP fibrils and protects pancreatic INS-1 cells against the toxic effects 
of hIAPP (Cheng et al., 2013). 
Many phenolic compounds, including baicalein (Caruana, et al., 2011; Zhu, et 
al., 2004), epigallocatechin gallate (EGCG) (D. E. Ehrnhoefer, et al., 2008), 
rosmarinic acid (Caruana, et al., 2011; Rao, Dua, & Ulmer, 2008), tannic acid 
(Caruana, et al., 2011; Ono & Yamada, 2006) and myricetin (Caruana, et al., 2011; 
Ono & Yamada, 2006), have been previously shown to inhibit the oligomerization 
and fibrillation of -syn, which is in accordance with our findings. Furthermore, 
several lines of evidence indicate that polyphenolic compounds inhibit the elongation 
phase of amyloid aggregation (Ono et al., 2003; Zhu, et al., 2004), which may 
explain why salvianolic acid B and dihydromyricetin inhibited -syn fibrillation 
(Fig. 6.1 and Fig. 6.2) and generated small aggregates with a sheared appearance and 




dihydromyricetin (CMC7) are phenolic compounds containing four and two phenyl 
rings in their structures, respectively. The mechanism by which phenolic compounds 
inhibit -syn aggregation is believed to be mediated by interactions between the 
phenolic compounds and the aromatic residues of the amyloids, directing the former 
towards the amyloidogenic core and thus interfering with the -stacking of the rings 
of the aromatic residues that promote amyloid aggregation (Porat, et al., 2006). In 
addition, the hydroxyl moieties attached to the phenyl rings of the phenolic 
compounds are considered to play an essential role in the inhibition of the -sheet 
structure by competitive hydrogen bonding (Porat, et al., 2006).. Interestingly, 
CMC7 was able to disaggregate the preformed fibrils (Fig. 6.8 B), whereas CMC1 
failed to do so (Fig. 6.8 A). Moreover, both CMC1 and CMC7 were shown to block 
the seeding of α-syn monomers with preformed fibrils, and CMC7 was capable of 
inhibition at both tested concentrations (Fig. 6.9 B), while CMC1 had this effect only 
at 50 µM (Fig. 6.9 A). In this study, we showed also that CMC1 has the ability to 
bind to oligomers (Fig. 6.10 C), while CMC7 was found to bind to both monomers 
and oligomers (Fig. 6.11 C), which could be a starting point to investigate the 
mechanism behind the activity of these two compounds, to inhibit the fibril 
formation of α-syn. 
Regarding the neuroprotective effect that salvianolic acid B exerted on 
neuroblastoma cells, we assumed that it is due to the anti-aggregating activity that 
both compounds demonstrated, but we cannot exclude the possibility that the anti-
oxidant properties of salvianolic acid B (Lin, et al., 2006) also contribute to this 
effect. Membrane permeabilization and alteration in calcium homeostasis, which can 
cause cytotoxicity, resulted from the binding of the rich -sheet amyloid fibrils 




2012; Reynolds, et al., 2011). The fluorescence pattern of α-syn aggregates that we 
observed in cultured BE(2)-M-17 cells treated with aggregated α-syn alone is 
indicative of the localization of these aggregates to the plasma membrane, while the 
cells lost their characteristic neuronal shape as they appeared rounded and unhealthy 
(Fig. 6.7 B) While treatment of the cells with α-syn aged in the presence of CMC1 
and CMC7, which did not result in α-syn fibrillation, appeared healthy without the 
accumulation of α-syn at the cell membranes (Fig. 6.7 C and D), whereas exposure to 
α-syn aged in the presence of CMC10 or CMC11, which were poor inhibitors of α-
syn fibrillation, led to the formation of membrane-bound aggregates where the cells 
appeared unhealthy and rounded (Fig. 6.7 E and F). This observation is in 
accordance with the results obtained from the MTT assay, wherein cells treated with 
aged α-syn alone or in the presence of CMC10 or CMC11 displayed cytotoxicity, 
which was not observed when the cells were exposed to α-syn aged in the presence 
of CMC1 or CMC7. Since both CMC1 and CMC7 were found to inhibit α-syn 
fibrillation and stabilize soluble, non-toxic oligomers without a -sheet content (Fig. 
6.1), we hypothesize that the neuroprotective role of CMC1 and CMC7 stems from 
its ability to inhibit the formation of mature amyloid fibrils containing -sheet 
structures and thereby prevent plasma membrane disruption in neuroblastoma cells.  
Our findings using both NMR and SEC combined with UV spectroscopy, 
suggested that salvianolic acid B inhibits α-syn fibrillation not by interacting with the 
monomeric α-syn and preventing it from fibrillation, but rather by stabilizing the 
structure of soluble oligomeric α-syn without any β-sheet content (Fig. 6.10 A, and 
Fig. 6.12), which appears to be non-toxic (Fig. 6.6 A and Fig. 6.7 C). While 
dihydromyricetin binds to both oligomers and monomers as shown in the FPLC 




compound with monomeric α-syn (Fig. 6.13). Since some interactions between α-syn 
and binding partners are not revealed in chemical shift changes, we also analyzed for 
changes to resonance intensities, which can sometimes reveal interactions that are 
otherwise overlooked. In this case, neither chemical shifts nor intensities changed. 
Nevertheless, it remains possible that a very weak interaction occurs that is missed 
by both measures, as indeed was the case in the analysis of Hsp70 binding by 
Dedmon et al. (Dedmon, et al., 2005). The NMR data suggests that if any interaction 
is present with monomeric α-syn, it is a very weak and transient one. When 
combined with the size exclusion data, we conclude that the predominant interaction 
of dihydromyricetin is with oligomeric α-syn rather than with the monomeric protein. 
These findings are in accordance with previous studies indicating that some 
polyphenolic compounds, such as baicalein, curcumin and epigallocatechin gallate 
induce the formation of soluble, non-toxic oligomers of α-syn or Aβ (Porat, et al., 
2006). 
In conclusion, two compounds from a small library of eleven CMCs isolated 
from widely used CHMs, salvianolic acid B and dihydromyricetin, were shown for 
the first time to inhibit -syn aggregation and toxicity in vitro. The next step is to 
elucidate the mechanism by which these compounds inhibit α-syn aggregation and 
toxicity and to assess their effect on PD animal models. The compounds we 
identified in this study could represent the starting point for designing new molecules 








7 Chapter 7: Conclusion 
7.1 Conclusion 
Several studies supporting the hypothesis that the aggregation of native 
protein is directly seeded by exogenous aggregates. Overall, these studies support 
the notion that amyloid toxicity is mediated by a nucleation-dependent 
polymerization process. In agreement with those studies, our in vitro data also 
showed that the a-syn amyloid toxicity is mediated by the ongoing nucleation-
dependent polymerization ‘seeding’. In contrast with wt-α-syn, p-S129 α-syn 
found to inhibit the seeded aggregation of wt-α-syn, and failed to aggregate and 
form amyloid fibrils. These finding prompted us to screen compounds that can 
inhibit the fibril formation and the seeding of α-syn aggregation. From the 
compounds screened, only gallic acid, ginsenoside Rb1, salvialonic acid B and 
dihydromyricetine found to inhibit the seeding aggregation of α-syn and also 
displayed an inhibitory effect on α-syn fibril formation by stabilizing non-toxic 
soluble oligomers with no β-sheet content, while only dihydromyricetine was 
found to bind with both monomeric and oligomeric forms of α-syn. Those 
compounds may represent the starting point for designing new molecules that 
could be used for the treatment of PD and related disorders. 
7.2 Future work 
There is an immediate need to further investigate the correlation between 
the aggregation and toxicity of α-syn and the phosphorylation at S129, especially 
in the light of recent findings supporting the idea that α-syn mediated toxicity is 




Based on our in vitro screening, together with previous findings, those 
potent compounds need to be tested in vivo to investigate their ability to inhibit 
the seeded aggregation of α-syn and their effect on the motor behavior and 
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